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Summary
The common theme of this thesis is the characterisation of cardiac and vascular 
hypertrophy in animal models of cardiovascular disease. The pathophysiology of 
hypertension, left ventricular hypertrophy and heart failure are discussed, with particular 
emphasis on cardiac and vascular' alterations in animal models. Echocardiography was 
validated for use in rats, and applied to a genetic model of hypertension, the stroke- 
prone spontaneously hypertensive rat (SHRSP), and to the rat coronary artery ligation 
(CAL) model of heart failure. Likewise, laser scanning confocal microscopy (LSCM) 
was utilised to exaruine vascular remodelling in both these models.
The utility of trans-thoracic eehocardrography for estimating left ventricular (LV) mass 
was validated in lightly sedated SHRSP and WKY rats. Two-dimensional and M-mode 
parasternal short-axis views were readily obtainable and used to calculate LV mass 
using the cubed formula, which was then compared to blotted LV weight at autopsy. A 
significant correlation between estimated and autopsy LV mass was obtained, r = 0.86, 
n = 75, equation of line y = 0.92x + 0.08. Left ventricular hypertrophy (LVPI) was 
defined for this colony of rats as a LV mass-to-body weight ratio of greater than 
2.86g/Kg. The accuracy of echocardiography in detecting LV hypertrophy was 
determined: sensitivity 92%, specificity 64%, false-positive rate 22%, and false negative 
rate 14%. LVH in the SHRSP was apparent as a 28% higher LV mass compared to 
WKY rats. The anterior wall was 23% thicker, and the posterior wall 17% thicker. 
Differences in systolic function were measured by ejection fraction and fractional 
shortening, and were found to be anaesthetic dependent, with the SHRSP being more 
prone to halothane-induced cardiac depression. Intra-observer variability was 
quantified using repeat examinations in a sub-group of 18 rats. Co-efficient of 
repeatability was calculated for a range of echocardiographic parameters. The most 
reliable measurements were myocaidial cross-sectional area (15%), LV wall thiclaiess 
(16%), and end diastolic dimension (18%). LV mass had a co-efficient of repeatability 
of21%.
The ability of antihypertensives to prevent the rise in blood pressure and associated 
complications of cardiac and vascular hypertrophy were examined in the SHRSP. At
XIV
weeks 6-7 of age, 24 SHRSP (M:F=12:12) were assigned to thi'ee groups and given in 
their food either irbesartan (Irb, 16mg/kg/Day), hydroehlorothiazide + hydralazine 
(H+H, 4mg/kg/day of each), or control (C). Systolic blood pressure was measured 
twice weekly by tail cuff plythesmography, and cardiac hypertrophy quantified using 
echocardiography at 0, 4 and 8 weeks of treatment. LV gene expression of natriuretic 
peptides was assessed by Northern blot analysis. To examine the effects on vascular 
hypertrophy, 3“’ order mesenteric resistance arteries were fixed in formalin at half 
systolic blood pressure, stained with propidium iodide, and imaged using LSCM. One­
way ANC VA was used to compare between groups, correcting for multiple 
comparisons using the Newman-Keuls test. There was no initial difference in blood 
pressure between groups, but from week 4 onwards, blood pressure in the control group 
was significantly higher e.g. by week 8 Irb 127+5, H+H 131+7 versus control 
166+6mmHg (P<0.001). By 4 weeks, ventricular wall thickness and left ventricular 
mass were significantly increased in the control group when compared to either drug 
group: wall thickness Irb 1.75+0.05, H+H 1.80+0.47 vs. C 2.14+0.05mm (P<0.01), LV 
mass Irb 322+19, H+H 347+15 vs. C 428+19mg (P<0.01). LV myocardial expression 
of mRNA for atrial natrimetie peptide (ANP) was significantly higher in control 
animals compared to either treatment group (P<0.001), and gave a good positive 
correlation with systolic blood pressure. Myocardial gene expression of brain 
natriuretic peptide (BNP) was similar in control and H+H groups and correlated with 
LV mass, but was significantly lower in irbesartan treated animals (P<0.01). Vascular 
hypertrophy was also evident in control rats. Arterial wall thiclaiess was 53+7, 
compared to Irb 43+8 and H+H 44+7pm (P<0.05). This difference was mainly due to a 
significantly thicker media layer in controls, without an increase in cell number. In 
conclusion, both regimens were equally effective in preventing the rise in blood 
pressure, and associated cardiac and vascular hypertrophy.
Cardiac and vascular remodelling were examined in a rat model of heart failure. Male 
WKY rats (300-400g) were subjected to coronary ai'tery ligation (CAL; n=10) or sham 
operation (n=9) and cardiac function and structure were determined by 
echocardiography at two-week intervals. After 8 weeks, animals were euthanased by 
anaesthetic overdose and plasma ANP and BNP concentrations were determined, along 
with mRNA expression in atria and surviving LV. Rings of thoracic aorta were 
mounted in an organ bath for testing of endothelial function. Third order mesenteric
XV
resistance arteries were pressure-fixed in formalin at 50mmHg, stained with propidium 
iodide, and imaged using LSCM. Ligated animals had significantly reduced ejection 
fraction at all time points after surgery (8 weeks: 46+7% versus 77+5% for sham), and 
showed progressive LV dilatation (P<0.001) and LVH (P<0.001) by echocardiography. 
Atrial levels of natriuretic peptide were unaffected by CAL, but ANP mRNA expression 
in the ligated LV was double sham values (P<0.05), this was reflected in higher plasma 
concentrations (P<0.01). There was a non-significant trend for increased BNP mRNA 
in the LV and for plasma concentrations in the ligated animals. Functional responses of 
the thoracic aorta to noradrenaline, acetylcholine, L-NAME and sodium nitroprusside 
were identical for both groups. Only minor, non-significant, changes were observed in 
lumen diameter and wall thiclaiess of mesenteric resistance arteries. However, ligated 
animals had 24% fewer smooth muscle cells in the media layer (P<0.01), suggesting 
extensive eutrophic remodelling. Conclusion -  Heart failure was mild and well 
compensated in these animals. Despite this, a novel type of remodelling was observed 
in mesenteric resistance arteries, which could have implications for small ai’tery 
function.
A small study was undertaken to examine the feasibility of performing CAL in the 
SHRSP. Of eleven animals, six survived to 2-weeks, while only three of these, with the 
smallest infarcts, survived the full 8 weeks. Peri-surgical death was similar to WKY, 
but arrhytlimic death more common. Future approaches to bring mortality within 
acceptable limits could include the use of anti-arrhythmic drugs or blood pressure 
lowering immediately after sui’gery.
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1. Introduction
1.1 Epidemiology of cardiovascular disease 
i. 1.1 Epidemiology of hypertension
Hypertension is often defined clinically as a resting blood pressure greater than 140/90 
mmHg measui'ed on multiple occasions. It has a very high prevalence, affecting almost 
1 in 4 adults in the USA and is the most common risk factor for cardiovascular and 
renal disease (Kamiel, 1996).
Much of our laiowledge of cardiovascular epidemiology is derived from the 
Framingham Heart Study, which will be referred to frequently in this section. This was 
a cohort study set up in 1948 to determine the incidence of heart failure, and has 
included 36 years of follow up over two-generations in 9405 subjects (Cowie, 1999). In 
the Framinghaiu Heart Study, two-thirds of the originally normotensive population 
developed hypertension over a 30-year follow up. This is because prevalence of 
hypertension increases with age, with an average 20mmHg rise in systolic blood 
pressure occurring between the ages of 30 and 65 years. Before middle age, women 
have lower blood pressure than men, however, the increase with age is more 
pronounced, probably due to the menopause. Hypertension is also more common in 
African-American blacks than in whites. Prevalence has not changed despite health 
education aimed at primary prevention of hypertension e.g. advice on diet, smoking, 
exercise and alcohol, probably because of an increasingly elderly population (Kannel, 
1996).
Hypertension is a risk factor for all types of cardiovascular disease. Compared to age- 
controlled normotensives, middle-aged hypertensive men have a 4-fold risk of 
developing heart failur e and stroke, and a 2-fold increased risk o f coronary disease such 
as myocardial infarction (MI), angina and sudden death. Relative risks are even higher 
when other risk factors are present such at old age, diabetes, smoking or elevated 
cholesterol. In addition, hypertensives have an increased prevalence of metabolic 
disorders that add to the atherogenic risk e.g. dyslipidemia, obesity and diabetes. 
(Kannel, 1996).
Effect o f  treatment
Treatment of hypertension has a significant impact on cardiovascular risk. For each 5-6 
mmHg drop in diastolic blood pressure, the incidence of stroke falls by 38% and 
coronary heart disease by 16% (Hedner, 1998). However, a couple of recent studies 
have shown that the risk is not normalised. In a prospective study by Andersson et a l 
(1998), 686 middle-age hypertensive men being treated for hypertension were compared 
with 6810 non-hypertensive men over a 22-year follow-up period. Cardiovasculai’ and 
all cause mortality between groups did not differ in the first 10 years, but increased 
steadily over the next 12-years in the treated hypertensives to become highly significant. 
Therefore, despite good blood pressure control, treated hypertensives still had twice the 
death rate from stroke and ischaemic heart disease.
Similarly, Alderman (1998) followed morbidity and mortality over an 18-year period in 
8690 mild to moderate hypertensive patients. The most common morbid events where 
Ml and stroke, which occurred at a stable rate throughout the years. However the rate 
of heart failure increased 10-fold after 10 years of treatment to become the second most 
common outcome after Ml. Together these studies indicate a failure of antihypertensive 
medication to normalise cardiovascular risk in the long-term. There may be a number 
of reasons for this. It may be necessary to treat hypertension more aggressively by 
aiming for below 140/90mmHg (Hedner, 1998). Control of blood pressure may not 
result in regression of cardiac and vascular hypertrophy, that are themselves 
independent risk factors. Fui'ther, treatment requires optimising as out-with the clinical 
trial situation only 21% of treated hypertensives have good blood pressure control. This 
may be due to sub-optimal dosing and/or poor compliance (Kannel, 1996). It is also 
worth noting that in the general population, around one-third of hypertensives may be 
unawai'e of their condition. Vascular' daiuage or LV hypertrophy may well be present 
before treatment begins, or the first indication of hypertension may present as end-organ 
daiuage (Kannel, 1996).
1.1.2 Epidemiology of cardiac hypertrophy
When discussing the incidence of LVH, older studies using electrocardiograms (EGG) 
for diagnosis of hypertrophy probably grossly underestimated the scale of the problem. 
In the Fraiuingham Heart Study, EGG diagnosed LVH occurred in 5-7% of the elderly 
population. In similar cohorts diagnosed by echocardiography, the incidence ranges 
from 25-30% of elderly men and 30-50% of elderly woiuen. However, despite the
unreliable nature of the ECG for diagnosis, clear EGG evidence of LVtl was associated 
with a very poor prognosis (Levy, 1991).
The Framingham Heart Study used echocardiography to identify the major independent 
risk factors for LVH in 3220 subjects over 40 years old, free from cardiovascular 
disease on entry. LVH is relatively rare in young subjects, but increases with age. The 
age dependency is particularly strong in females, where the risk increases by 67% per 
decade after the menopause. The incidence of LVH increases with increasing blood 
pressure for all age groups and with obesity. The single biggest risk factor was having 
had a previous myocardial infarction. Table 1.1 shows the risk associated with a given 
factor expressed as an odds ratio using multivariate analysis.
Table 1.1 Risk factors for developing LVH established in the Framingham Heart 
Study (Levy, 1991; Levy et a l , 1990)
Risk factor Males odds ratio Females odds ratio
Age (per 10 years) 1.15 1.67
Systolic BP (per t  20mmHg) 1.43 1.25
Body mass index (per 2Kg/m^) 1.47 1.51
Previous myocardial infarction 3.45 3.52
Valvular heart disease 3.42 2.35
The presence of LV hypertrophy is in itself a major risk factor for other cardiovascular 
disease. For each 50g rise in LV mass there is a 60% increase in the incidence of 
coronary artery disease in men and 45% in women. Likewise, all cause luortality 
increases from 4.0% in men without, to 9.1% for men with LVH. The risk appears to be 
continuous with no obvious tlireshold apparent (Levy, 1991).
The prevalence of LVH in hypertensive subjects has been more difficult to quantify 
satisfactorily, as the figures obtained depend heavily not only on the criteria for defining 
hypertrophy, but on the severity of hypertension and treatments given. In one study, 
42% of hypertensive patients with mild to moderately severe hypertension had LVH on 
echo examination. In another, 17% of borderline hypertensives and 21% of established 
hypertensives were affected (Devereux et a l, 1987). In genetic models of hypertension 
such as the SHRSP, the incidence of LVH is 100% in the adult rat (Yamori et a l,  1979).
For obvious ethical reasons, it has not been established whether all hypertensives, if left 
for long enough without treatment, would also develop LVH.
In man, LVH predisposes to ventricular arrhythmias. McLenachan et a l (1987) 
compared the incidence of ventricular arrhythmias in a group of hypertensive patients 
with patients exhibiting hypertension and LVH. Of the patients with LVH, 28% had 
episodes of ventricular' tachycardia, compared to 8% of non-LVH hypertensives and 2% 
of normal controls. These results may explain why LVH patients are at higher risk of 
sudden death.
1.1.3 Epidemiology of heart failure
Estimates of the hurden heart failure exerts on society vary according to methodology, 
age of the population and the definition of hear t failure applied. Wliat they all agree on 
is that heart failure is increasing in prevalence in the elderly, prognosis remains poor 
despite optimising treatment and the economic costs are huge.
Prevalence
Around 15 million people world-wide are thought to suffer from heart failure. In the 
USA, the annual incidence is 400 000, with an estimated prevalence of 2.3 - 3 million. 
At any given time the Germans estimate that 3% of their population are affected 
(Eriksson, 1995). There is no clear consensus for diagnosing heart failure and this is 
reflected in the variation in prevalence between studies. For example, the Framingham 
Heart Study may have underestimated prevalence, as the criteria used identified only 
patients with severe heart failure. In the Swedish “study of men born in 1913” the 
prevalence of heart failure increased with age affecting 2% at 50 years of age and 13% 
by the age of 67 (Eriksson, 1995). It is a consistent finding in all studies that age is a 
major risk factor. The Helsinki ageing study followed 501 subjects aged 47-86 years 
over a 4-year period. Prevalence of heart failure in this elderly population was 
approximately 8% (Kupari et a l, 1997). Closer to home, the number of discharges 
from Scottish hospitals where CHF was the principal diagnosis rose steadily in the years 
1980-1990 (Dargie et a l, 1996).
Epidemiological studies have consistently found that heart failure is becoming more 
prevalent and a nmnber of reasons have been postulated. Firstly, the population is 
ageing. Secondly, survival after MI has much improved due to specialised coronary care 
units and the widespread use of aspirin and tlnombolytics. Patients who may otherwise
have died after MI are surviving only to develop heart failure later (Dargie et a l,  1996). 
And thirdly, there are improved diagnostic tests for heart failure (Eriksson, 1995).
Mortality & morbidity
Mortality and morhidity of untreated heart failure is unknown, even the earliest studies 
had access to diuretics. Mortality depends on severity of the disease. In severe CHF 
requiring hospitalisation, mortality in the CONSENSUS 1 study was as high as 52% 
after 1 year in the placebo group, and was still 36% with ACE inhibitors (Dargie et a l,
1996). As a consequence of the diagnostic criteria, mortality rate may have been over­
reported in the Framingham Heart Study. Six years after diagnosis of heart failure, 82% 
of men and 67% of women were dead. In the “study of men born in 1913” five year 
mortality was not as severe, mainly because most subjects had mild to moderate heart 
failm'e (Eriksson, 1995). For the Helsinki ageing study, mortality in the CHF 
population was 46% over 4 yeai's, representing a 4.2-fold increase in mortality (Kupari 
e ta l ,  1997).
Approximately half of all deaths from heart failure are sudden. Anti-arrhytlmiics have 
little influence on this type of death, and the occurrence of ventricular arrhythmias does 
not appeal' to correlate with sudden death in CHF. Meta-analysis of trials for ACE 
inliibitors show a 23% decrease in mortality by slowing progression, however the gain 
in life expectancy is measured in months not years (Cowie et a l, 1997).
Aetiology
In the Framingham Heart Study, hypertension was the primary underlying cause of 
heart failure (Eriksson, 1995). With more effective anti-hypertensive therapy the 
balance has shifted towards ischaemic heart disease as the most common primary 
aetiology. In the SOLVD trial (Studies of LV Dysfunction), ischaemic heart disease 
accounted for 53% of eases in men and 42% in woman, while hypertension was 
responsihle for 15% in men and 22% in women. Aortic or valvular disease accounted 
for most of the remainder (Eriksson, 1995). The assignation of a primary underlying 
cause may be misleading, as in reality many patients have several co-morbid conditions 
which may all contribute to the onset of heai*t failure. In the Helsinki ageing study, 
ischaemic heart disease was the most common cause, however, 54% had co-existing 
hypertension, 54% had coronary artery disease (CAD), 51% had heart valve disease and 
62% LVH at echocardiography (Kupari et a l, 1997). Flypertension as a primary
underlying cause may also be underestimated since patients with heart failure may no 
longer exhibit high blood pressure, therefore hypertension may be missed if it has not 
been observed prior to heart failure (Cowie et a l, 1997).
After myocardial infar ction, 35% of patients develop either established or transient heart 
failure. When heart failure is transient LV function may be compromised but patients 
are asyruptomatic. Some may go on to have recurrent Mis, but with time many will 
progress to heart failure in the absence of other major morbid events (Dargie et a l,
1996). The process governing disease progression is poorly understood, but is likely to 
include neuroerrdocrine, vascular and renal responses.
The presence of heart failme increases the risk of other cardiovascular events. Heart 
failure patients in the Framingham Heart Study had a 4-fold increased risk of stroke and 
a 2.5 -  5 fold increased risk of myocardial infar’ction (Eriksson, 1995).
Ecconomic burden o f  heart failure
Heart failure represents a major financial strain on national health budgets. In Europe 
this amounts to approximately 1% of the health budget, with inpatient treatment the 
major contributor to this cost (Cowie et a l, 1997). In the USA, the estimate is even 
higher at almost 5% of the health budget, which in 1991 was $38 billion. It is estimated 
that 35% of those diagnosed with heart failure are admitted to hospital per year 
(Eriksson, 1995). In the UK, there ar-e between 100 000 and 200 000 hospital 
admissions per annum due to heart failure (Eriksson, 1995).
Risk factors for heart failure
The risk factors for developing heart failure ai’e similar to those for coronary artery 
disease (CAD), and so it is unsurprising that CAD is also a risk factor for heart failure. 
The major risk factors of hypertension and LV hypertrophy are mentioned earlier. In 
the Framingham Heart Study, 20% of those who had a MI developed heart failure 
within 5-6 years. Dilatation of the LV greatly increased the risk, and LVH was the 
single biggest risk factor for developing heart failure (15-fold increase) (Cowie et a l,
1997). Others include smoking, obesity (especially abdominal fat), excess alcohol 
consumption, stress and metabolic disorders such as diabetes (Eriksson, 1995).
In clinical trials, treatment with antihypertensives may decrease incidence of heart 
failure by up to 50% (Cowie et a l, 1997). However, this figiu'e is unlikely to remain 
true in the general population where poor compliance is often a problem, and changes in
medication are common. The continuation rate for all classes of antihypertensive agents 
after 6 months treatment is only 40-50% (Jones et a l, 1995).
The progressive deterioration from normal non-hypertrophied myocardium to overt 
failure is summarised in figme 1.1. LVH is central to this process and progression may 
be driven by a number of interacting factors such as hypertension, trophic hormones and 
increased afterload.
Haemodynamic overload (e.g. hypertension, valviilai- heart disease) 
Myocai'dial Infarction
Hormones (e.g. Angll, aldosterone, catecholamines.)
Normal
Heart
Compensated
Hypertrophy
Decompensated
Hypertrophy HeartFailure
Wall stress
Myocardial dysfunction
■time
Figure 1.1 Schematic representation of the progression from normal myocardium to 
heart failure. Adapted from Izumo & Aoki (1998).
1.2 Hypertension
1.2.1 Animal models of hypertension
Animal models are required for studying the basic mechanisms of blood pressure 
control that are not possible in humans. Rats are by far the most common species used 
in hypertension research (mouse, dog and cat trail far behind). Hypertension in the rat 
may either be surgically induced e.g. aortic stenosis, Goldblatt rats, or more commonly, 
selectively bred for genetic hypertension (Pinto et a l, 1998). There are at least eight 
genetically hypertensive rat strains currently available, and their salient characteristics 
are outlined in table 1.2. For the purposes of this introduction only the spontaneously 
hypertensive rat (SHR) and it’s stroke-prone relative (SHRSP) will be discussed fully, 
as the SHR is the most commonly used in hypertensive research and the SHRSP is used 
in chapters 3 and 4 of this thesis.
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Rat models offer a number of advantages for hypertension research. They aie relatively 
low cost, with a short life span and accelerated disease progression, which allows 
breeding/genetic studies, and the opportunity for prevention studies. Rats are suitable 
for invasive tecliniques eg. nephrectomy, coronary artery ligation, sympathectomy, LV 
catheterisation, and there are fewer problems with variability i.e. uniform age, severity 
of disease, compliance (Ganten, 1987). Primary essential hypertension accounts for 
95% of human hypertension, therefore genetically transmitted models are of particular 
interest. Inbred rats are often used to fix genetic traits and offer an advantage as 
symptoms and complications occur at a predictable age (Ganten, 1987).
1.2.2 Spontaneously Hypertensive Rat
The SHR is over 10-fold more popular than that of the next nearest model of 
hypertension, the closely related SHRSP (Pinto et a l, 1998). In 1959 Okamoto and 
Aoki started selective breeding for high blood pressure in a colony of Wistar rats. The 
normal blood pressure in these animals ranged from 120-140mmHg. However, their 
starting point was identifying a male animal which consistently had a systolic blood 
pressure of 145-175mmHg, which they mated with a female at 130-140mmITg. After 6 
generations of selecting for blood pressui'e and brother-sister mating, a population of 
rats had been produced where blood pressure was consistently >180mmHg by 20 weeks 
of age. Subsequent brother-sister mating was used to fix this strain, culminating in 
October 1969 with the SHR as we now know it (Yamori & Lovenberg, 1987).
The SHR has since been distributed world-wide, with many institutions and commercial 
breeders maintaining colonies 20 years or more distant from their progenitors. It can 
therefore be expected that significant genetic drift due to chance mutations will have 
occurred over this time frame, which may lead to variability in data generated from 
different laboratories (Yamori & Lovenberg, 1987).
The SHR has many similarities with man in the pathophysiology of hypertension. For 
example;
1. Blood pressure increases with age (however, onset during development in the rat).
2. Haemodynamic pattern is similar. In established hypertension both have normal 
cardiac output and increased total peripheral resistance.
3. Both exliibit LVH with poor correlation to blood pressure and involvement of non- 
haemodynamic factors.
4. Heart failure develops in a sub-set of animals at 18-24 months of age.
5. Both show increased vascular resistance across most vascular beds.
6. Impaired endothelium-dependant relaxation (as with all rat models of hypertension).
7. Increased proteinuria, decreased creatinine clearance, although renal failure has not 
been described in the SHR
8. Resetting of the baroreceptors (increased heart rate)
9. Salt-sensitive: further increase in blood pressui'e with dietary NaCl.
10. Genetic susceptibility (polygenic).
11. No loiown primary aetiology (95% of human hypertensives are essential)
12. Treatment that is effective in rats is usually effective in man.
13. Early neuronal involvement i.e. sympathetic nervous system.
However, unlike humans, the SHR, in common with all other rat models, does not 
exhibit tluombotic or atherosclerotic lesions, and has a low incidence of stroke. It also 
has a lower body weight than age-matched controls, whereas, there is a tendency for 
human hypertensives to be overweight (Frohlich, 1986; Pinto et a l,  1998).
The underlying defects contributing to hypertension in the SHR are poorly understood. 
The initiating event is thought to be an increase in peripheral resistance due to increased 
neurogenic vasoconstriction, which is maintained due to structural alterations in the 
vessel walls (Yamori & Lovenberg, 1987). Evidence for this will be discussed below. 
The Wistar Kyoto rat (WKY) is commonly used as a normotensive control strain for 
both SHR and SHRSP, but may not be ideal for the job. In the original selection by 
Okamoto and Aoki, 26% of WKY males and 16% of WKY females exhibited 
spontaneous systolic blood pressure greater than 150mmHg (Yamori & Lovenberg, 
1987). This contrasts with the Sprague-Dawley strain where no rats were in this range 
when selecting for Lyon hypertensive animals (Vincent & Sassard, 1987). This suggests 
that WKY may not always be a true normotensive control. When other genetically 
hypertensive strains such as the Sabra rat and Milan hypertensive rat were developed, 
the normotensive reference strain was developed simultaneously with selection for low 
blood pressure (Ben-Ishay et a l, 1987; Horie et a l, 1986). This type of bi-directional 
selection was not employed for the WKY and may explain why the WKY has the 
highest blood pressure of any of the normotensive reference strains (Horie et a l,  1986). 
However, the WKY is the only option with the appropriate genetic background for the 
SHR.
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The genetic homogeneity of SHRs and WKY was tested in five different breeding 
colonies using DNA fingerprinting with mini-satellite markers to identify areas of 
genetic variability, by Samani et al. (1989). The authors found the SHR from all 
sources to be identical, but WKY rats showed genetic heterogeneity. The most likely 
explanation is that the founding animals of the WKY colonies were distributed before 
they were fully inbred. The genetic heterogeneity of WKY colonies may explain, along 
with environmental interactions, why discrepancies occur in results comparing SHR 
with WKY in different laboratories. (Samani et a l, 1989)
1.2.3 SHRSP
Working with the SHR in 1971, Okamoto and colleagues had three main substrains. 
They noticed that the incidence of cerebral lesions (or stroke) was high in substrain A, 
but low in substrains B and C. They used this as a basis for selectively breeding the 
stroke-prone phenotype, using the offspring of couples in which one or both parents had 
developed spontaneous stroke. This was no mean feat requiring thousands of cross 
matings and over 10 000 offspring. Before selective breeding, the incidence of stroke in 
males from sub strain A was 39% and was increased by the mating programme to 77%. 
In contrast, B and C substrains had an incidence of only 5%.
The SHRSP exhibited a more rapid increase in blood pressure compared to the SHR, 
and peaked at 240-25OmmHg systolic compared with a maximum of 200mmHg in the 
SHR. In those developing strokes, the lifespan of the male was 33-41 weeks, and in the 
females 68 weeks (Okamoto et a l, 1974).
Most animals dying of stroke had macroscopically visible lesions. The most common 
lesion site was in the left occipital area, affecting 38%, and in the right occipital area 
(26%). The remainder tended to occur in the left or right frontal and medial regions. 
The area affected corresponded with the boundary between the main cerebral arteries, 
the middle cerebral and anterior or posterior cerebral artery. The authors noted a poor 
collateral supply in this area. Lesions included both intracerebral haemorrhage and 
infarction. The incidence of stroke was intricately linked with blood pressure, with 
large increases in blood pressure at an early age being associated with an increased 
incidence of stroke. However, blood pressure is not the only factor controlling stroke 
incidence. When fed 1% NaCl in drinking water, SHRs had a blood pressure similar" to 
SHRSP, but still had fewer cerebral lesions (50% versus 80% in SHRSP) (Okamoto et 
a l, 1974).
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Hypertensive rat models have seldom been compared directly, with most of the data 
coming from independent studies. However, Horie et al. (1986) compared seven 
genetically hypertensive rat strains in the same laboratory under identical conditions at 
12 weeks of age. Ranlc blood pressure order was SHRSP>SHR>Lyon>NZ genetically 
hypertensive>SS/Jr>Milan>Sabra. Two populations of SHRSP were tested, one colony 
from Japan, another from the USA. These had systolic blood pressures of 227mmHg 
and 193mmHg respectively, which may suggest genetic drift in this strain. The SHRSP 
also had the most severe left ventricular hypertrophy when normalised to body weight 
and was the only strain to show a significant increase in aortic weight compared to its 
control at 12 weeks (Horie et a l ,  1986). Since the SHRSP clearly has the most severe 
hypertension and cardiac and vascular hypertrophy, it is often used as a model of 
hypertension, but is obviously limited by a short life-span due to stroke.
Pathogenesis of hypertension
1,2.4 Genetics
The genetic basis of hypertension is apparent in the observation that offspring of 
hypertensive parents are themselves much more likely to develop hypertension. In 
addition, correlations between blood pressure in related individuals improves in 
proportion to the genetic similarity of the subjects studied. For example, blood pressuie 
correlates are better between identical twins, than between non-identical twins (Feinleib 
et a l ,  1977). In families with both adopted and biological children, parental blood 
pressure significantly correlates with the blood pressure of biological, but not adopted, 
offspring (Biron et a l ,  1976; Mongeau et a l,  1986).
Several unknown genes are thought to contribute to hypertension, each with a small but 
additive effect. These interact with environmental factors such as stress and a high salt 
diet. Sensitivity to NaCl may itself be genetically controlled, and not all hypertensives 
are sensitive to salt. Thus, the combination of genes contributing to hypertension may 
differ in different etlmic populations (Burke & Motulsky, 1992).
The candidate gene approach has been utilised to link alterations in a specified gene 
with hypertensive phenotypes. Candidates have been selected for their Icnown 
involvement in the pathophysiology of the disease e.g. RAS components, ion transport 
systems, and ANP. However, results have been inconsistent and no consensus has been 
formed on the involvement of any single gene, with the possible exception of
12
angiotensinogen. Total genome scans are now being used by linking traits with a large 
number of polymorphic markers spread throughout the genome. This approach is more 
powerful due to its ability to identify novel genes (Hoike & Jacob, 1998).
In genetically hypertensive rats, several putative gene loci on at least ten chromosomes 
have been described as cosegregating with hypertension. For SHR crosses, the loci 
have been described in or around genes for ACE, neuropeptide Y, nerve growth factor, 
renin, and substance P receptor. However, this does not prove the direct involvement of 
these genes as they may simply be cosegregating with other nearby genes (Dominiczak 
et a l ,  1998; Hoike & Jacob, 1998). In the SHRSP, three quantitative trait loci for blood 
pressure have been described by this laboratory, with two found on chromosome 2 and 
one on clnomosome 3 (Clark et a l ,  1996).
Further work in this laboratory has demonstrated that a proportion of the genetic 
influence of hypertension resides in the Y chromosome. SHRSP and WKY crosses were 
created with the male progenitor being either SHRSP or WKY. Blood pressure in the 
resulting F% generations were measured by radiotelemetry. Those animals with an 
SHRSP Y clnomosome had significantly higher systolic and diastolic pressures at 
baseline and after salt loading (Davidson et a l ,  1995).
1.2.5 Sympathetic nervous system
An overactive sympathetic nervous system has been implicated in the pathogenesis of 
hypertension. There is evidence of perivascular sympathetic hyperinnervation in the 
pre-hypertensive SHRSP. At 30 days of age, SHRSP had significantly higher densities 
of adrenergic nerve fibres in the middle cerebral artery compared to WKY. This 
difference gradually decreased in the fully hypertensive stage. Such hyperinnervation 
may play a role in the development and maintenance of hypertension by increasing 
peripheral resistance, and similar differences have been observed in the SHR (Kondo et 
a l,  1991).
The association of sympathetic hyperinnervation with hypertension was confirmed in a 
study by Brock et al (1996). They injected a single dose of anti-serum to nerve growth 
factor (NGF) in 3-week-old SHR and WKY. They found that when blood pressure was 
measured at 3-4 months, mean blood pressure was significantly reduced in the SHR, 
while it remained normal in the WKY. This indicates that hyperinnervation is 
necessary to initiate hypertension in this model. More wholesale destruction of the 
sympathetic nervous system using sympathectomy by anti-NGF, guanethidine injections
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and removal of the adrenal medulla at an early age, prevents not only hypertension, but 
cardiac and vascular hypertrophy too (Lee ei al., 1991a).
Nerve growth factor itself has been reported to be elevated in mesenteric artery, spleen 
and sciatic nerves, in 3 week old SHR (Ueyama et al., 1992). The renin angiotensin 
system may participate in regulating tissue concentrations of NGF in the SHR. Infusion 
of exogenous angiotensin II to young WKY rats increases nerve growth factor to SHR 
levels. In addition, treating young SHR with Losartan completely prevents the nerve 
growth factor elevation (Jefferson et al., 1995). It has been suggested that a decrease in 
sympathetic iimervation could explain why ACE inhibitors can maintain lower blood 
pressure for some time after cessation of treatment (Charchar et a l ,  1998).
There is also increased density of neuropeptide Y-containing nerve fibres in the 
mesenteric and caudal arteries of the SHR at one month and ten months old. 
Neuropeptide Y is vasoconstricting and is trophic for vascular smooth muscle cells, so 
an increase in the prehypertensive stage may have a role in the pathogenesis of 
hypertension (Fan et a l,  1995; Michel & Rascher, 1995).
In summary, there is strong evidence for activation of the sympathetic nervous system 
in the pre-hypertensive SHR and SHRSP, which may be an important early factor in the 
development of hypertension.
1.2.6 Atrial natriuretic peptide (ANP)
ANP is expressed in the normal heart with the atria being the major site of production. 
In normotensive WKY rats, expression of ANP niRNA in the left ventricle is only 
aromid 7% of atrial levels, with peptide concentrations at about 1%, such that 95% of 
secreted ANP originates from the atria (Ogawa et a l,  1991). Similar patterns for 
relative abundance have been demonstrated in normotensive human subjects 
(Mukoyama et a l ,  1991; Saito et a l,  1989). In the SHRSP, ANP secretion from the 
whole heart increases by approximately 50%, particularly in the LV, which experiences 
a 30-fold elevation in ANP secretion, so much so in fact, that in the hypertensive heaid, 
the LV becomes the primary source of ANP secretion (Ogawa et a l ,  1991). The role of 
the natriuretic peptides in blood pressure control is outlined in figure 1.2.
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Figure 1.2 The role o f natriuretic peptides in blood pressure control. Adapted from 
Levin et al. (1998).
ANP is released from the atria in response to stretch, but also from the LV when it 
hypertrophies. In models of renal hypertension with volume expansion 
(1 Kidney,!Clip), there is a positive correlation between plasma ANP and blood 
pressure. Interestingly, within 6 hours of reversing hypertension, plasma ANP 
concentrations are close to normal, despite continued presence of LVH. This suggests 
that control of ANP secretion responds in a sensitive and dynamic way to increased 
atrial stretch (Garcia et a i ,  1987). The left ventricle can also respond to stretch with 
secretion of ANP. In isolated perfused rat hearts, increased LV pressure elicits a 
stretch-dependent increase in active ANP secretion. Both hypertensive and 
normotensive animals can react in this way, however, there is also a significant 
correlation between ANP secretion and LVH in the SHR (Kinnunen et a i ,  1992). In 
patients with mild untreated hypertension, ANP plasma levels may be normal, although 
there is a positive relationship with atrial size and LV septal thickness. In long-term 
treated hypertensives, ANP is generally increased and probably reflects chronic 
exposure to increased blood pressure or cardiac involvement (Testaert et a i ,  1989).
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Infusion of ANP is loiown to have acute vasodilator effects, which result in a reduced 
mean arterial pressure and LV filling pressure, with no change in cardiac output. By 
comparing the haemodynamic effects of ANP and sodium nitroprusside infusion in 
hypertensive subjects, Semigran et al (1994) demonstrated that the haemodynamic 
profile of ANP is due to reduced pre- and after-load, with no direct effects on the heart 
to alter systolic or diastolic performance (Semigran et a l , 1994). However, ANP is not 
without effect in the heart. In normotensive rats, ANP may enhance reflex bradycardia 
in response to rapid blood pressure elevation via an influence on afferent cardiac vagal 
nerves. In the SHR, this effect is lost, and appears to be related to the presence of LVH 
(Thomas C.J. et a l ,  1998). The consequences for patients with LVH is a loss of a 
potentially cardioprotective action of ANP to protect from rapid rises in afterload.
1.2.7 Brain natriuretic peptide (BNP)
BNP is also expressed in the normal heart, but with a different pattern of distribution. 
In the normotensive WKY, BNP mRNA is expressed in all four chambers. Expression 
in the LV is around 40% of atrial levels, but when corrected for tissue weight, it 
becomes clear that the LV is the dominant source of BNP in the heart, accounting for 
around 60% of total heart secretion (Ogawa et a l,  1991). This does not appear to be the 
case in the dog, where BNP levels in the LV are virtually undetectable, and atrial 
sources are dominant (Luclmer et a l,  1998). However, the rat pattern of distribution 
more closely mirrors the situation in normotensive human subjects (Mukoyama et a l,
1991).
In the hypertensive heart from SHRSP there is a 2-fold increase in BNP mRNA 
expression and BNP secretory rate (Ogawa et a l ,  1991). Brosnan et al  (1999b) describe 
significantly higher plasma concentrations of BNP in SHRSP compared to WKY. BNP 
gene expression is switched on in the process of myocyte cellular hypertrophy, 
discussed later (Molkentin et a l ,  1998). The haemodynamic and natriuretic properties 
of BNP are similar to ANP.
1.2.8 Vascular function
Endothelium-dependent relaxations are impaired in the SHR and in a wide variety of 
other hypertensive models. This parallels the blunted response to acetylcholine found in 
the forearm of hypertensive patients, while responses to NO-donating vasodilators are
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normal, confirming that the defect is at the endothelial level and not the smooth muscle 
cells. Further to this, NOS blockade (eg with L-NAME) causes less vasoconstriction in 
hypertensive patients than in normal controls suggesting that basal as well as stimulated 
release of NO is impaired (Vanlioutte, 1996). Such defects in the nitric oxide pathway 
have been implicated in the pathogenesis of hypertension and may contribute to the 
increase in peripheral resistance.
Classical organ bath studies using aortic rings have shown that endothelium-dependent 
relaxation in response to ACh is impaired in both SHR and SFIRSP versus WKY. This 
dysfunction may be secondary to elevated blood pressure since it was not present in 12- 
week-old rats despite already being fully hypertensive (Shimamura et a l ,  1991). 
Impaired endothelium-dependent relaxation and reduced basal activity of NOS have 
also been described for the SHRSP compared to WKY in this laboratory (McIntyre et 
a l,  1997).
Other studies suggest that impaired NO production is not the primary underlying factor 
in the pathogenesis of hypertension in the SHR. Indeed, Vaziri et al  (1998) 
demonstrated that NO production was actually increased in the plasma and aorta in both 
3-week-old prehypertensive and 12-week-old SHR, perhaps to compensate for increased 
tone. At the protein level, SHRs had more eNOS and iNOS in the aorta and kidney 
(Vaziri et a l ,  1998). Basal nitric oxide release is normal in the small coronary arteries 
(200pm in diameter) of the 20-week-old SHR, (Garcia & Bund, 1998) as measured in 
isolated vessels using a pressure myograph (Bund, 1998). However, conflicting results 
are obtained in the coronary circulation in rats of the same age when using a whole- 
heart Langendorff preparation. Basal and maximal coronary flow is reduced in the SHR, 
as is the L-NAME sensitive flow suggesting a reduced production of NO (Crabos et a l ,
1997). It seems likely that different vascular beds and vessel sizes will produce 
dissimilar results, depending on their exposure to elevated pressure and shear stress 
(Qiu et a l,  1998).
Human resistance arteries from hypertensive subjects have been studied using perfusion 
myography of subcutaneous vessels obtained from buttock biopsies. The results 
obtained are in broad agreement with results from animal models. In such a study by 
Falloon and Heagerty (1994) endothelium-dependent relaxation to ACh was 
significantly impaired in hypertensive patients compared to normotensive controls, 
while relaxation to nitrovasodilators was unaffected. Contractions to noradrenaline 
were identical, but on removal of the endothelium, the increased response to
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noradrenaline was significantly greater in the normotensive subjects. This suggests that 
endothelium-dependent relaxation is defective in hypertensive patients at the level of 
the endothelium, and that basal release of endothelium-derived relaxing factors 
(EDRFs) is lower in hypertensives (Falloon & Heagerty, 1994).
Role o f  superoxide
Impaired endothelium-dependent relaxation and increased basal tone may be explained 
by differences in nitric oxide production or availability i.e. how much nitric oxide 
actually reaches the smooth muscle cells. In vivo, nitric oxide may be inactivated by 
superoxide before it has time to diffuse to the site of action. Tschudi et al. (1996) used 
a porphyrinic microsensor to directly measure nitric oxide released from isolated third 
order mesenteric resistance arteries in SHRSP and WKY. On maximal stimulation of 
nitric oxide by calcium ionophore, the concentration of nitric oxide was significantly 
lower in the 15-week-old SHRSP compared to WKY. This difference was abolished in 
the presence of superoxide dismutase (SOD), which scavenges superoxide. This 
suggests that NO production is similar between SHRSP and WKY, but that NO 
availability is lower due to inactivation by superoxide (Tschudi et a l ,  1996).
Grimfeld et al (1995) used endothelial cells cultured from the aortas of SHRSP and 
WKY rats to directly measure nitric oxide production using a porphyrinic microsensor. 
Stimulated release of NO in response to bradykinin was much lower in the SHRSP cells 
at approximately one-third of WKY values. Pre-treatment with superoxide dismutase 
(SOD) increased NO production in both groups. However the relative increase in 
released NO was significantly greater from SHRSP cells suggesting the SFIRSP 
produces more superoxide to reduce NO availability. This was confirmed by direct 
measurement of superoxide using a chemiluminescent teclmique, where SHRSP cells 
produced almost double the concentration of superoxide (0%') than WKY cells.
These results were mirrored in organ bath studies of aortic rings. As expected, 
endothelium-dependent relaxation to carbachol was impaired in the SHRSP. They then 
added diethyldithiocarbamic acid (DECTA), an inhibitor of endogenous SOD, to 
quantify the accumulation of O2’ by measuring its effect on reducing carbachol 
relaxations. The percentage decrease in relaxation to carbachol was greater in SHRSP 
aortic rings, indicating enhanced O2 ' accumulation in hypertensive animals (Grunfeld et 
a l,  1995).
An increase in O2 ' production in the SHRSP was confirmed in a further study by this 
group using lucigenin chemiluminescence (Kerr et a l,  1999). If this were the case, we 
would expect some benefit of antioxidant treatment in removing excess superoxide. 
Indeed, infusion of Vitamin C into the forearm of humans increases the response to 
acetylcholine presumably due to an antioxidant effect (Taddei et a l,  1998).
Other defects are suggested by rat models. Acetylcholine can cause contraction in 
quiescent aortic rings of the SHR due to release of endothelium-derived contracting 
factors (EDCFs), which ai'e not observed in the WKY. These contractions can be 
abolished with indomethacin, indicating that EDCFs are cyclooxygenase products 
(Vanhoutte, 1996). A similar effect is observed in the mesenteric arteries of the SHRSP 
(Sunano et a l , 1999), and in hypertensive subjects where indomethacin can restore 
normal responses to infused acetylcholine (Vanlioutte, 1996). It has been increasingly 
realised in recent years that the endothelium releases hyperpolarising factors (EDFIF) 
which may participate in normal relaxation of some arteries, and may be reduced in 
hypertensive animals (Taddei et a l, 1998). Using electrophysiological techniques, 
Simano et a l  (1999), observed that the hyperpolarisation in response to acetylcholine 
was smaller in the SHRSP compared to WKY, implicating that a reduced release of 
EDHF contributes to vascular dysfunction in the SHRSP.
Significance o f  endothelial dysfunction
Endothelial dysfunction is associated with increased cardiovascular risk and further 
deteriorates if associated with other risk factors such as ageing, diabetes mellitus, 
smoking and post-menopause. This close association with risk is probably related to the 
loss of the inhibitory effects of NO on platelet aggregation, smooth muscle cell 
proliferation and expression of adhesion molecules. Thus loss of NO availability 
promotes thrombosis and atherosclerosis. This suggests that correcting endothelial 
dysfunction should be a major goal of antihypertensive treatment in order to reduce 
long-term cardiovascular risk. Successful treatment must specifically correct NO 
availability and not simply improve endothelium-dependent relaxations (Taddei et a l ,
1998). ACE inhibitors may improve vascular function in two ways by preventing the 
local production of the potent vasoconstrictor Angll, and preventing the breakdown of 
vascular bradykinin. (Vanlioutte, 1996). However, even after two to tliree years of ACE 
inliibition, relaxation to acetylcholine was improved, but not normalised in patients with
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essential hypertension. This may be explained by a genetic component to endothelial 
dysfunction. Impaired acetylcholine relaxations have been observed in young 
normotensive offspring of patients with essential hypertension (Taddei et a l ,  1998).
To summarise, impaired endothelium-dependent relaxation probably occurs secondary 
to hypertension. NO production may be normal or even elevated in the young SHR, but 
deteriorates with age until marked defects in the L-Arginine/NO axis may become 
apparent. Both a decrease in NO production and decreased availability may be involved 
in the advanced stages.
1.2.9 Vascular structure
Hypertension is characterised by an increased total peripheral resistance (Struyker 
Boudier et a l ,  1990). Elevated neurohormonal output is thought to increase blood 
pressure, which results in structural adaptations in the vasculature such that blood 
pressure is maintained or deteriorates (Mulvany, 1991). The structural alterations 
governing this consist of:
1) Reduction in lumen diameter of arterioles and resistance arteries
2) An increase in arterial wall mass
3) Rarefaction of arterioles and capillaries (fewer parallel vessels and/or , reduction in 
vessel luunber)
The relative importance of structural versus functional abnormalities is poorly 
understood (Struyker Boudier et a l,  1990; Mulvany, 1991). However, structural 
changes need not be great to have a powerful effect, as vascular resistance is determined 
by Poisseuille’s law: 
l . S n L  
R = N
Wliere N = number of blood vessels 
L = length of vessels 
n = viscosity of blood 
r = radius of the vessel 
R = total resistance
Therefore, a small change in lumen diameter can have large effects on resistance, as the 
relationship is to the power of four.
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Vascular remodelling
The term “remodelling” was originally coined to describe a change in wall/lumen ratio 
with no change in media cross sectional area, i.e. rearrangement of material around a 
smaller or larger lumen. Since then “remodelling” has been used to describe any 
structural alteration in blood vessels. In order to restore descriptive power to the term, 
Mulvany ei al. (1996) suggested a new terminology with recent modifications 
(Mulvany, 1999). This is shown below in figure 1.3.
hypotrophic eutrophic hypertrophic
inward
outward
Figure 1.3 The Mulvany nomenclature for describing re-modelling of blood vessels 
in cross-section from the central starting point (reproduced from Mulvany, 1999).
In brief, they proposed that remodelling could result in inwai'd or outwai'd remodelling 
of the lumen diameter and be subclassified as hypotrophic (decrease in cross sectional 
area), eutrophic (no change in cross sectional area) or hypertrophic (increase in cross 
sectional area) (Mulvany, 1999).
They also included some important clarifications:
1) That the term remodelling only truly applies to changes that occur in one vessel e.g. 
before and after an intervention, or pathology, and not between. For example age-
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matched normotensive and hypertensive. When used in this context, remodelling 
describes a “difference in development” as the hypertensive artery may never have 
been identical to the normotensive and so it is wrong to say that it has remodelled 
from it.
2) Remodelling of an artery is not necessarily towards a pathogenic state. It may for 
instance describe an element of normal growth.
3) Eutrophic remodelling describes a situation of no net change in cross sectional area. 
This does not preclude considerable structural alterations which balance each other 
out e.g. smooth muscle cell hypertrophy and apoptosis resulting in no net change 
(Mulvany, 1999).
However, a consensus view has yet to be established on the proposed terminology, 
which provoked considerable debate when first published. In the ensuing 
correspondence, a number of pertinent points were raised which are worth mentioning 
here. In the SHR (and SHRSP) hypertensive remodelling occui's at a young age and so 
is superimposed upon a growing and developing vasculatine and is therefore not simply 
a rearrangement of materials (Korner & Angus, 1997). The remodelling process is 
therefore likely to be different from human arteries, where alterations in response to 
hypertension develop within a matm'e vasculature, and may be a product of many years 
of elevated blood pressure.
With regard to the nomenclature, Lee et al  (1997) make several important points. 
Firstly, there is no agreement on standard methods for measuring structural changes. 
Thus, results may be method dependent. Wire-myography requires stretching the vessel 
on wires, which is distinctly non-physiological. Pressme-myography may cause vessel 
elongation thereby affecting lumen size, and there is no agreement on intravascular 
pressure at which to take measurements. Lee et a l  conclude that in situ methods such 
as intravital microscopy or confocal microscopy of pressure-fixed vessels represent the 
best techniques for quantifying structure in the relaxed state. Secondly, Lee and 
colleagues highlight that the Mulvany terminology fails to include scenarios where no 
change in lumen diameter occurs.
In a commentary by Folkow (1997) he questions the pre-occupation with wall thiclaiess 
and stresses the importance of inner radius (q), as it is q that determines vasculai" 
resistance and therefore flow. Folkow makes the reasonable suggestion that 
remodelling can be adequately described by simply stating percentage changes in q and
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wall/ii ratio, which is far more descriptive, and provides quantitative information on 
haemody namics.
Differences of structural adaptations often occur between different vascular beds. Given 
the number of factors that may control vascular growth, this should not be surprising 
e.g. growth factors, neurotransmitters, hormones, cytokines, extracellular matrix 
components, mechanical stimuli, and local autocrine factors (Daemen & de Mey, 1995). 
It would be remarkable if  all these factors maintained similar profiles regardless of the 
organs they serve. This point is illustrated in table 1.3, which lists some of the ways in 
which the vascular endothelium can effect vascular growth.
Table 1.3 Possible mechanism for endothelial control of vascular growth
Effect of endothelium Example
Shields smooth muscle cells from circulating 
growth factors
Insulin, IGF, growth hormone
Shields smooth muscle cells from platelet-derived 
growth factors
PDGF, TGF-p
Controls monocyte and T lymphocyte infiltration, 
therefore controls exposure to cytokines
IL-l,IL-2, IL-6
Local ACE monoamine oxidase activity Ang II, 5-FIT
Production of growth promoters EGF, FGF, IL-1, IL-6, PDGF, 
endothelin
Production of growth inliibitors TGF-|3, interferon-y, PGH
Respond to haemodynamic changes, therefore 
affects wall/lumen ratio
Blood flow, shear stress 
-»  Control lumen diameter by 
release of PGH, NO etc.
Compiled from Struyker Boudier et a l ,  1990; Owens, 1989.
Resistance arteries
Resistance arteries have been defined as pre-capillary arteries with internal diameter no 
greater than 500pm. They aie so called, as it is in these small aiteries where the 
increased peripheral resistance of essential hypertension is thought to reside (Heagerty 
et a l ,  1993). Pressure measurements in the SHR from aorta to capillaries suggests that
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the greatest resistance to blood flow resides in the small arteries and more distal 
arterioles (Mulvany, 1991).
In a study by Aalkjaer et a l,  (1987), resistance arteries were obtained by subcutaneous 
biopsy from subjects with essential hypertension, and mounted on a myograph. Vessels 
from hypertensives had an increased media/lumen ratio and gave an increased maximal 
response to all contractile agonists tested, with no change in sensitivity. This increase 
was directly related to greater media thiclaiess as active media stress (force per CSA of 
smooth muscle) was normal (Mulvany, 1991a). Likewise in the SHR, as a consequence
 -5of increases in media-to-lumen ratio, the maximum force generated in response to 
contractile agonists is higher (Mulvany, 1991b). This increase in wall/lumen ratio is j
most prominent in vessels larger than 100pm lumenal diameter (Mulvany, 1991a).
Structural alterations may be a result of growth or loss of material, or as rearrangement 
of existing material (remodelling). Vascular smooth muscle cells in the SHR are not 
thought to exhibit hypertrophy, i.e. individual cell volume does not change. Likewise in 
human subcutaneous resistance arteries re-organisation of existing material probably 
accounts for medial changes (Mulvany, 1991b). In human essential hypertension, most 
evidence suggests that resistance vessels exhibit inward eutrophic remodelling. That is, 
a rearrangement of existing material around a smaller lumen (Mulvany, 1999).
However, data from this laboratory using confocal microscopy, has demonstrated 
hypertrophic inward remodelling in the mesenteric resistance aiteries of the SHRSP. 
Compared to WKY, lumen diameter was decreased, while wall CSA and thickness 
increased, indicating an increase in material. This was not due to smooth muscle cell 
hyperplasia as there was no change in cell number (Arribas et a l ,  1997). The same 
group, (Arribas et al  (1996) used the same technique in basilar arteries of SHRSP 
versus WKY. The pattern of remodelling was similar. Uniquely, they also discovered 
smooth muscle cell disorientation in the SHRSP, (normal smooth muscle cells lie 
perpendicular to the longitudinal axis of the vessel), which they speculated may 
represent a wealaress in the vessel and therefore could contribute to the pathogenesis of 
stroke in the SHRSP.
There is a wealth of evidence implicating Angll in vascular remodelling. Infusion of 
Angll results in hypertrophy of rat mesenteric resistance arteries (Daemen & de Mey,
1995), and resistance artery hypertrophy is regressed by ACE inhibitors, but not 
hydralazine (Struyker Boudier et al., 1990). Treatment, with ACE inliibitors, results in 
outward hypotrophic remodelling (Mulvany, 1999).
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Conduit arteries
During hypertension, flow-rate in large arteries is unchanged, and therefore so is lumen 
diameter. The media exhibits hypertrophy and hyperplasia to compensate for the 
elevated pressure i.e. to normalise wall-stress (Mulvany, 1999).
In the aorta of SHRSP, vascular smooth muscle cells exhibit polyploidy (multiple DNA 
copies in the absence of cell division) suggesting an increased cell mass. This can be 
prevented by treatment with perindopril or losartan (Dominiczak et al., 1996). Since a 
hypotensive dose of hydrochlorothiazide + hydralazine is ineffective in this regard, this 
indicates a role for Angll in smooth muscle cell hypertrophy independent of elevated 
blood pressure (Devlin et a l,  1995).
Angll could regulate vascular growth in several ways; 1) a direct trophic action on 
smooth muscle cells, 2) by releasing neuropeptides and/or growth factors, 3) via 
mechanical forces produced during Angll vasconstriction (Owens, 1989). Angll does 
not produce proliferation in rat aortic smooth muscle cells cultured in serum-free 
medium, but does result in cellular hypertrophy with associated protein synthesis. In 
the presence of serum, there have been conflicting reports stating that growth rates are 
either normal or greater with Angll present (Owens, 1989). In organoid culture of rat 
aortic segments, Angll stimulates protein synthesis but not DNA synthesis i.e. 
hypertrophy not hyperplasia, even under conditions of passive stretch (Holycross et a l ,  
1993).
There is good evidence for a local renin angiotensin system in the vascular wall. On a 
molecular level, all the necessary components have been described e.g. 
angiotensinogen, ACE and AT-receptors (Min et a l,  1993). On a functional level, ACE 
inliibitors can relax vessels in vitro. Also, the local tissue RAS can alter tone in vessels 
downstream. In an elegant study using carotid (donor vessel) and mesenteric resistance 
artery (recipient) perfused in series, Angll was released from the carotid to cause 
constriction in the recipient. Blocking this with ACE inhibitors increased the diameter 
of the recipient artery (Henrion et al., 1997).
The carotid artery of hypertensive rats exhibits reduced compliance (dv/dP) i.e. a stiffer 
vessel wall. Vasomotor tone is one component of this, as compliance increases when 
smooth muscle cells are poisoned with potassium cyanide. However, compliance 
remains lower than normotensive animals, indicating an influence of underlying 
structural changes. Alterations in the elastin-to-collagen ratio are thought to be
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intimately involved in this process, as these components contribute considerably to the 
mechanical properties of the vessel. For example, collagen content has been found to 
increase with both age and hypertension thereby stiffening the vessel wall. In man 
concomitant atherosclerosis may play a contributory role (Safar et a l ,  1992).
The consequences of reduced large artery compliance are an increase in pulse pressure, 
which in the older patient is an independent risk factor for LVH and coronary heart 
disease (Safar et a l ,  1992). Likewise, elevated pulse pressure was found to be a major 
predictor of LVH in a F2 cohort of a SHRSP x WKY cross (Dominiczak et a l,  1996).
Microcirulation
The structure of the microcirculation may also be altered in the hypertensive state via a 
variety of mechanisms e.g. increased tone, temporaiy shut-down of microvascular 
networks or rarefaction of capillaries and terminal arterioles. The microcirculation 
consists of arterioles and capillaries distal to the resistance arteries with a diameter of 
less than 120pm. It functions to maintain optimal hydrostatic pressure to allow efficient 
capillary transfer. The blood pressure entering the microcirculation is a matter of 
continuing debate, and may range anywhere from 3 5-9OmmHg depending on tissue and 
species studied. There is however, consensus that by the level of the capillaries, no 
difference in blood pressure is observed between hypertensives and normotensives. 
Therefore, the microcirculation must be responsible for a considerable proportion of the 
pressure gradient (Vi cant, 1992). As with the resistance arteries, the micro circulation of 
hypertensive rats demonstrates an impaired endothelium-dependent relaxation. For 
example, the very small pre-capillary arterioles in skeletal muscle have increased 
vascular tone in the SHR versus WKY, as measured by dilatation to locally applied 
vasodilators using intravital microscopy (Schmid-Schonbein, 1987). Changes in media- 
to-lumen ratio or medial CSA may also occur but are highly variable between and even 
within, vascular beds. The mechanisms involved are likely to be similar to those 
discussed above for resistance arteries (Vicaut, 1992).
A potentially important additional mechanism is arteriolar rarefaction. This has been 
described in the skeletal muscles of genetic and renal hypertensive models, whereby 
constriction of terminal arterioles occludes the vessel to such an extent, that 
erythrocytes can no longer pass (Vicaut, 1992). This has also been described in the 
fingers of patients with moderate hypertension, where both temporary closure and 
anatomical absence of capillaries were noted (Antonios et a l ,  1999). Such closure of
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whole vessels may have consequences for end-organ damage. For example, reduction 
in capillary density due to rarefaction may significantly increase oxygen diffusion 
pathways, affecting the ability of the circulation to meet tissue oxygen demands at times 
of increased metabolic need. This may sensitise tissue to hypoxic damage (Vicaut,
1992).
Coronary arteries
Vascular changes in the left anterior descending (LAD) coronary artery occm* early in 
the development of hypertension in the SHR, mirroring the early rise in LVH. At 45- 
days-old, Anversa et al. (1984) demonstrated marked fibrotic changes within the aterial 
wall with a 119% increase in collagen and ground substance. In addition, elastin 
increased 77% and smooth muscle mass by 34% compared to age-matched WKY. 
These changes were not observed at 28 days when blood pressure was already higher in 
the SHR. This suggests that such alterations occur secondary to hypertension, but early 
enough (at 6 weeks) to influence blood pressure development, which does not peak until 
12 weeks. Changes in structural proteins such as collagen and elastin may reduce 
vascular compliance, while smooth muscle cell mass may alter media-to-lumen ratio. 
The role of these changes in end-organ damage e.g. MI and heart failure, needs to be 
assessed. These findings have been confirmed in twenty-week-old SHR (Crabos et al., 
1997). Coronary flow-pressure curves in isolated perfused hearts indicate that in 
coronary resistance vessels the media encroaches into the lumen even when maximally 
dilated and at normal vascular tone (Hallback-Nordlander et a l,  1979).
Cause or effect?
Wliether structural changes have a primary role in the pathogenesis of blood pressure or 
represent a secondary adaptation is open to debate. Increased media thickness of small 
arteries has been described prior to blood pressure elevation in the SHR. However, 
some commentators deny the existence of a prehypertensive stage in the SHR, stating 
that blood pressure is always higher than WKY (Mulvany, 1991). The rate of blood 
pressure rise after antihypertensive treatment may provide an indirect method of 
assessing importance of structural changes. In the SFIR, hydralazine has minimal effect 
on mesenteric resistance artery wall/lumen ratio and blood pressure rises rapidly after 
discontinumg treatment. In contrast, captopril is much more effective in normalising 
wall/lumen ratio and elevated blood pressure returns slowly when treatment is stopped.
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(Mulvany, 1991) However, given the multivarious mechanisms of ACE inhibition 
caution must be applied in interpreting such data in this way.
Early treatment of SHR with ACE inhibitors or ATi receptor antagonists for 10 weeks 
from weaning prevents the elevation in blood pressure that normally occurs in the first 
12 weeks of life. Upon cessation of treatment, a small residual antihypertensive effect 
is observed for up to 30 weeks, which does not occur when treatment is with [3-blockers, 
vasodilators, or calcium-channel antagonists (Mulvany, 1991). This indicates a role for 
Angll in the developmental stage of hypertension that has long-term implications for 
maintenance of elevated blood pressure. Mesenteric resistance arteries from these 
treated animals had a reduced media-to-lumen ratio as measured by wire myography. 
However, animals treated for four weeks post-weaning exhibited a similar long-term 
antihypertensive benefit with no reduction in media-to-lumen ratio, suggesting that 
small artery structural changes do not accomit for the long-term effects on blood 
pressure control (Mulvany, 1991).
To examine the question of whether structural changes are a cause or consequence of 
raised blood pressure, a partial ligatme of the iliac artery has been used in the 5-week- 
old SHR, such that distal to the ligature intravascular pressure was normal. Small 
femoral arteries from this distal portion were comparable to WKY vessels, while small 
arteries from the control hypertensive leg had a reduced internal diameter and increased 
media thickness. Thus, vessels from the same genetically hypertensive animal exhibit 
remodelling only when exposed to elevated blood pressure, suggesting structmal 
changes are a secondary adaptation (Heagerty et n/.,1993).
Regardless of structui’al changes, it appears that certain factors can override any effect 
they may have. For example, blood pressure in renal hypertensive rats (IK IC) returns to 
normal within hours of removing the clip, despite structural wall changes in the 
vasculature. A renal vasodilating factor has been implicated. Similarly, Angll infusion 
causes gradual rise in blood pressure over ten days accompanied with structural 
alterations in small arteries. However, blood pressure falls rapidly on stopping the 
infusion (Mulvany, 1991) This is evidence against a primary fundamental importance of 
vascular structural remodelling in the hypertensive state.
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1.3 Cardiac hypertrophy
As discussed earlier, cardiac hypertrophy is a common consequence of hypertension in 
response to pressure overload. In hypertensive patients, cardiac hypertrophy is an 
independent risk factor for increased cardiovascular mortality (Levy et a l ,  1990). The 
same process of hypertrophy is also observed in the surviving myocardium after 
myocai'dial infarction to compensate for loss of function. It seems likely, therefore, that 
maladaptive cardiac hypertrophy is one of the most important factors in the progressive 
deterioration in left ventricular function observed in hypertensive heart disease.
In discussing the pathophysiology of cardiac hypertrophy it is important to recognise a 
number of interacting factors. The hyperti'ophic response involves cardiomyocytes and 
non-myocytes and is linked to perivasculai' and interstitial fibrosis. The process of 
hypertrophy is not confined simply to enlargement of existing cells, but includes a shift 
to foetal isoforms of proteins that may be important in contraction. The relative roles of 
hypertrophic stimuli need to be examined. For example, the importance of pressure- 
overload or wall-stress compared to the pro-mitogenic effects of neurohumoral factors 
such as noradrenaline, angiotensin 11 or endothelin. Other systems may be in place to 
counteract these effects, and so keep hypertrophy in check e.g. nitric oxide and 
bradykinin. Hypertrophy may require the presence of permissive factors such as growth 
hormones or genetic susceptibility. In recent years progress has been made on 
elucidating intracellular signalling pathways that linlc the hypertrophic stimuli on the 
cell surface with changes in myocyte gene expression. All these factors will be 
discussed below with particular emphasis on disease progression.
1.3.1 The hypertrophic response
Hypertrophy may be defined at the organ level as an increase in LV internal diameter 
and/or wall thickness (Levy, 1991), or at a cellular level as an increase in cell size 
without cell division (Izumo & Aoki, 1998). Most commentators hold to the belief that 
cell division does not occur in myocytes after 3 weeks of age. Hypertrophy of 
myocytes and non-myocytes and hyperplasia of non-myocytes accounts for increased 
LV mass after this point (Tanase et al (1982b). It is possible to distinguish between 
hypertrophy and hyperplasia as the latter involves an increase in DNA content per 
milligram tissue.
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Not only do myocytes hypertrophy by increasing cross-sectional area they also change 
cellular composition, with a shift from adult to foetal phenotypes of several contractile 
and structural proteins. In the untreated SHRSP, gene expressions of the foetal 
contractile proteins skeletal a-actin and [3-myosin heavy chain (p-MHC) are increased, 
while mRNA for the adult isogene, a-MHC, is decreased (Kim et a l ,  1996). There is a 
strong positive relationship between LV a-M HC protein content and maximum rate of 
pressure development in rat hearts in vitro (Boluyt et a l ,  1991). Such changes may 
result in significant alterations in contractile performance, and represent a mechanism 
for the progressive deterioration of cardiac function leading to heart failure. 
Concomitant changes occur in molecules involved in interstitial fibrosis. For example, 
there is an increase in collagen type IV gene expression and in transforming growth 
factor-pi (TGF-pi) mRNA, which are laiown to stimulate collagen production. 
Interstitial fibrosis may lead to diastolic dysfunction by altering myocardial stiffness, 
thereby impairing left ventricular relaxation. There is also a 7.5 fold increase in ANP 
gene expression in the left ventricle of SHRSP compared to WKY (Kim et a l ,  1996). 
Similar results are obtained with LVFI due to aortic banding in the mouse, with 
upregulation of gene expression of ANP, BNP, p-MHC, and a down-regulation of 
SERCA (sarcoplasmic-endoplasmic reticulum calcium ATPase) (Harada et a l ,  1998), 
and after myocardial infarction in the rat (Reiss et a l,  1993), indicating that such 
changes occur across species and aetiologies.
1.3.2 Apoptosis in hypertrophy
The apoptotic index is higher in the heart of the SFIR at 8- 16- and 30-weeks-old versus 
WKY controls (Hamet et a l,  1995). This has been confirmed in the LV at 30-weeks, 
when the majority of affected cells were identified as myocytes. This could be 
prevented by treatment with losartan, even in animals where blood pressure was not 
normalised, suggesting blockade of ATi-receptors prevents apoptosis in the heart 
independent of haemodynamic effects (Fortuno et a l, 1998). This does not necessarily 
directly implicate Angll, as ATi-receptor blockade will effect other parameters such as 
ANP. Similarly, induction of apoptosis is more pronounced in cultures of vascular 
smooth muscle cells from the SHR (Hamet et a l,  1995). Therefore, at a time of active 
LV hypertrophy in the SHR, this is counterbalanced by an increase in apoptosis, 
suggesting a role in cardiac remodelling.
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1.3.3 LV function in hypertrophied hearts
When we talk about the hypertrophied heart being compensated, it means that despite 
the structural changes and increased afterload, systolic function is uncompromised. 
Indeed, the process of myocyte hypertrophy is a compensatory response to maintain 
function when faced with a prolonged increase in afterload. For instance, in isolated 
perfused hearts, maximal cardiac performance at high afterloads is better in 
hypertrophied SHR hearts than in hearts from normotensive animals. At any given 
pressure, the average tension per unit layer of cardiac muscle is actually lower than in 
non-hypertrophied myocardium. The structural adaptation of wall thickening allows 
normal stroke volume to be produced despite pumping against an increased arterial 
pressure. However, hypertrophy does result in a rightward shift in the Frank-Starling 
mechanism i.e. the SFIR has a lower stroke volume at diastolic filling pressures under 
1 OmmHg. This is compensated for by doubling the left atrial pressure to 1 OmmHg, at 
which stroke volume is almost normalised (Hallback-Nordlander et a l ,  1979). A 
similar picture of well compensated LV hypertrophy was described by Pfeffer et al  
(1979) for the 6 month old SHR in vivo. They found no difference between SFIR and 
normotensive controls for rate of developed pressure, stroke volume, end-diastolic 
volume, ejection fraction or maximum acceleration of aortic blood flow, indicating 
normal systolic function. Only peak developed pressure was higher in the SHR, which 
of course is necessary to pump normal stroke volumes against the increased afterload. 
More recently, echocardiography has been used in animal models to assess systolic 
function in vivo, and the results are consistent. Four to five weeks after aortic banding 
of the abdominal aorta in rats, LV mass is increased by 35%, but the heart remains well 
compensated. There are no changes in systolic or diastolic cavity dimensions, fractional 
shortening, ejection fraction or cardiac index and Doppler flow velocities through the 
aortic root and pulmonary valve are normal (Pawlush et a l, 1993).
With time, for reasons that are poorly understood, the hypertrophied heart is no longer 
able to maintain normal fimction, and this is termed decompensation. Systolic function 
may get progressively worse and when the heart can no longer meet the energy demands 
of the body, the heart is said to be in failure. By 18 months of age, SFlRs exhibit signs 
of cardiac decompensation. In males, left ventricular end diastolic pressure (LVEDP) is 
elevated, maximum stroke volume is decreased, as is ejection fraction from 73% in 6 
month old animals to 44%. There is also marked LV dilatation as end-diastolic volume
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increases, while -dP/dt, an indicator of ventricular relaxation, is normal. In short, 
systolic function is impaired while diastolic function is normal (Pfeffer et a l,  1979). 
Factors influencing decompensation and the consequences for the failing heart will be 
discussed later in this section.
Age is a major risk factor for cardiac hypertrophy (Levy, 1991), and the functional 
outcome of hypertrophy may also be less favourable. After aortic constriction in adult 
Fischer 344 rats, mild cardiac hypertrophy was associated with an increase in pressure- 
generating capacity, representing a beneficial adaptive response. However, the same 
procedure in aged rats (25-28 months) resulted in a decrease in pressure-generating 
capacity. The reasons for this age-related difference in adaptation are unknown, 
although aged-rats already have a lower proportion of a-M HC in the left ventricle 
(Boluyt et a l , 1989).
1.3.4 Influence of blood pressure
In both animal studies and man it is a common finding that blood pressure exhibits a 
poor correlation with LV mass. Although measuring ambulatory or maximum blood 
pressure during exercise achieves some improvement, the correlation co-efficient 
typically remains around 0.50-0.65 (Devereux et a l,  1991), and the correlation with 
diastolic pressure is even weaker (Devereux et a l,  1987). This suggests that although 
elevated blood pressure may be a trigger, it is not the sole determinant of hypertrophy. 
Blood pressure may not even be the initiating trigger in animal models of hypertension. 
In both the SHRSP and SHR, cardiac hypertrophy compared to WKY rats has been 
reported as young as 30 days when there is still no difference in blood pressure (Yamori 
et a l ,  1979). Although this result depends on the accuracy of measuring blood pressure 
in such young animals, it suggests greater importance for genetic or other trophic 
factors in determining LVH.
It is perhaps unsurprising that LV mass correlates poorly in established hypertension. 
Pfeffer et a l  (1979a) found that 6 month old female SHRs exhibited an increased LV 
mass of 25% compared to normotensive controls, and that 18 month old SHRs showed 
64% more hypertrophy, despite no further increase in blood pressure. Other factors 
must be involved in the continued increase in LV mass. A lack of dependence on blood 
pressure is also indicated in the SHR after peripheral sympathectomy. In that model, 
the elevation in blood pressure is prevented, and yet LV mass continues to rise
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(Cutilletta et a l,  1977), In a similar fashion, hydralazine may control blood pressure in 
the SHR but does not prevent LVH (Jespersen et a l ,  1985). Therefore, an increase in 
systolic blood pressure is not a requirement for LVH in the SHR.
In man, a clear relationship is also elusive. In one study examining normal and mildly 
hypertensive patients, combining measures of stroke volume and LV contractility with 
arterial pressine, gave a good correlation co-efficient with LV mass of 0.82. Neither 
parameter alone had a correlation co-efficient above 0.60, and this demonstrates that 
cardiac performance may also influence the hypertrophic response (Devereux et a l,  
1991). This makes sense as a decrease in function after myocardial infaiction is a 
trigger for hypertrophy (discussed later).
1.3.5 Influence of genetics
Tanase et al (1982a) attempted to quantify the extent to which LV mass is determined 
by genetics. In a large study of 23 inbred rat strains (including SHR & SHRSP), 
segregation analysis estimated that between 65-75% of the variability in LV mass was 
attributable to genetic causes. This suggests that genetic factors are more influential 
than blood pressure in determining heart weight. Analysis of normotensive strains 
alone showed a similarly large influence of genetic factors. It is not clear, therefore, 
from this study whether genetic influence plays a greater role in the development of 
hypertrophy compared to determination of normal heart weight. The authors conclude 
that LV mass is a highly heritable trait.
Since then, a number of studies have used the candidate gene approach to identify 
genetic loci that co-segregate with LV hypertrophy, independent of blood pressure. 
These include loci in or around the ACE gene on chromosome 10, the ET-3 gene on 
chromosome 3 and the renin gene on cluomosome 13. Genome wide scans have 
identified a QTL on chromosome 17 that is protective for LVH, and a QTL on 
cliromosome 14 in the SHRSP, which is a susceptibility gene (reviewed in Dominiczak 
e ta l ,  1997).
1.3.6 Role of the renin-angiotensin system
Neurohumoral activation during hypertension or after myocardial infarction is thought 
to have an important role in determining cardiac hypertrophy. A great deal of evidence 
exists to implicate activation of the RAS and in particular angiotensin II in this process. 
This has been strengthened by the discovery of a local cardiac RAS. Protein and
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mRNA expression of renin, angiotensinogen, ACE, and AT; receptors have all been 
identified in the heart (Yaniazaki & Yazaki, 1997). Stretching cardiomyocytes in 
culture has been showai to stimulate secretion of Angll directly from secretory granules 
in the ventricular myocytes, the concentration of which is high enough to trigger the 
hypertrophic response. There is concomitant increase in angiotensinogen and ANP 
gene expression and of proto-oncogenes associated with hypertrophy. An AT] receptor 
antagonist, but not an ATz receptor antagonist, nor antagonists of a - or p-adrenoceptors 
could prevent these responses (Sadoshima et a l ,  1993).
This autocrine action of Angll in the heart may explain why ACE inhibitors are so 
effective at regressing LVH in low renin-dependent models of hypertension such as the 
SHRSP (Kim et a l,  1996), and in patients with essential hypertension despite a normal 
or decreased plasma renin activity (Trippodo & Frohlich, 1981). Indeed, experimental 
hypertrophy in the rat correlates with myocardial Angll levels (Johnston, 1994), and the 
cardiac RAS is activated with increased mRNA for angiotensinogen, ACE and the ATi 
receptor (Yamazaki & Yazaki, 1997). This mechanism is not unique to pressure- 
overload hypertrophy. Activation of the cardiac RAS also occurs within three days of 
myocardial infarction in the rat, when there is an increase in Angll receptor mRNA, and 
a 44% increase in Angll receptors measured by radioligand binding (Reiss et a l ,  1993), 
However, over the time period that SHR and SHRSP develop LVH, plasma Angll 
concentration is not elevated (Campbell et a l ,  1995; Devlin et a l,  1995).
Conflicting results for the role of tissue RAS have been obtained in the SHR, when 
compared to normotensive Doni'yu rats at 6, 10 and 20 weeks of age. The authors found 
the SHR to have lower plasma renin and ACE activity, and importantly lower Angll 
tissue levels in the adrenal, aorta, brown adipose tissue, lung and similar levels in 
kidney and heart (Campbell et a l,  1995). Therefore, hypertrophy in SHR does not 
appear to be due to increased plasma or tissue Angll. However, this does not exclude 
Angll acting as a permissive factor for LV hypertrophy.
The property of ACE inhibitors and ATi receptor antagonists to regress cardiac 
hypertrophy over and above their effect on blood pressure is one of the most convincing 
arguments for the intimate involvement of Angll in the hypertrophic response. These 
drugs can lower LV mass at subpressor doses (Yamazaki & Yazaki, 1997). After aortic 
banding in rats, a low dose of enalapril totally prevented LVH despite having no effect 
on blood pressure. After surgery, plasma levels of angiotensin I and renin were elevated
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only transiently, suggesting that any hypertrophic effect of Angll was due to local tissue 
conversion. This was reinforced by finding increased angiotensinogen mRNA in the 
hypertrophied LV (Baker et a l,  1990). In a similar fashion, again in aortic-banded rats, 
low dose ramipril prevented LVH despite an increased blood pressure (Linz & 
Scholkens, 1992). Clu'onic administration of the same non-hypotensive dose of ramipril 
was studied in SHRSP. After 15 weeks of treatment these animals exhibited myocyte 
hypertrophy and interstitial fibrosis and changes to foetal gene expression characteristic 
of LVH. However, these changes were prevented in rats given an antihypertensive dose 
of ramipril (Zimmerman et a l ,  1999). Therefore low dose ACE inliibition may be 
sufficient to prevent LVH despite elevated blood pressure in the short term, but 
ultimately loses efficacy with time. Possible explanations for this may be 1) influence 
of blood pressure on LVH increases with length of exposure, 2) difference in models, 
genetic hypertension versus acute surgical, 3) other trophic mechanisms gain in 
influence.
In the SHRSP, the ATi-receptor antagonist, losartan, caused a significantly greater 
reduction in LV mass compared to a calcium chamiel blocker, despite an identical effect 
in lowering blood pressure (Kim et a l , 1996). This effect is also observed in man. A 
recent meta-analysis of published randomised double blind clinical trials examined the 
effectiveness of anti-hypertensive medication to regress cardiac hypertrophy. ACE 
inhibitors were found to be the most effective in this regard with an average 13% 
decrease in LV mass, compared with 9% for calcium channel blockers, and only 7% and 
6% for dimetics and (3-blockers respectively (Sclrmeider et a l,  1996).
Another important finding is that administration of exogenous Angll mimics the 
hypertrophic responses to pressure overload. Kim et al (1995) infused low dose Angll 
in rats. After 24 hours, gene expression of skeletal a-actin, (3-MHC, ANP and 
fibronectin were all increased, and by three days TGF-f31 and collagen types I and III 
were also increased, as was LV mass. An ATi receptor antagonist prevented these 
changes in LV mass and gene expression, while hydralazine did not, despite 
normalisation of blood pressure (Kim et a l,  1995). This strengthens the assertion that 
Ang II contributes to hypertrophic remodelling in vivo independent of blood pressure. 
The transgenic rat TGR(mRen2)27 has been used in this laboratory to examine the 
effect of over expression of the renin gene. As expected, these animals have elevated
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systolic blood pressure, LVH and increased plasma concentrations of Angll and renin. 
Further, the extent of cardiac hypertrophy was positively related to the number of copies 
of the renin gene (Brosnan et a/., 1999a).
Despite the wealth of evidence implicating a central role for Angll in the development 
of all kinds of cardiac hypertrophy, it appears that its role is not obligatory, and that the 
heart can hypertrophy perfectly well without it. Knockout mice lacking the AT]a 
receptor which were subjected to aortic banding developed LVH, with associated switch 
to foetal gene expression, identical to the wild type controls. This result was not due to 
an ineffective laiockout, as infusion of Angll resulted in LVH in wild type but not 
knockout mice (Harada et a l,  1998).
1.3.7 Adrenergic stimulation
An increase in noradrenaline turnover has been observed in the SHR at 30 to 60 days 
old, before blood pressure increases. This has led to speculation that the adrenergic 
system may be involved in LVH in this model (Yamori et a l ,  1979). This is apparently 
contradicted since LVH is not prevented in the SHR by peripheral sympathectomy 
using nerve growth factor antiserum, despite preventing the increase in blood pressure 
(Cutilletta et a l , 1977). However, this procedure causes compensatory catecholamine 
release from the adrenal medulla, which may be responsible for LVH (Yamori et a l,  
1979).
Further evidence for adrenergic involvement has been obtained from experiments on 
cultured cardiomyocytes. Cardiomyocytes in serum-free medium exposed to 
noradrenaline exhibit a 1.5 to 2-fold increase in cell size with no change in cell number 
i.e. hypertrophy without hyperplasia. This was accompanied by hallmark changes 
towards foetal gene expression (Bishopric et a l ,  1987). Molkentin et al  (1998) also 
showed the a  i-adrenoceptor agonist phenylephrine (PE) to stimulate hypertrophy in 
cultured myocytes, and that this was via a calcineurin-dependent pathway. This is 
discussed further in the section “intracellular signalling”.
1.3.8 Roie of nitric oxide
Nitric oxide (NO) appears to have an antihypertrophic effect on the myocardium 
analogous to its antiproliferative action on vascular smooth muscle cells (Garg & 
Hassid, 1989). In cultured rat cardiomyocytes stimulated to hypertrophy with
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phenylephrine, addition of a NO donor inhibited the increase in protein to DNA that is 
indicative of cellular hypertrophy. Bradykinin gave an identical response by 
stimulating production of NO, which was measured as an increase in its stable nitrite 
and nitrate metabolites. In addition, nitrite and nitrate concentrations gave a good 
negative correlation with protein/DNA ratio (Ishigai et a l ,  1997). This suggests a 
further mechanism for ACE inliibitors to elicit regression of cardiac hypertrophy. Since 
bradykinin is also a substrate for angiotensin converting enzyme, then ACE inhibition 
results in an increase in bradykinin levels and hence nitric oxide. This was tested in the 
same study, where addition of an ACE inhibitor prevented an increase in protein/DNA 
ratio. In turn, this effect could be abolished by a kinin Bz-receptor antagonist, a NO 
synthase inhibitor, or methylene blue which inhibits guanylate cyclase (Ishigai et a l ,  
1997). The NO system has also been implicated in mediating the beneficial effects of 
ACE inhibition in vivo. A  Bi-bradykinin receptor antagonist abolished the prevention 
of LVH by ramipril after aortic banding in rats (Linz & Scholkens, 1992).
Therefore, ACE inliibitors may regress hypertrophy even when the hypertrophic 
stimulus is not Angll dependent by activation of the bradykinin/NO pathway. In theory, 
this suggests a benefit of ACE inhibitors over ATi antagonists, which do not elevate 
bradykinin levels. However, in practice, there appears to be no evidence for this 
distinction, perhaps because Ang II associated hypertrophy is most dominant.
Basal release of nitric oxide may keep hypertrophy in check in the normal rat heart. In 
WKY rats, inliibition of nitric oxide in vivo using L-NAME resulted in elevated systolic 
blood pressure and cardiac hypertrophy. Hypertrophy was accompanied by an increase 
in skeletal a-actin gene expression with no change in collagen type 1, indicating 
myocyte hypertrophy in the absence of interstitial fibrosis (Devlin et a l ,  1998). Plasma 
concentrations of both renin and Angll were significantly increased in this model which 
reinforces the importance of the RAS in hypertrophic remodelling. It was not possible 
fi'oni this study to distinguish whether hypertrophy was due to elevated Angll or loss of 
nitric oxide.
Similarly, in eNOS knockout mice, blood pressme is elevated and there is concentric 
LV hypertrophy, while LV function and chamber dimensions are normal. This suggests 
that endothelium-derived NO has a role in blood pressure homeostasis, and is not 
detrimental to function (Yang et a l ,  1999).
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NO on the heart and vessels of the SHRSP has an important role in preventing a 
runaway effect of hypertension as administration of L-NAME in these animals causes 
death within 24-48 hours (Dominiczak et a l,  1997). This can be prevented by 
concomitant treatment with perindopril, suggesting the importance of NO in keeping the 
RAS in check (Dominiczak et a l,  1996).
Conflicting evidence exists concerning alterations in NO activity in the SHR heart. In 
one study, treatment with large doses of L-arginine in the drinldng water for 12 weeks 
did not alter blood pressure, but did decrease LV mass in the SHR but not WKY. Also 
cGMP and nitrite/nitrate content were lower in the hearts of the SHR indicting impaired 
NO production in the heart of the SHR that could be corrected for by L-arginine, 
independent of blood pressure (Matsuoka et al., 1996). However, a proposed NO defect 
may by species dependent. It has been reported that L-arginine does not decrease LVH 
in the SHRSP (Stier et a l ,  1991). Neither is it a consistent finding in the SHR. In a 
separate study, NOS enzyme activity was determined in heart homogenates from SHR 
and WKY rats. eNOS activity was found to be 2-3x higher in the adult SHR heart, with 
most of the activity residing in endocardial or coronary endothelial cells. Since young 
SHR had normal eNOS activity, and the right ventricle had lower activity than the LV, 
this suggests the increase in eNOS activity is compensatory to the increase in blood 
pressure. No iNOS activity was detected in any of the hearts (Nava et a l ,  1995).
1,3.9 Cytokines in L VH
Tumour necrosis factor-a (TNF-a) may have a role hi ventricular remodelling in 
chronic pressure-overload. In the 6-month-old SHR, Bergman et a l  (1999) found an 
increased secretion of bioactive TNF-a from LV tissue homogenates when compared to 
Sprague-Dawley controls. In addition, TNF-a secretion gave a good positive 
correlation with LV mass (r = 0.76) and blood pressure (r = 0.68). However, at 12 
months and 18 months these differences were no longer apparent and circulating levels 
of TNF-a were undetectable in serum at all ages. In the same study, spontaneously 
hypertensive-heart failure prone rats (SHHF) followed the same pattern, but exhibited 
increased TNF-a again when overt failine had developed (there is a wealth of evidence 
for the involvement of cytokines in heart failure, and this will be discussed in a later 
section). This study suggests that TNF-a is elevated in the early stages of genetic 
hypertension, where it may participate in LV hypertrophy. However, any putative role
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is lost once hypertension/hypertrophy is established. The effect of TNF-a antagonism 
on LVH development has yet to be studied.
1.3.10 The cytoskeleton in LVH
In feline right ventricular hypertrophy caused by surgical constriction of the pulmonary 
artery, there is an increase in microtubule density within the hypertrophied 
cardiomyocyte. This has been shown to exert a viscous load on the contractile 
apparatus, which could explain the increased energy expenditure of the hypertrophied 
myocardium (Tagawa et a l ,  1997). However, this phenomenon appears to be 
dependent on species, hypertrophic stimuli, and in the right ventricle only. Similar 
defects have not been observed after aortic banding in guinea pigs, or in feline right 
ventricular hypertrophy due to atrial septal defect (Walsh, 1997). Other types of 
cytoskeletal abnormalities may have importance in cardiac hypertrophy or failure, and 
the work by Tagawa et al  (1997) demonstrates how such changes could have a direct 
effect on function.
1.3.11 Intraceliuiar Ca *^ and LVH
There is precious little data regarding molecular changes in human compensated LVH. 
This is due to the relatively few opportunities for obtaining tissue, as opposed to the 
failing heart that can be collected at transplantation. One study by Schotten et al 
(1999) confirms the theory of altered Ca^^ regulation as being pertinent to LVH in man. 
They obtained LV tissue during surgery from patients with either hypertrophic 
obstructive cardiomyopathy or aortic valve stenosis who had a normal cardiac index, 
and compared it with tissue from heart donors free of cardiovascular disease. Western 
blot analysis revealed a 30% reduction in protein expression of SERCA in patients with 
LV hypertrophy. There was no compensatory change in the relative abundance of 
phospholamban, calsequestrin or the Na'/Ca^’^ -exchanger. Further, there was a 
significant negative correlation between SERCA expression and interventricular 
thickness i.e. patients with the greatest LVH also had the lowest SERCA expression.
The SERCA pump is central to control of intracellular [Ca '^ j^. It is located on the 
membrane of intracellular calcium stores and functions to pump Ca^^ from the cytosol 
against its electrochemical gradient into the stores at the expense of ATP. The activity 
of this pump is largely responsible for the very low resting Ca^^ concentration in the
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cytosol (Simpson et a l ,  1995). The Schotten study indicates a decrease in the SERCA 
pump protein in hypertrophied hearts. If this translates into a functional abnormality, 
then it may explain impaired relaxation in LVH, due to impaired Ca^ "^  sequestration into 
the intracellular stores. Unfortimately, the authors failed to examine diastolic function 
in these patients (Schotten et a l ,  1999).
1.3.12 Intracellular signalling
It is not proposed to provide a detailed description of intracellular signalling involved in 
LV hypertrophy, as it does not have direct impact on the results in this thesis. However, 
one study is of particular interest as it unites the theories of increased foetal gene 
expression and intracellular Ca^’’’ mismanagement as the trigger for cardiac 
decompensation and ultimately the transition to heart failure.
Molkentin et al (1998) developed transgenic mice that express activated forms of the 
Ca^^ regulatory protein calcineurin in heart tissue. These mice exhibited marked 
hypertrophy of the left and right ventricles, and progressed to develop left ventricular 
dilatation and pulmonary oedema characteristic of heart failure. They were also highly 
susceptible to sudden death. Other hallmarks of hypertrophy were present such as a 
change to foetal gene expression, with up-regulation of mRNA for p-MHC, a-skeletal 
actin, BNP and down-regulation of a-MHC, SERCA and phospholamban. This 
suggests that calcineurin has a pivotal role in hypertrophic signalling, which was further 
supported by the complete prevention of hypertrophy by treatment with the 
immunosuppressant drugs cyclosporin A (CsA) and FK506, both of which are known to 
inlaibit calcineurin signalling. In cultured cardiomyocytes exposure to Angll or 
phenylepluine (PE) could induce hypertrophy. Since this could be abolished by CsA or 
FK506, this indicates that calcineurin signalling is a mechanism common to both 
hypertrophic stimuli (Molkentin ei a l ,  1998).
All hypertrophic stimuli increase intracellular Ca^”*" (including the binding of Angll and 
PE to their receptors), and the role of calcineurin may be to integrate this signal into the 
hypertrophic response of foetal gene expression. Elevated intracellular [Ca^ "*"] has been 
implicated in the pathophysiology of hypertrophy and heart failure, but the mechanism 
was missing by which the myocyte might interpret this signal from the background of 
calciimi oscillations occurring within each cycle of contraction and relaxation (Izumo & 
Aoki, 1998). Calcineurin fulfils this role. It is a ubiquitously expressed phosphatase
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with calmodulin and Ca^ "^  binding domains, which is only activated by prolonged 
exposure to elevated intracellular Ca '^ ,^ being insensitive to transient fluctuations 
(Molkentin et al., 1998). This raises the possibility of using the immunosuppressant 
drugs CsA or FK506 to treat cardiac hypertrophy if the serious immunological side- 
effects of these drugs could be overcome.
1.3.13 Coronary reserve
The consequences of endothelial dysfunction and vascular remodelling in hypertension 
are a reduced coronary reserve, which may contribute to the pathogenesis of coronary 
artery disease, myocardial ischaemia and congestive heart failure, through an inability 
to increase myocardial perfusion upon demands of exercise or stress. Coronary reserve 
represents coronaiy resistance at rest, as a ratio of coronary resistance when the arteries 
are maximally dilated (Harrison et al., 1991). In hypertensive patients free of coronary 
artery disease, coronary flow is normal under resting conditions, however when 
coronary vessels are maximally dilated, coronary vascular resistance is 20% higher than 
in control subjects, i.e. coronary reserve is decreased. As a result, blood flow is reduced 
by 40%. In addition, around half of such patients with reduced coronary reserve exhibit 
ST-segment depressions during electrocardiography consistent with transient 
myocardial ischaemia similar to patients with established coronary artery disease (Motz 
et a l,  1991). With treatment that normalises blood pressure, but not coronary reserve, 
patients may be unable to dilate coronary vessels to maintain perfusion pressure 
(Harrison et a l,  1991).
Left ventricular hypertrophy may play a role to exacerbate the decrease in coronary 
reserve. As left ventricular mass increases, coronary vessels fail to increase in diameter 
to accommodate the perfusion demands of the greater tissue mass. The result is a 50% 
decrease in the ratio of vessel diameter to left ventricular mass (Harrison et a l ,  1991). 
In human hypertension this may contribute to the large reduction in coronary reserve 
observed after prolonged hypertension. The relative importance of this mechanism 
probably depends on the ability to compensate by producing new coronary resistance 
arteries, suggesting that the control of angiogenic factors may be important. 
Angiogenesis is thought to account for the gradual normalisation of coronary reserve 
that occurs in the SHR when maximal left ventricular hypertrophy has been attained. 
However, this species difference may be related to the duration of hypertension, as 
coronary reserve is reduced in the STIR during left ventricular development (Harrison et
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a/., 1991). It is worth noting that left ventricular hypertrophy is not an overriding 
influence on coronary reserve and diminished coronary reserve can occur independently 
of left ventricular hypertrophy (Motz et a l ,  1991).
1.4 Heart failure
Heart failine can be defined as an inability of the heart to maintain an adequate supply 
of oxygen to the major organs (Katz, 1992). The aetiology of the condition may be 
acute such as myocardial ischaemia after infarction of a coronary artery, or may be 
insidious such as the long-term structural changes that occur in cardiac hypertrophy. 
What both have in common as triggers for heart failure is a convergence on a series of 
complex haemodynamic and neurohumoral changes, that are initiated to protect against 
the insult, but which in the longer term are detrimental, feeding back to worsen the 
failing heart. This section on the pathophysiology of heart failure will discuss the 
“syndrome” of heart failuie and how this may lead to decompensation of the failing 
heart with subsequent morbidity and mortality. Particular emphasis will be placed on 
findings from animal models of heart failure secondary to MI as they pertain to the 
work presented in this thesis.
1.4.1 Models of heart failure
At least 30 different models of heart failure have been developed in 11 species. 
Induction of heart failure may be genetic, surgical or due to administration of cytotoxic 
agents as summarised in table 1.4. It is a commonly held view that no single model 
mimics the full range of alterations with heart failure in man, but that all involve certain 
pertinent features. It would not be appropriate to review all the models here, for 
reviews see (Dogrell & Brown, 1998; Verdouw et a l, 1998; Hasenfuss, 1998). This 
introduction will concentrate on the most popular model of coronary artery ligation 
(CAL) in the rat, which is utilised in chapter five of this thesis.
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Table 1.4 Animal models of heart failure.
Method Species Comments
Surgical
Coronary artery ligation Rat, dog, Model of human ischaemic h.f. 2° to MI
rabbit, pig, Variable infarct size as in man.
mouse Partial occlusion or reperfusion studies.
Aortic banding Rat, sheep. LVH then high output failure in some animals
guinea-pig at 20 weeks. No human equivalent.
Pacing tachycardia Dog 200bpm for 3-6 weeks
Rabbit 400bpm for several weeks, reversible.
Neurohumoral activation without LVH
Pulmonary artery Cat Pulmonary hypertension, RV hypertrophy
banding leading to failure at 14-90 days.
Micro-embolism Dog Weekly microspheres IV. H.f. after 3 months.
Mitral valve damage Dog Mitral regurgitation, LVH, failure by 3 months
Aortic valve perforation Rabbit Severe aortic regurgitation, LVH, failure.
Renal artery occlusion Rat Hypertensive, LVH then failure at 2 weeks
Genetic
Systemic hypertension Rat SHR: transition LVH to h.f. at 18-24 months
Ageing SHR, SHHF SHHF :transition LVH to h.f. before 18 months
Salt-sensitive Dahl rat LVFI at 8 weeks, h.f. at 15-20 weeks.
hypertension
Spontaneous Syrian LVH and overt h.f. at 7-10 months
cardiomyopathy hamster.
Dog, Doberman Pinschers
Cow Hereditary dilated cardiomyopathy
Toxicity
Chronic ethanol Rat
Catecholamine infusion Rat Isoprenaline or NA infusion
Doxorubicin Rabbit H.f. after bi-weekly injection for 6-9 weeks.
Transgenics (examples)
Myogenic factor 5 Mouse Overexpression -  cardiomyopathy and h.f.
Gsa Mouse Overexpression -  cardiomyopathy and h.f.
TGF-p Mouse Knockout -  myocarditis & h.f.
Muscle DIM protein Mouse Knockout -  dilated cardiomyopathy & h.f.
Adapted from Hasenfuss (1998), Dogrell & Brown (1998), lannini & Spinale (1996). 
LVHdeft ventricular hypertrophy; h .f: heart failiue; MI: myocardial infarction; RV: 
right ventricle.
As a heart failure model the rat is more popular than all the other species combined. It 
has obvious advantages over larger mammals in terms of cost, gestation period and life 
span. Studies involving large numbers of animals can be performed relatively easily 
with follow-up from birth to death. The sheer number of studies in the rat means that 
cardiovascular physiology and pharmacology are better characterised than in any other
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species. The disadvantages of rat models for heart failure research are mainly centred 
around differences in cardiac physiology when compared to man.
1) The action potential in rat hearts is shorter, without a sustained plateau phase.
2) The SERCA pump has an entranced role over the Na'^-Ca '^  ^ exchanger in removing 
Ca^^ from the cytosol.
3) a-MHC is the dominant isoform in the rat heart.
4) Heart-rate at rest is five times higher than humans and there is an altered force- 
frequency relationship.
5) Cholesterol levels are half that of humans.
(Hasenfuss, 1998; lannini & Spinale, 1996)
Coronary artery ligation in the rat
In 1960, Selye et al. described a simplified method for coronary artery occlusion in the 
rat. This superseded previous attempts, which produced highly variable infarcts 
limiting the usefulness of the teclinique. They described a thoracotomy similar to the 
technique described in appendix II, but in unventilated rats. For this reason, emphasis 
was on speed, with a window of only 2-3 minutes to tie the ligature around the left 
anterior descending (LAD) coronary artery and close the chest wall. The authors 
claimed a siu'gical mortality of only 10% and could produce up to 60 ligated rats in a 
single afternoon. This early study also provides an excellent description of the rat 
coronary vasculature, with a detailed guide to placing the ligature. Since 1960, the 
teclmique has been refined considerably, and virtually all laboratories now use 
mechanical ventilation. Even with the thorax open for less than one-minute animals 
experience severe hypoxia in the absence of ventilation, a possible experimental 
confounder (Horstick et a l,  1999).
CAL in the rat results in a wide range of infarct sizes. Pfeffer et a l  (1979b) saw this as 
an advantage that provided the opportunity to mimic the full range of cai'diac failure 
found in man. They stratified animals depending on infarct size on an ai'bitrary basis 
that many labs still use today. Since then there has been interest in trying to standai'dise 
infarct size with a recent report that CAL in Lewis inbred rats results in a uniformly 
large infarct with paradoxically reduced mortality (Liu et a l,  1997).
The study by Pfeffer et al  (1979b) examined the effect of infarct size on haemodynamic 
and cardiac performance after the scar was healed at 3-weeks post-ligation. They
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observed a wide range of function that was directly proportional to infarct size. 
Animals with small infarcts were well compensated, with no alterations in cardiac 
haemodynamics, whereas those with large infarcts had congestive heart failure 
evidenced by a reduced rate of developed pressure (+dP/dt) and impaired pressure 
development in response to aortic occlusion.
Studies on the pathophysiology of Ml-induced heart failure are hampered by the 
difficulty in comparing results from different laboratories. The genetic homogeneity of 
the SHR provides a good reproducible hypertrophy associated with hypertension, but no 
equivalent model for myocardial infarction exists. Most studies of MI-induced heart 
failure use outbred Sprague-Dawleys or Wistars, providing a genetically heterogeneous 
population. In addition, the measurements obtained are heavily dependent on infarct 
size. There is not even universal agreement on how infarct size should be measured e.g. 
as percentage of whole left ventricle, % of free ventricular wall, or % of area at risk. 
Add to this the variable time course of starting medication i.e. early or late after MI, the 
dose or route of administration of drugs, and whether animals are in failure or not, and it 
is easy to understand how conflicting results may ai'ise.
1.4.2 Haemodynamics in heart faiiure.
In the absence of symptoms, heart failme in animal models is often described in terms 
of cardiac haemodynamics (see table 1.5). After myocardial infarction the damaged left 
ventricle must continue to meet the oxygen demands of the body despite a reduced 
myocardial mass. Loss of working muscle causes a fall in stroke volume such that less 
blood is pumped with each beat (Hu et a l,  1998a). Sensing the decreased arterial 
volume, the sympathetic nervous system and RAS are activated to maintain perfusion 
pressure by increasing afterload and preload. With a reduced power-generating capacity 
with which to push against an increased total peripheral resistance (TPR) (ITu et a l,  
1998a), there is an increase in left ventricular end diastolic pressure (LVEDP) (Nasa et 
al,\99€), which together with the neurohormonal activation, provide a signal for 
hypertrophy of the surviving myocardium. This serves to compensate for lost tissue and 
so normalise wall stress (Hu et a l,  1998a). LV mass gets progressively lower in the 
first three weeks as the infarcted myocardium is replaced by the much thimier scar 
tissue, but over the next few months, returns to normal or higher values as hypertrophy 
takes hold (Pfeffer et a l ,  1991).
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Elevated LVEDP represents a resistance to blood returning from the pulmonary 
circulation, and if sufficiently high, right ventricular pressure will increase to maintain 
the pressure gradient across the pulmonary bed. The result is pulmonary congestion and 
right ventricular hypertrophy (Pfeffer et a l,  1984; Pfeffer et a l ,  1979b). This may be 
exacerbated by increased preload due to elevated central venous pressure (Mulder el a l , 
1996).
In the early stages post-MI, LV volume increases due to ballooning of the infarct zone. 
This is particularly evident at low filling pressures (<2.5mmHg) when the pressure- 
volume relationship shifts to the right. A progressive thinning and dilatation of the 
infarct zone occurs over the first week before scai* tissue forms. This is termed infarct 
expansion and is thought to be due to myocyte slippage as more cells are lost from 
around the infarct region (Pfeffer et a l ,  1991).
After one week, LV volume at high filling pressures (20nimHg) also becomes enlarged 
(Pfeffer et a i ,  1991). In order to maintain stroke volume in the face of a lower ejection 
fraction, the LV evokes the Frank-Starling mechanism by dilating. This provides a 
mechanical advantage, as the same stroke volmne can be attained with a decrease in 
myocyte circumferential shortening (Pfeffer et a l,  1984).
This type of change in LV structure and geometry allows the heait to compensate in the 
short-term. For example, for small and moderate sized infarcts, the maximum 
developed pressure during aortic occlusion is close to normal (Pfeffer et a l ,  1979b), 
indicating an ability of the heart to compensate via the mechanisms outlined above. 
However, structural and geometrical alterations to the LV become more pronounced 
with increasing infarct size and time since insult, and are ultimately detrimental (Pfeffer 
et a l ,  1991).
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Table 1.5 Cardiac haemodynamic signature and structural alterations after
coronary artery ligation in the rat.
Measured parameter A Example references
Haemodynamics
Mean blood pressure Drexler & Wenyan (1992); Feng et a l (1996), Baggia et al 
(1997)
Heart rate -O' Hu et a l (1998a); Oie et a l (1998); Mulder et a l (1997b)
LV systolic pressure i Nasa et a l (1996); Toyoshima et al. (1998); Mulder et a l (1996)
LV end diastolic pressure t Gaudron et a l (1994); Sakai et a l (1996); Mulder et a l (1997a)
Right atrial pressure t Hu et a l (1998b); Gaudron et al. (1994)
Central venous pressure t Mulder et al. (1996); Mulder et a l (1997a); Mulder et al. (1997b)
Peak developed pressm-e i Pfeffer et al. (1979b); Pfeffer et a l (1984); Hu et a l (1998)
LV dP/dt Baggia et a l ( 1997); Teerlink et al. (1994); Latini et al. (1998)
Aortic flow Toyoshima et al. (1998); Yamaguchi et al. (1998)
Cardiac output Nekooeian & Pang (1998); Xu et a l (1997)
Stroke volume : Hu et a l (1998b); Hu et a l (1998a)
Ejection fraction L m e ta l  (1997)
Fractional shortening Mulder et al. (1997b); Oie et al. (1998)
Cardiac structure
LV mass t Thomas D. et al. (1998); Feng et a l (1996); Oie et a l (1998)
RV mass t Lindsay et al. (1992); Drexler & Wenyan (1992); Pfeffer et a l (1979b)
Atrial weight t Drexler & Wenyan (1992); Fabris et a l (1990); Gu et al. (1998)
Wall thickness (surviving) t Mulder et a l (1997b); Gaudron et a l (1994)
LV end diastolic volume t Mulder eraA (1997b); Oie e?«/. (1998); Liu e ta l  (1997)
LV circumference t Mulder et al. (1997b); Orenstein et al. (1995); Mulder et a l (1997a)
LV % collagen density t Taylor e/a/. (1998); Latini e/nr/. (1998); Miilder e /<7/. (1997b)
With time, too much LV dilatation becomes unfavourable and is no longer sufficient to 
maintain stroke volume. Indeed LV dilatation is a marker for poor prognosis in man 
(Pfeffer et a l,  1984; Sutton et a l ,  1997). The mechanism by which LV dilatation 
becomes deleterious leading to decompensated failme has yet to be elucidated. 
Contributing factors are likely to include insufficient hypertrophy, reduced contractility 
at a cellular level or increasing afterload due to peripheral vascular dysfunction (Pfeffer 
et al., 1991).
In rats after CAL, structural changes in the LV allowed normalisation of wall stress 
within 3 weeks in animals with small infai'cts. However, even after 106 days, rats with 
large infarcts had significantly higher wall stress. The authors concluded, that in those 
animals there is a continued drive towards LV hypertrophy and dilatation in an effort to
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normalise wall stress, for which they are unable to compensate (Pfeffer et a l ,  1991). In 
man, continued progressive LV dilatation has been described two years after MI despite 
treatment with ACE inliibitors. Again this indicates a long-term drive towards altered 
LV geometry (Sutton et a l , 1997).
Early dilatation and thinning of the infarct zone predicts later deterioration in ventricular 
function. Subjects with the greatest infarct expansion are much more likely to develop 
dilatation affecting the whole myocardium, and significantly more of these patients die 
(Eaton et a l,  1979). Preventing early dilatation of the infarct area may provide 
significant advantages. In sheep after CAL, surgically applying a mesh to give 
mechanical support to the infarct zone allowed cardiac haemodynamics to return to 
normal within one week. Animals without the mesh showed progressive deterioration 
in LV function (Kelley et a l ,  1999).
1.4.3 Neuroendocrine response in heart failure
This syndrome of heart failure takes a similar course independent of aetiology, and 
leads to the overt clinical symptoms of heart failure of shortness of breath, exercise 
intolerance, and pulmonary & peripheral oedema. At this stage the heart is said to be 
decompensated when the neurohumoral changes no longer compensate adequately for 
the failing heart.
The heart failure syndrome involves the activation of a whole host of neurohumoral 
systems involved in homeostasis of blood pressure and cardiac performance. These 
include the sympathetic nervous system, renin-angiotensin system, vasopressin, 
natriuretic peptides, nitric oxide, endothelin, prostaglandins and cytokines. The 
interactions are complex, with counter-regulatory systems feeding back on themselves 
and each other (Schrier & Abraham, 1999). This makes the relative importance of these 
systems difficult to ascertain.
Sympathetic nervous system
The chain of events probably starts with activation of the sympathetic nervous system 
(SNS). For example, an ischaemic insult to the myocardium reduces cardiac output, 
and results in underfilling of the arteries. This is sensed by the carotid baroreceptors, 
which signal to the nucleus tractus solitarius to activate the sympathetic nervous system 
and so start a reflex of sodium and water retention to aid the troubled heart (Schrier & 
Abraham, 1999). Activation of the SNS is essential for survival immediately after ML
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In rats given a sympathectomy, coronary artery ligation causes death within five 
minutes due to a drastic fall in cardiac output (Dotting et al, 1983).
There is a wealth of evidence for sympathetic nervous system activation in heart failure. 
Plasma noradranaliiie (NA) concentration is significantly elevated (3-fold) three weeks 
after MI in the rat and remains elevated at three months (Deck et al, 1992; Latini et al, 
1998). In patients with congestive heart failure there is an increase in sympathetic nerve 
firing, and more NA is released from nerve endings, resulting in an increased 
noradrenaline spillover from the heart (Meredith et al, 1993), with a concomitant 
reduction in plasma clearance of up to 30%. The combined effect is to double the 
plasma noradrenaline concentration (Kaye & Esler, 1995). The increase in sympathetic 
tone together with the release of adrenaline and noradrenaline from the adrenal medulla 
act directly to increase force and rate of cardiac contraction via Pi-adrenoceptors. 
Stimulation of a-adrenoceptors causes a generalised arterial and venous constriction, 
thereby increasing both afterload and preload, and so increasing cardiac workload 
(Sclirier & Abraham, 1999). Sodium and water retention is promoted in three ways
i) Activation of RAS by direct stimulation of renin release from the cells of the 
juxtaglomerular apparatus via P-adrenoceptors.
ii) Renal vasoconstriction causing a decreased glomerular capillary filtration 
pressure and hence lower glomerular filtration rate, resulting in less sodium and 
water excretion
iii) A direct a-adrenoceptor effect to increase sodium transport in the proximal 
convoluted tubule. This results in a decreased concentration of sodium reaching 
the distal portion of the nepluon and collecting duct, which stimulates release of 
renin and aldosterone (Scluier & Abraham, 1999).
These effects may be beneficial in the short-term to maintain perfusion pressure and 
bolster left ventricular dysfunction, however, there are consequences of prolonged 
exposure to an activated sympathetic nervous system. Noradrenaline is cytotoxic to 
cardiac myocytes, and may trigger cell death due to calcium overload or apoptosis. 
Noradrenaline may also increase cardiac hypertrophy, directly, via a i-  or p- 
adrenoceptors, or indirectly by activating the RAS by the mechanisms just outlined 
(Schrier & Abraham, 1999).
In addition, p-adrenoceptor function is impaired, probably as a direct consequence of 
prolonged exposure to elevated noradrenaline concentrations. The cluonotropic and
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inotropic response to p-agonists is attenuated via a number of mechanisms; 1) 
catecholamine depletion from vesicle stores (Krum, 1997), 2) reduced receptor density 
(Gu et a l ,  1998), and 3) uncoupling of adenylyl cyclase from Pradrenoceptors (Jaber et 
a l,  1996). A 50% decrease in Pi-adrenoceptor mRNA has been observed in hiunan 
heart failure coupled with an increase in mRNA and enzyme activity of P-adrenergic 
receptor kinase, which deactivates the receptor (Kaye & Esler, 1995).
The baroreceptor reflex is also blunted in heart failure. The increase in NA spillover 
that occurs in response to systemic vasodilatation is reduced in heart failure patients i.e. 
subnormal change in heart rate for any given change in blood pressure (Newton & 
Parker, 1996).
Parasympathetic nervous system
Activity of the parasympathetic nervous system is depressed in human heart failure. In 
subjects where adrenoceptors have been blocked by propranolol, parasympathetic 
blockade with atropine elevates heart rate to a greater extent in normal subjects than in 
those with heart disease (Eckberg et a l,  1971). There is some evidence to link high 
initial plasma renin activity with this process (Osterziel et a l ,  1994), and Angll is 
thought to directly inhibit central parasympathetic outflow (Du et a l ,  1998). This may 
in part explain how ACE inhibitors improve barorelex control and have an anti- 
arrhythmic action in the ischaemic heart (Deck et a l,  1992).
1.4.4 Renin-Angiotensin-Aldosterone System
The RAS is stimulated both directly and indirectly by the sympathetic nervous system 
via the mechanisms above. It is also sensitive to a drop in cardiac output, as the 
resultant decrease in glomerular filtration rate, lowers sodium concentration in the distal 
tubule, which stimulates the release of renin. In mild heart failure there is little or no 
increase in plasma renin or aldosterone concentrations, however, levels can be 
considered to be inappropriate due to the high blood volume of these patients. In severe 
heart failure both renin and aldosterone concentrations are elevated (Schrier & 
Abraham, 1999).
Angiotensin II has numerous effects on the cardiovascular system,
i.) It increases afterload by a generalised vasoconstriction.
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ii.) Vasoconstriction of afferent and efferent renal arterioles helps to maintain 
glomerular capillary pressure and hence filtration rate. This is why ACE 
inliibitors may cause a decrease in renal function in some patients with severe 
heart failure.
iii.) Angiotensin II is mitogenic for myocytes and is thought to have an important 
role in hypertrophic cardiac remodelling.
iv.) Angiotensin II increases thirst by stimulation of the central thirst centre and 
thereby increasing water retention,
V.) Increases synthesis and release of aldosterone from the zona glomerulosa of the
adrenal medulla.
(Schrier & Abraham, 1999; Molkentin et a l,  1998)
Aldosterone increases sodium reabsorption in the distal tubules via a poorly understood 
mechanism. It may also be released in direct response to low plasma sodium or high 
potassiiun concentrations. The importance of aldosterone in this cycle of sodium and 
water retention has been emphasised recently by the success in adding spironolactone, 
an aldosterone receptor antagonist, to existing therapy in the treatment of severe human 
heart failure. The trial was stopped early due to an overwhelming benefit of 
spironolactone to decrease both mortality and non-fatal hospitalisation by 30% (Pitt et 
a l,  1999).
Renin acts to split angiotensinogen into angiotensin I, which is then converted to the 
active angiotensin II form by angiotensin converting enzyme (ACE). The formation of 
Angll from Angl may also take place via the serine protease, chymase. This appears to 
be a source of local tissue Angll, and is not thought to contribute to plasma levels 
(Wolny et a l,  1997). The relative importance of chymase over ACE is a matter of 
considerable debate, but there is some evidence to suggest that Angll production by 
chymase increases in importance to compensate for long-term inhibition of ACE, and in 
the failing human heart where it is the major source of Angll generation in the 
myocardium and coronary vessels (Wolny et a l,  1997). Indeed, in one study, captopril 
only reduced Angll forming activity by 11% in the LV of patients with ischaemic 
cardiomyopathy, whereas a serine proteinase inhibitor blocked 80% of Angll activity 
(Urata et a l ,  1990). This suggests that the RAS is incompletely blocked by ACE 
inliibitor therapy in heart failure, and may explain why ultimately these drugs fail to halt 
progression of the disease. Since AT, antagonists will block all Angll regardless of 
source, this argues for an additional benefit for AT] antagonists over ACE inliibition.
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There is strong evidence from numerous studies that the local RAS is activated after 
CAL in the rat. Plasma Angl and Angll concentrations are significantly elevated within 
six hours of MI and local Angll is increased for three days in the non-infarcted 
myocardium and for seven days in the infarct zone. These changes can be attenuated by 
ACE inliibition but not nephrectomy confirming that local production is of primaiy 
importance (Leenen et a l ,  1999). AT-receptor mRNA, receptor density and ACE 
activity are also all up-regulated within days in the surviving myocardium (Reiss et a l,  
1993). The findings are not universal, and may be related to the severity of insult. One 
group reports mRNA for ACE and renin is only increased in the border zone of the 
infarct area, with no increase in the rest of the left ventricle, arguing against a major role 
in LV hypertrophy (Passier et a l ,  1996; Passier el a l,  1995). Since the highest ACE 
content appears in the infarct zone (5-fold increase), it has been suggested that Angll 
may be involved in the wound healing process (Fabris et a l,  1990).
Other studies have indicated that in the longer-term (after one month) when animals are 
often regarded to be in failure, plasma ACE and renin activity are normal (Flirsch et a l , 
1991; Yoshida et a l ,  1998). However, again, evidence is strong for a local production 
in the sui'viving LV. There is also an increase in the right ventricle where ACE activity 
positively correlates with infarct size (Hirsch et a l,  1991). In humans with idiopathic 
cardiomyopathy, ACE protein is elevated in both the left and right ventricles (Zisman et 
a l,  1998). At this stage, renal involvement may gain in importance. At 4-6 weeks post- 
MI, there is a doubling of glomerular ATi receptors despite an increase in plasma Angll 
that would normally result in down-regulation of the receptor. Renin and 
angiotensinogen mRNA are also increased in the renal cortex. These results may 
explain the strong intra-renal vasoconstriction observed with heart failure (Mento el a l,  
1998).
Numerous studies using CAL in the rat have demonstrated beneficial effects of both 
ACE inliibitors and ATi receptor antagonists. A reduction in LVH is almost universal, 
with corresponding decrease in myocyte CSA (Liu et a l , 1997), ANP gene expression 
(Ambrose et a l ,  1999), and subsequent improvements in capillary density and oxygen 
diffusion distance (Liu et a l,  1997). Fibrosis of the sm'viving myocardium is reduced, 
with a decrease in collagen deposition (Richer et a l ,  1992; Liu et a l ,  1997; Smits et a l,  
1992) and a reduction in non-myocyte proliferation (Taylor et a l ,  1998). LV dilatation 
is improved with normalisation of LVEDP, LV wall stress and an increase in maximal
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stroke volume (Liu et a l,  1997; Liu et a l ,  1998b). These are fairly consistent findings 
for a wide range of compounds from both classes. Where a study has failed to show 
major benefits, this is usually due to sub-optimal dosing e.g. losartan (Hu et a l,  1998b). 
The benefits obtained in blocking the RAS underlines its major role in the 
pathophysiology of heart failure.
1.4.5 Arginine-vasopressin (antidiuretic hormone)
Arginine vasopressin has also been reported as elevated after CAL in the rat (Stassen et 
a l,  1997a). The important effects of vasopressin in the cardiovascular system are,
i.) Vasopressin activates V2 receptors in the collecting duct to promote synthesis 
and translocation of aquaporin-2 water channels from cytoplasmic vesicles to 
the cell surface thereby promoting increased water retention. This occurs even 
at very low concentratons.
ii.) At higher concentrations, vasopressin activates vasoconstriction via V 1 receptors 
on vascular smooth muscle cells. Vasoconstriction is generalised, equally 
affecting all vascular beds, including the coronary circulation (Sclnier & 
Abraham, 1999).
1.4.6 Atriai natriuretic peptide
In human subjects with healed MI, ANP protein and mRNA levels are markedly 
increased in the LV adjacent to the infarct scar, and also in both atria. Both atrial and 
LV secretion correlate well with severity of heart failure as measured by LVEDP, 
suggesting LV stretch as the initiating factor in increasing gene expression (Saito et a l, 
1989). Plasma ANP also correlates with systolic and diastolic dysfunction in heart 
failure patients, and is related to increased filling pressures (Wijbenga et a l ,  1999). 
Impaired renal clearance may also contribute as ANP levels correlate with creatinine 
clearance (Missouris et a l,  1998).
In the rat after CAL, ANP mRNA expression is consistently elevated in all parts of both 
ventricles from day one onwards (Passier et a l,  1996; Die et a l ,  1998; Gidh-Jain et a l,
1998), and plasma levels ai’e also increased (Yoshida et a l, 1998; Stassen el a l ,  1997a). 
In rats with heart failure secondary to aortocaval fistula, ANP gene expression increases 
in the LV but not the atria. In these animals, urinary ANP concentration remains 
normal; suggesting increased ANP secretion not reduced clearance elevates plasma 
levels. ANP mRNA was also elevated in the stomachs of these animals. This extra-
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cardiac source of ANP may explain why BNP is a better marker of prognosis in heart 
failure (Poulos et a l,  1996).
Atrial natriuretic peptide (ANP) can be thought of as an endogenous antagonist of the 
renin-angiotensin system. Inftision of ANP in dogs with heart failure prevents sodium 
retention, renal vasoconstriction and activation of aldosterone and renin (Lee et a l,
1989). Likewise in post-MI rats, when ANP is markedly raised, then salt retention, 
renin and aldosterone activity aie normal, again suggesting as inhibitory role on the 
RAS (Llodsman et a l ,  1988; Stassen et a l ,  1997a).
Usually, increased blood volume due to sodium and water retention increases atrial 
pressure, causing the atria to stretch. This is sensed by atrial myocytes, which respond 
by releasing ANP. The stimulus for ANP production in heart failure may be raised LV 
pressure (stretch) and/or cardiac hypertrophy. Plasma ANP correlates with LVH in rats 
post-MI, but not with body sodium, and so is probably released independent of salt and 
water retention in this scenario (Hodsman et a l,  1988).
The effects of ANP and BNP are similar,
i.) Afferent arteriolar dilatation results in an increased glomerular filtration rate and 
therefore enlianced sodium excretion (Schrier & Abraham, 1999).
ii.) In the collecting duct, sodium reabsorption is decreased, thereby increasing 
sodium excretion (Scinder & Abraham, 1999).
iii.) Inliibition of renin and aldosterone secretion which may prevent overt activation 
of the RAS in heart failure patients (Missouris et a l ,  1998)
iv.) Stimulation of cGMP in smooth muscle cells giving rise to vasorelaxation 
(Nakamura et a l,  1998).
These are all beneficial effects that counteract the over-stimulation of the sympathetic 
nervous system and RAS observed in heart failme. Llowever, heart failure patients 
derive little benefit from exogenous natriuretic peptides, and appear to be resistant to 
their effects. Vasodilatory responses to infused ANP and BNP are impaired in heart 
failure patients (Nakamura et a l ,  1998). In rats with chronic heart failure, infusion of 
ANP results in less natriuresis and blood pressure lowering than in sham animals 
(Kohzuki et a l,  1989). A number of reasons have been suggested for this. For 
example, down-regulation of renal receptors, or increased degradation by neutral 
endopeptidase. In addition, the activated RAS means that less sodium is delivered to 
the collecting duct resulting in less sodium available for excretion (Sclmer & Abraham,
1999).
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1.4.7 Brain natriuretic peptide
BNP elevation associated with heart failure occurs across models and species. Even in 
the dog, where initial BNP levels are low in the LV, there is an increased BNP secretion 
from the LV after rapid ventricular pacing (Luchner et a l,  1998).
In human congestive heart failme secretion of BNP from the LV increases in direct 
proportion to the severity of the disease, correlating with NYHA classification. In 
normal subjects, plasma ANP concentration is higher than BNP, but with development 
of heart failme BNP levels dominate (Mukoyama et a l,  1991).
Yamamoto et al (1996) report a prospective study to examine plasma natriuretic 
peptide concentrations as markers of LV dysfunction in patients with heart failure. 
Plasma BNP concentration was found to be superior to ANP in detecting LV 
hypertrophy, elevated LVEDP or ejection fraction below 45%, providing good 
correlations with depressed systolic and diastolic function (Yamamoto et a l ,  1996). 
This has been confirmed in further studies in chronic heart failure patients, where 
plasma BNP is superior to ANP or noradrenaline as a prognostic marker. Survival in 
patients with high plasma BNP is significantly reduced, which may indicate that the 
beneficial effects of BNP to compensate for RAS activity may be blunted in patients 
with severe heart failure (Tsutamoto et a l,  1997; Yu & Sanderson, 1999). Indeed, in 
patients with CHF, infusion of BNP results in an impaired natriuretic response 
compared to normal controls. The distal portion of the nephron is thought to have 
reduced responsiveness to BNP (Jensen et a l,  1999).
Immediately after MI in humans, plasma BNP is elevated. In those patients who 
develop LV dilatation, BNP levels are much higher than in those without, and BNP 
remains higher over the next six months. Both the acute and sustained elevation of 
BNP has prognostic significance in accurately detecting patients with LV dilatation 
(Nagaya et a l,  1999). It seems likely that BNP concentration reflects levels of wall 
stress aromid the infarct zone, giving rise to the correlation with LV geometry.
1.4.8 Prostacyclin and prostaglandin E
Elevated levels of angiotensin II, noradrenaline and renal nerve stimulation all act to 
increase synthesis of prostacyclin and prostaglandin E from arachidonic acid. Both 
these prostanoids are potent vasodilators that attenuate the vasoconstrictor effects of 
angiotensin II and noradrenaline. They may be particularly important as a counter
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balance to neurohonnonal induced renal vasoconstriction, as blocking their production 
with non-steroidal anti-inflammatory drugs can precipitate acute renal failure in patients 
with severe heart failure (Schrier & Abraham, 1999).
1.4.9 Nitric oxide
Nitrates and nitrites are the stable degradation products of nitric oxide (NO). Patients 
with heart failure have elevated plasma nitrate levels regardless of aetiology (dilated 
cardiomyopathy, rheumatic valvular disease or ischaemic heart disease) suggesting an 
overall increase in NO production (Winlaw et a l,  1994; Ramesh et a l,  1999). In 
addition, there is a positive correlation between plasma nitrate concentration and NYHA 
functional class (Winlaw et a l ,  1995). This difference could be explained by increased 
release of basal nitric oxide via eNOS or by induction of the calcium independent 
isoform iNOS.
However, most evidence suggests that endothelial nitric oxide synthase (eNOS) is 
down-regulated in heart failure resulting in lower production of NO. This means that 
there is less basal NO to counteract the actions of angiotensin II, noradrenaline and 
vasopressin, resulting in augmented vasoconstriction by these agents (Sclnier & 
Abraham, 1999). This will be discussed below under “vascular function”. Attention 
has therefore focused on iNOS activity in heart failure.
The normal rat heart contains only eNOS activity (Nava et al., 1995; Schulz et a l,  
1992). However, Schulz et al  (1992) demonstrated that myocytes, and not just 
inflammatory cells, were capable of iNOS activation with resultant increase in cGMP 
when exposed to lipopolysaccharide or cytokines such as TNF-a and IL-lp. After CAL 
in the rabbit iNOS activity is increased in the infarct zone, associated with macrophage 
infiltration, but remains normal in non-infarcted myocytes. Maximal activity occurs at 
3-5 days, returning to normal within three weeks, which coincides with scar maturation 
(Wildhirt et a l ,  1995). Plasma nitrate/nitrite (NOx) concentration shows excellent 
positive correlation with iNOS activity in the infarcted region. Also, administration of a 
specific iNOS inhibitor prevented the increase in plasma NOx. Taken together, these 
results suggest that increased iNOS activity accounts for most of the elevated NOx post- 
MI (Akiyama et a l ,  1997).
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Similar results have been obtained from human failing hearts, where iNOS activity was 
greatest in the infarcted regions, and correlated strongly with density of macrophage 
infiltration. However, in this study, eNOS activity was also elevated, principally in 
subendocardial layers of the LV (Fukuchi el a l ,  1998). In human heart failure, iNOS 
activity is not only increased in the acute healing phase, but is elevated in patients with 
old infarcts and in other aetiologies such as dilated cai’diomyopathy and valvular heart 
disease (Haywood el al., 1996). However, the expression of iNOS is variable and not 
universal to all failing hearts. Haywood el al. (1996) found iNOS mRNA expression in 
71% of biopsies from human hearts with various aetiologies. In these patients, iNOS 
protein was detected in all four chambers in the cytoplasm of cardiomyocytes.
The mechanism for iNOS activation is likely to be driven by cytokines, which are 
discussed below. Both TNF-a and IT-1(3 can induce iNOS in the rat heart in vivo 
(Schulz et a l ,  1992). Activation of a-adrenoceptors may be synergistic in this regard 
enhancing cytokine-induced NO activity via a protein kinase C dependent pathway 
(Ikedac/a/., 1996).
The functional significance of elevated NO production in the myocardium is a 
deleterious effect on myocyte contractility. In vitro, contractility of cultured rat 
cardiomyocytes decreases when exposed to NO from LPS-activated macrophages (Joe 
et a l ,  1998; reviewed in Balligand et a l,  1996). Nitric oxide may also have direct 
cytotoxic effects, and trigger apoptosis, thereby contributing to loss of myocyte mass 
(Wildhirt e /n /., 1995).
1.4.10 Cytokines in heart failure
TNF-a is released from immune cells such as macrophages and monocytes. Cardiac 
myocytes are also capable of synthesising TNF-a in response to ischaemia and are 
probably as active as LV macrophages in this regard (Meldrum, 1998). There aie two 
receptor subtypes TNFRl and TNFR2, both of which are expressed in adult human 
cardiomyocytes. After exposure to TNF-a these receptors can be cleaved from the 
membrane and circulate as soluble receptors, which may bind and inactivate TNF-a. 
However, they may also act as a slow-release mechanism for bound TNF-a (Bozkurt et 
a l,  1996).
57
TNF-a functions to increase synthesis of inflammatory mediators such as eicosanoids, 
oxidative free radicals, NO and other cytokines e.g. lL-1 (Meldriun, 1998). While 
activating iNOS, TNF-a, has the opposing effect on eNOS (Yoshizumi, 1993).
Levine et al. (1990) observed that plasma TNF-a was significantly elevated in around 
40% of patients with heart failure. High TNF-a levels were linked to activation of the 
RAS, as these patients also had significantly higher plasma renin activity (Levine et a l ,
1990). Elevated TNF-a has since been confirmed in a number of studies reviewed by 
Bozkurt et a l  (1996).
After CAL in the rat, mRNA expression for several cytokines (TNF-a, IL-ip, lL-6) are 
increased transiently in the infarct zone. Of greater interest is the continued elevation in 
the non-infarcted myocardium at twenty weeks. Further, all three cytokines provided 
good positive correlations with LV dilatation, and 1L-1(3 also correlated with collagen 
density (Ono et a l,  1998). The implication is a possible role for pro-inflammatory 
cytokines in the pathophysiology of LV remodelling post-MI. Bioactive TNF-a 
secretion from the LV is also increased as SFIHF rats make the transition into failure 
(Bergman et a l ,  1999), implicating cytokines in the process of decompensation. 
Artificially raising TNF-a activity can mimic many of the hallmarks of failure. 
Infusion of TNF-a at levels found in heart failure patients resulted in LV remodelling 
and dysfunction in normal rats. Cardiac contractility was depressed within five days of 
starting the infusion and recovered on cessation, suggesting a causal relationship 
(Bozkurt et a l ,  1998). TNF-a also promoted LV dilatation and a thinning of the 
posterior wall. Wall thinning was not reversible, as it involved loss of myocytes by 
apoptosis and reduced deposition of fibrillar collagen. Corroborating these findings, 
transgenic mice that overexpress TNF-a in cardiac myocytes developed severe LV 
dilatation with markedly depressed ejection fraction, pulmonary oedema and premature 
death (Bryant et a l ,  1998). The severity of LV dysfunction is related to the level of 
transgene expression (Franco et a l ,  1999).
TNF-a may directly impair contractility by two mechanisms. Elevating NO causes 
myofilament desensitisation to calcium resulting in sustained dysfunction, while 
sphingosine-mediated interruption of calcium-induced calcium release may be involved 
in immediate dysfunction (Meldrum, 1998).
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1A.11 Endothetin
Endothelin (ET-1) is a 21 amino acid peptide with tlii'ee isoforms cleaved from its pre­
cursor pro-ET-1 by the activity of endothelin converting enzyme (ECE). ET gene 
expression has been reported in numerous tissues e.g. cardiomyocytes, kidney, vascular 
smooth muscle cells and vascular endothelial cells. Rat neonatal cardiomyocytes can 
synthesise and secrete ET-1 suggesting the existence of local ET systems. Two receptor 
subtypes have been identified, ETa and ETb. The ETa receptors on smooth muscle 
cells mediate the potent vasoconstricting effects of endothelin, with involvement of ETb 
receptors in some vascular beds. ETb receptors in the vascular endothelium can 
stimulate the release of NO to cause vasorelaxation (Love & McMurray, 1996; 
extensively reviewed in Rubanyi & Polokoff, 1994).
In the heart, ET has positive inotropic and chronotropic effects and is a potent 
vasoconstrictor of coronary arteries (Rubanyi & Polokoff, 1994). Both ETa and ETb 
receptors are found in the human heart, although only ETa are thought to be functionally 
significant (Sakai et a l ,  1996). In the atria, ETa are linked via Gq/u to the 
phosphoinositide system and to inhibition of adenylyl cyclase via G,. In the LV, ETa 
are only coupled to phosphoinositide (Ponicke et a l,  1998). In subjects with severe 
heart failure these systems remain at normal levels, with no change in receptor density, 
G-proteins or inositol phosphate levels. This is despite elevated plasma ET-1, which 
would be expected to down-regulate the system, suggesting that in the failing heart ET- 
1 signalling is inappropriately normal (Ponicke et a l ,  1998).
In the infarcted rat heait ET has been implicated in wound healing. The gene 
expression of ET precursor preproendotheIin-1 (ppET-1) was upregulated 25-fold in the 
infarct zone over the first three weeks, and the presence of ET-1 in the infarct was 
confirmed by immunostaining. In the same study, ppET-1 mRNA was also expressed at 
high levels in the non-infarcted LV. Since ET-1 has been demonstrated to stimulate LV 
hypertrophy, fibroblast proliferation and collagen deposition, it has been postulated that 
ET-1 may have a role in LV remodelling post-MI (Oie et a l ,  1997).
ET may have a role in pulmonary hypertension secondary to congestive heart failure by 
causing excessive pulmonary vascular constriction. It is noteworthy that tissue ET-1 
and mRNA concentrations are elevated in the lung and right ventricle in rats with heart 
failure (Sirvio et a l ,  1997). Infusion of the non-specific ET receptor antagonist, 
bosentan, into patients with heart failure reduces pulmonary vascular resistance to a 
greater degree than systemic vascular resistance. In addition, the elevated plasma levels
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of ET-1 in heai't failure have been found to correlate with severity of pulmonary 
hypertension, filling pressures and pulmonary vascular resistance (Kiowski et a l ,
1995).
The local (autocrine) actions contribute to systemic and renal vasoconstriction (Sclirier 
& Abraham, 1999). Release of ET from the vascular endothelium contributes to basal 
vascular tone in both normal and heart failure subjects. Even non-constricting levels of 
ET-1 sensitise vessels to the contractile responses of catecholamines or Angll, There 
are numerous interactions between ET-1 and other vasoconstrictors. For example, ET-1 
can increase synthesis of NO and Angll in vascular endothelial cells. The effect is a 
synergistic action to promote vasoconstriction and sodium retention. However, to 
counteract this, the vasodilators NO, prostacyclin and ANP may all inhibit ET-1 
synthesis in the endothelium (Love & McMurray, 1996).
Further evidence for the role of ET arises from the beneficial effects of endothelin 
antagonism in animal models of heart failure. Using an ETa receptor blocker in rats 
post-MI, Sakai et al  (1996) demonstrated a dramatic improvement in survival. 
Treatment normalised central venous pressure, RV systolic pressure and improved LV 
contractile function (Sakai et a l,  1996). Long-term treatment with bosentan 
significantly reduced mortality nine months after MI in rats (Mulder et a l ,  1997b; 
Fraccarollo et a l,  1997). Similar beneficial effects have also been obtained in short­
term (16 days) treatment with bosentan. However, ET-receptor antagonism did not alter 
changes towards a foetal gene expression char acteristic of LVH, arguing against a direct 
regulatory role for ET in MI induced hypertrophy (Oie et a l ,  1998). Bosentan has been 
tested in human heart failure with similar beneficial results (Sutsch et a l,  1998).
There remains controversy concerning whether to use selective ETa receptor 
antagonists over non-selective antagonists. In rats eight weeks after CAL, ETa 
blockade resulted in increased LV dilatation, and there was no effect on mortality or 
cardiac haemodynamics (Hu et a l,  1998b). Similarly, a different ETa antagonist caused 
scar thimiing and LV dilatation in the same model (Nguyen et a l ,  1998). That bosentan 
is clearly better, implicates ETb receptors as unfavourable after MI. Although 
mediating vasodilatation via endothelial cells, ETb on smooth muscle cells cause 
vasoconstrtiction. One hypothesis is that ETb vasoconstriction in the kidney may 
promote water and sodium retention, resulting in the increased LV volume (Hu et a l , 
1998b). However, in healthy volunteers, administration of a selective ETb receptor 
antagonist resulted in peripheral vasoconstriction, which suggests endogenous ETb
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receptors have a predominately vasodilatory role, at least in the non-diseased state 
(Strachan ei a l,  1999).
Finally, ET-1 is a powerful prognostic indicator of mortality in heart failure patients and 
is elevated in proportion to NYFIA functional class. As an independent indicator, it is 
more powerful than NYHA, ANP, NA or ejection fraction in predicting outcome 
(Pousset el a l,  1997).
1.4.12 LVH after MI
Hypertrophy of the surviving myocardium occurs in response to MI. As with pressure- 
overload hypertrophy, LVH is associated with a change to foetal gene expression. In 
the first few weeks after CAL in the rat, mRNA expression is elevated for p-MHC, a - 
skeletal actin, collagen types I & III, ANP, BNP and there is a decrease in a-MHC 
(Gidh-Jain et a l ,  1998; Nakayama et a l,  1997). As with pressure-overload 
hypertrophy, transition to foetal gene expression can be prevented by either ACE 
inhibition or ATi-receptor antagonists, suggesting a role for Angll in the response 
(Yoshiyama et a l,  1999). Therefore, control of hypertrophy after MI is likely to 
involve all of the mechanisms discussed earlier for hypertrophy in the hypertensive 
heart.
Cellular morphometry has indicated that within tlnee days of a large MI in rats, 
individual myocytes have an increased cell volume per nucleus of 28%, due to increases 
in both cell length and diameter (Anversa et a l ,  1985a). Depending on the size of the 
infarct, such changes may take four weeks to become significant. At 4-6 weeks, 
myocyte length has increased by 38% and may be an important factor in the 
development of LV dilatation (Anand et a l,  1997). As with pressure-overload 
hypertrophy, elevated wall stress is thought to be a major stimulus. In the case of MI, 
wall stress is high due to asymmetric ventricular geometry (Anversa et a l,  1985a). 
Cellular growth is mirrored by tissue growth of 29% in the viable myocardium (Anversa 
et a l ,  1985b). However, while the surviving myocardium hypertrophies, there is a 
failure of the capillary network to compensate with equivalent growth. There is no 
change in capillary length or luminal or endothelial volumes. The consequence is that 
the same blood supply must supply more tissue, with a subsequent increase in the path 
length of O2 transport. This may predispose the post-infarct heart to further ischaemic 
damage (Anversa et a l,  1985b; Liu et a l ,  1997).
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The contractile function of myocytes from surviving myocardium may be normal 
despite hypertrophy and the confirmation of global systolic dysfunction. This is not a 
consistent finding, and may vary depending on how distal the myocyte is from the 
infarct area, and on time since infarction. However, it does suggest that factors such as 
wall stress, extracellulai' changes and LV geometry are sufficient to explain LV 
dysfunction, in the absence of a decrease in myocyte contractility (Anand ei a l,  1997).
As with pressure-overload hypertrophy, there has been interest in fmther dissecting the 
role of Angll in the hypertrophic response. In one study, a reduction in LVH was 
achieved using a dose of perindopril that had no effect on LV systolic or filling 
pressures, indicating that this effect was not due to simply lowering blood pressure 
(Chiba et a l ,  1994). A similai' result has been obtained for the AT] antagonist 
irbesartan (Ambrose et a l ,  1999). Conflicting results have been observed for 
perindopril. When the hypotensive effect was prevented by salt-loading, the ACE 
inhibitor no longer prevented cardiac hypertrophy, suggesting that it is blood pressure 
and not local ACE inhibition that is important for LVH after MI in the rat (Yoshida et 
a l,  1998).
Hu et al  (1998b) found that reduced LV mass with quinapril was abolished by co­
administration of a B2-kinin receptor antagonist, suggesting a bradykinin mediated 
effect. Similarly, Liu et al  (1997) showed that reductions in myocyte CSA and 
collagen deposition by ramipril were also kinin-dependent. In the same study, the 
authors found an AT] antagonist could decrease LVH, myocyte CSA and LV dilatation. 
Interestingly, these benefits could be mostly prevented by co-administration of an AT2 
antagonist. The authors speculate that blocking AT] receptors increases renin and 
angiotenin levels resulting in increased activation of AT2 receptors that mediate the 
benefits on LVH (Liu et a l,  1997).
1.4.13 Extracellular changes in the L V
After MI, there is a 70% increase in myocardial fibrosis i.e. a deposition of myofibrillar 
collagen. Such changes alter the stiffness of the myocardium and result in impaired 
relaxation i.e. diastolic dysfunction (Thai et a l,  1999). ATj-receptor antagonism 
inliibits collagen deposition in the rat heart after MI (Smits et a l,  1992), and decreases 
mRNA expression of collagen I and III (Yoshiyama et a l ,  1999). This decreased
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fibrosis has functional significance as it normalises passive myocardial stiffness and 
provides a partial improvement in relaxation (Thai et a l,  1999).
In one study comparing enalapril and losartan, the ACE inhibitor was more effective in 
reducing non-myocyte proliferation in the surviving myocardium and reduced collagen 
deposition. The authors concluded that fibrotic changes in the LV were not a result of a 
direct Angll effect on ATi-receptors (Taylor et a l,  1998). This is in contrast to the 
aforementioned studies. In support of this is a beneficial effect of the [3-blocker, 
metoprolol, to reduce interstitial fibrosis and collagen deposition (Latini el a l,  1998). 
Although myofibrillar collagen is increased in heai't failure, this belies the fact that there 
is also significant breakdown of the collagen matrix, and a wholesale restructuring of 
the extracellular components. This may be vitally important as aligmnent of the 
collagen matrix is thought to be seminal in translating myocyte contractions into global 
LV performance (Mann & Spinale, 1998). Recently, attention has focused on matrix 
metalloproteinases (MMPs), which can be secreted from fibroblasts and cardiac 
myocytes and act to degrade the extracellular matrix. The balance between MMPs and 
their endogenous inhibitors, tissue inhibitors of metalloproteinases (TIMPs), are thought 
to be important in remodelling of the extracellular matrix (Mann & Spinale, 1998). For 
example, in the failing human heart MMP activity is also elevated and there is a 
corresponding down-regulation of TIMPs (Li et a l,  1998). Many neurohumoral factors 
have been implicated in MMP activation in the failing heart. These include all the usual 
suspects i.e. noradrenaline, Angll, endothelin, and TNF-a (Mann & Spinale, 1998).
1.4.14 Apoptosis in the failing heart
DNA laddering, indicative of apoptosis has been identified in the myocardium in 
response to a variety of insults in animal models, for example after, myocardial 
infarction, pressure-overload hypertrophy, hypertensive left ventricular hypertrophy and 
mechanical stretch (Davies, 1997).
In culture systems, NO has been shown to induce apoptosis in adult rat ventricular 
myocytes in a dose dependent manner. ANP can also induce apoptosis in both cultured 
vascular smooth muscle cells and in neonatal rat cardiomyocytes in a dose-dependent 
manner. In the heart, this has been shown to be mediated by cGMP. Noradrenaline, 
endothelin and Angll all promote smooth muscle cell growth and increase survival.
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The net effect in the heart or vasculature will depend on the balance of all these factors 
(W uefa/., 1997).
Apoptosis has also been described in the myocardium of patients with symptomatic 
end-stage heart failure, which has led to the hypothesis that loss of viable myocytes due 
to apoptosis may contribute to left ventricular remodelling and dysfunction in the 
terminal stages of heart failure. (Narula et a l ,  1997)
A huge range of apoptotic indices have been reported from 0.2% of total 
cardiomyocytes (Ruffalo & Feuerstein, 1998) to 35% (Davies, 1997). There is a 
problem in interpreting what this might mean, i.e. are enough myocytes lost via 
apoptosis to have a significant effect on ventricular function and progression of heart 
failure? At present, no-one is able to answer this question. Quantification of apoptosis 
represents a snapshot of cell death at that particular time. To extrapolate such results by 
estimating an apoptotic rate requires too many assumptions that are probably not valid. 
For example, 1) the time course of apoptosis is often quoted as within 24 hours (Ruffalo 
& Feuerstein, 1998), but this is based on cell cultine data, and it is not actually laiown 
how long the process may last in vivo. 2) It is assumed that the number of cells 
undergoing apoptosis within that 24 hours is constant for any given 24-hour period. 
This is obviously flawed as apoptotic index may be high in response to acute stimuli 
(for example after myocardial infarction), examination of the same tissue one week later 
could find no apoptotic cells, but this does not mean that apoptosis has not been 
prominent. 3) Apoptosis is evenly distributed in the tissue. Not true, as apoptosis has 
been described as higher in the infarct border zone, and may occur in focal areas in 
patients with idiopathic cardiomyopathy (Davies, 1997). 4) Apoptosis represents 
irreplaceable loss of myocytes as these cells are terminally differentiated. Recent 
evidence has cast doubt on this assumption. For the first time, true myocyte mitosis has 
been described in the human heart. Using confocal microscopy, myocardial sections 
were stained with a nuclear dye to visualise mitotic cells and counter-stained with a 
myocyte-specific antibody to confirm localisation of mitosis to the myocytes. Further 
to this, the authors found a ten-fold increase in mitotic index in hearts from patients 
with end-stage ischaemic heart disease and idiopathic dilated cardiomyopathy (Kajstura 
et a l ,  1998). For similar reasons to those outlined, it would be wrong to extrapolate a 
mitotic rate from this data to determine the significance of this process. However, if 
confirmed, this groundbreaking study would suggest a dynamic interplay between cell 
death and cell birth in the failing heai’t.
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1.4.15 Myocyte function
Depressed myocyte contractility has been described in animal models of LV 
hypertrophy and heart failure, with defective calcium handling a major culprit. Calcium 
transients are often reported as decreased in amplitude and prolonged, sometimes with 
high diastolic concentrations (de Tombe, 1998). Several key components of Ca^  ^
homeostasis are thought to be involved, described in both human and animal models.
1) There is considerable evidence for reduced expression of the SERCA pump at the 
mRNA and protein level, leading to depressed Ca^ "’ uptake into the sarcoplasmic 
reticulum (SR) (de Tombe, 1998; Balke & Shorofsky, 1998; Yamaguchi et a i,  
1998).
2) The ryanodine-sensitive receptor that releases Ca^^ from the intracellular stores may 
also be down-regulated, resulting in reduced function, although this finding has not 
been consistent (de Tombe, 1998; Yamaguchi et a l,  1998).
3) The L-type Ca^  ^ channel, which allows extracellular Ca^ "^  to enter the myocyte has 
variably been reported to decrease (de Tombe, 1998). Recently, an alteration in the 
juxtaposition between sarcolemmal Ca^^ channels and ryanodine-release chamiels in 
the sarcoplasmic reticulum, has been suggested to explain the reduced ability of the 
incoming Ca^ "^  current to trigger SR Ca^^ release in hypertrophied and failing rat 
hearts. This could explain defects in Ca^^ signalling in the face of normal levels of 
cellular components (Gomez et a l,  1997).
4) The Na"^  / Ca^ "*" -exchanger in the plasma membrane extrudes Ca^ "^  and so contributes 
to relaxation. Expression and activity is often increased in the failing heart, 
probably to compensate for decreased SERCA pump performance. Indeed, 
increased Na"^  / Ca^ "^  -exchanger is associated with preserved diastolic function, 
whereas, when there is no change despite reduced SERCA, this results in 
dysfunction (Hasenfuss ei a l ,  1999).
Since many of these changes are typically observed in both pressure-overload 
hypertrophy and in heart failure, it seems likely that depressed myocyte fmiction is 
involved in the gradual decompensation to overt failure. Such defects have been 
described in rats after CAL (Yamaguchi et a l ,  1998), however; it is not clear how large 
a contribution reduced myocyte contractility contributes to global dysfunction.
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1.4.16 Heart rate & arrhythmias
Patients with congestive heart failure have a decreased variability in heart rate with 
depressed diurnal rhytlmi, which may reflect a decreased parasympathetic or increased 
sympathetic activity (Casolo et a l,  1989). Blunting of the circadian rhythms for both 
blood pressure and heart rate in such patients correlates with poor cardiac function (van 
de Borne et a l,  1992). Similar depression of circadian rhythms have been observed for 
blood pressure and heart rate after MI in the rat (Teerlinlc & Clozel, 1993). Low heart 
rate variability correlates with high plasma NA concentration and so may be a marker 
for neurohormonal activity. In addition, drugs which reduce neurohormonal activity 
also improve heart rate variability e.g. digoxin, (3-blockers. This could explain why 
heart rate variability is a good predictor of mortality (Tuininga et a l ,  1994).
Arrhytlimias are a common complication of MI and are fatal in around 50% of patients 
in the first few hours after infarct. Rats have been used to study arrhythmias after MI 
using implantable radiotelemetry probes for continuous measurement of EGG. In 
common with humans, rats exhibit two distinct arrhytlimogenic periods, for the rat, 
these are between 0-33mins and 1.5-9 hours post-infarct, with relatively few 
arrhytlimias outwith these times. It is worth noting that ventricular tachycardia or 
ventricular fibrillation affected over 95% of rats, with a mortality of 65% only occurring 
during the arrhytlimogenic windows. The incidence of arrhythmias correlates positively 
with size of ischaemic area (Opitz et a l ,  1995). In patients with congestive heart 
failure, the incidence of ventricular tachycardia is strongly associated with sudden death 
(Dovak et a l,  1996).
1.4.17 Skeletal muscle abnormalities
Heart failure is associated with exercise intolerance maiiifesting as breathlessness and 
fatigue. Indeed, poor performance in a walk test is a useful diagnostic indicator 
(Harrington & Coats, 1997). Measurements of systolic or diastolic dysfunction (e.g. 
cardiac output and ejection fraction) fail to provide good correlations with markers of 
exercise capacity such as peak oxygen consumption. For this reason, abnormalities in 
skeletal muscle have been examined as contributing factors. A number of abnormalities 
have been described and are outlined below (see also reviews by Harrington & Coats, 
1997; and Coats, 1996).
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Muscle atrophy affects up to 70% of heart failure patients and is associated with a shift 
in fibre types, reduced fibre size, decreased mitochondrial density, and metabolic 
abnormalities resulting in increased early lactate build-up (Harrington & Coats, 1997; 
Coats, 1996). Vascular defects may be causative, as they occur prior to skeletal 
abnormalities (Thomas D. et a l,  1998). For example, hindlimb blood-flow in response 
to exercise is significantly decreased in rats after MI (Musch & Terrell, 1992), and the 
microcirculation exhibits enlianced responses to a range of vasoconstrictors (Didion et 
a l,  1997).
It has been hypothesised that these defects may contribute to the pathophysiology of 
heai't failure by over-sensitising the skeletal muscle ergoreflex system and so promoting 
sustained SNS activation (Coats, 1996).
1.4.18 Vascular function in heart failure
The elevated total peripheral resistance in chronic heart failure has stimulated interest in 
alterations to vascular function that may contribute to this effect. As described earlier, 
increased afterload maintains perfusion pressure in the face of a reduced stroke volume. 
However, in the long-term it is detrimental and could form part of a “vicious cycle”, 
whereby increased afterload places more strain on the heart (figure 1.4). The injured 
myocardium must pump against the increased resistance thereby increasing LVEDP, 
wall stress and the subsequent compensatory responses of LV hypertrophy and 
dilatation. If as a result, cardiac output falls further, the drive to increase afterload 
becomes greater and so on.
Many of the neurohormonal mechanisms outlined above will have a role in determining 
vascular tone in the heart failure patient. There is increased activity of vasoconstricting 
agents NA, adrenaline, Angll, endothelin, vasopressin, sympathetic nervous system, but 
also of vasodilatory agents such as ANP, BNP, nitric oxide. Obviously, the degree of 
tone will depend on the balance of all these factors. However, there is also evidence for 
altered vascular function at a local level.
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Figure 1.4 Relationship between peripheral vasoconstriction and impaired cardiac 
performance in heart failure. Modified from Hornig et a l ,  (1998a).
The best evidence for vascular dysfunction in heart failure is in the release of NO by the 
endothelium. One of the earliest reports was in rats with confirmed heart failure after 
CAL. In organ bath studies sensitivity to acetylcholine (ACh) was reduced in both the 
thoracic and pulmonary artery. Endothelium-dependent release of NO was implicated, 
as relaxation to nitro-glycerine (endothelium-independent) was normal or slightly 
increased. Basal release was measured by the increase in tension in response to excess 
haemoglobin, but was diminished only in the pulmonary artery. This vessel difference 
may reflect the presence of pulmonary hypertension, as RV weight was increased in 
these heart failure rats (Ontkean et a l ,  1991). Reduced endothelium-dependent 
relaxation has since been confirmed in the thoracic aorta of the rat heart failure model 
by Lindsay et al (1992), Nasa et al (1996), de Vries et al. (1997), and Toyoshima et al 
(1998). In the study by Nasa and colleagues, the impaired relaxation to ACh could be 
partially restored by addition of a cyclooxygenase inhibitor, suggesting that release of 
prostaglandin constricting factors may account for some of the dysfunction. In addition, 
release of basal NO was reduced in these animals (Nasa et a l,  1996).
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The above studies were performed in rats with heart failure and healed infarcts. 
Vascular function in thoracic aorta at one week post-MI exhibits different 
derangements. In these animals, stimulated NO release was found to be normal. 
However, an enlianced contractility to NA was observed, which could be explained by 
an impaired basal release of NO from the endothelium. In the absence of endothelium, 
maximal NA contractility was actually depressed, which was due in part to a reduced 
a  1-adrenoceptor sensitivity and a general decrease in smooth muscle cell contractility 
(Teerlink et a l ,  1994). One could speculate that the additional defects observed in this 
study may be related to the early stage after infarction when neurohormonal activation 
is at its highest (Stassen et a l ,  1997a) e.g. high plasma NA which could down-regulate 
receptors.
Resistance arteries
As discussed earlier, vascular resistance resides in the small arteries and dilator 
dysfunction has also been described in these vessels. In heart failure rats, where the 
hindlimb is perfused to allow study of an entire vascular bed, the maximal relaxation to 
ACh is diminished in rats with large infarcts, while response to nitro-glycerine and 
NOS-inliibition are normal (Drexler & Wenyan, 1992). Again, this suggests that 
endothelium-dependent release of NO is normal under basal conditions but that 
stimulated release is impaired. This result has been confirmed in isolated resistance 
arteries from the femoral and mesenteric beds. The femoral arteries exhibited
significantly greater impairment than the mesenteries (37 versus 63% maximal dilation 
respectively), suggesting endothelial dysfunction is heterogeneous between vascular 
beds (Mulder ei a l ,  1996). More evidence for this is the impaired stimulated and basal 
release of NO reported by Baggia et al. (1997) in the pulmonary arteries, but not in 
abdominal aorta or 3"^  order mesenteric resistance arteries (Baggia et a l ,  1997). Stassen 
et a l  (1997b) also report heterogeneity in contractile dysfunction between vessels in the 
ligated rat. In mesenteric resistance arteries they describe a generalised reduction in 
maximal response to a range of contractile agents, which could not be explained by a 
reduction in muscle mass. In contrast, the same agents demonstrated hyperreactivity in 
vessels from the non-infarcted myocardium, which they hypothesise may be due to 
exposuL'e to locally high levels of contractile / pro-mitogenic factors in the myocardium.
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Meanwhile, there was no evidence of contractile dysfunction in the thoracic aorta 
(Stassen a/., 1997b).
In contrast with many of the above studies, Buus et al. (1999) recently reported that 
maximal relaxation to ACh was normal In third order mesenteric resistance arteries 
from CAL rats at both 8 and 26 weeks post-MI. This time, a reduced basal release of 
NO was noted. However, the authors note that NOS inliibition induced contractions are 
very small in the mesenteric resistance arteries, and so basal NO may not be a major 
determinant of tone in these vessels (Buus et a l ,  1999). The between study 
discrepancies in ACh-induced relaxations may be due to differences in experimental 
protocol, in particular, whether endothelium-derived contractile prostanoids have been 
inhibited or by not controlling for EDHFs.
Since EDRF has been implicated in endothelial dysfunction, the most obvious approach 
is to measure the expression of eNOS mRNA and eNOS protein, by Northern and 
Western blotts respectively, to determine if the decrease in EDRF-mediated relaxation is 
due to a reduced expression of the eNOS enzyme. Smith et al. (1996) performed these 
experiments in dogs with pacing-induced heart failure, measuring eNOS expression in 
endothelial cells scraped from the thoracic aorta. Comparing heart failure animals with 
sham operated, they found a 56% reduction in eNOS mRNA expression with a 
corresponding decrease o f -70%  in actual eNOS protein, and reduced enzyme activity. 
In a similar fashion, Comini et a l  (1996) measured eNOS protein levels in the thoracic 
aorta of Sprague-Dawley rats given monocrotaline, which induces congestive heart 
failure secondary to pulmonary hypertension. They measured eNOS in both 
endothelium and smooth muscle and found it to be differentially regulated. In heart 
failure, endothelial eNOS decreased to 5% of sham levels, whereas smooth muscle 
eNOS increases by over 200% compared to the shaiu animals. This supports the 
assertion that vascular changes during CHF are complex and local, occurring in both 
endothelium and smooth muscle layers. In this experiment the total aortic eNOS fell to 
60% of control levels, and this is consistent with the physiological changes showing 
depressed relaxation in CHF. iNOS was not detected in this preparation (Comini et a l,
1996).
By measuring blood flow and noradrenaline gradient across an organ there is evidence 
to suggest that the degree of sympathetic activity displays regional differences. Cardiac 
sympathetic activity may increase between three- and fivefold, while renal activity 
tlireefold, and splanchnic sympathetic tone increases only twofold (Kaye & Esler,
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1995). This may help explain the regional differences in vascular function observed in 
human and experimental heart failure. For example, the popular use of mesenteric 
arteries for examining vascular function in the rat may not represent the best 
opportunity for observing alterations in noradrenergic transmission. Further evidence 
for this is that while p-adrenoceptor function is blunted in the heart, there appears to be 
no evidence for similar' down-regulation in the peripheral circulation, and this may be 
due to the higher sympathetic activity in the heart (Kaye & Esler, 1995).
Human vessels
Studies of vascular function in humans may be confounded by concomitant therapy and 
by underlying pathologies such as hypertension, atherosclerosis and by smoking. 
However, similar defects to the rat have been described. In gluteal subcutaneous 
resistance arteries from patients with heart failure of ischaemic origin, Angus et al 
(1993) described a generalised hyperreactivity to contractile agonists such as KCl, NA 
and Angll, and an impaired stimulated release of EDRF. In contrast, Stephens et al 
(1998) examining the same vessels found no alterations in contractile function, or 
relaxation. However, heart failure was mild in these patients.
Due to the difficulty in obtaining vessels from humans, many studies have examined 
blood flow of the whole forearm using plethysmography. This has the advantage of 
measuring responses from a whole vascular bed, and because vessels are in situ, they 
remain under the influence of the SNS and circulating vasoactive factors. Using this 
teclmique, heart failure patients were found to have impaired stimulated endothelium- 
dependent relaxation (Kubo et a l ,  1991). This result has been confirmed by Hirooka et 
al  (1992) and Katz et a l  (1993). In the latter study, several layers of dysfunction were 
apparent. As well as reduced EDRF release, cGMP-mediated relaxation was impaired 
at the smooth muscle level. Indomethacin did not affect basal blood flow, but did 
increase blood flow in response to ACh in heart failure, but not normal patients. 
Therefore endothelium-derived contracting factors of prostanoid origin may also 
contribute to the diminished ACh response in human heart failure (Katz et a l,  1993).
The extent of vascular dysfunction is directly related to the severity of heart failure. 
Carville et al (1998) found impaired relaxation to ACh in subjects with moderate heart 
failure, which was significantly worse in those with severe disease. In addition, only 
those with severe heart failure exhibited impaired relaxation to sodium nitroprusside.
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As with hypertension, abnormalities in the NO-system with heart failure have been 
linked to reduced availability of NO, probably via destructive interaction with oxygen 
free radicals. Acute intravenous and clii'onic oral treatment with the antioxidant vitamin 
C improved NO-dependent flow in the radial artery of heart failure patients compared 
with controls. (Hornig et a l, 1998b)
Coronary vessels
In the coronary vessels a reduction in maximal dilatory response (as discussed above), 
represents a loss of cardiac reserve. In the healed rat heart post-myocardial infarction, 
reduction in vasodilator response has been observed in the surviving hypertrophied 
myocardium, manifesting as a decreased maximal tissue perfusion. The authors 
speculate that resistance arteries feeding this part of the myocardium may already be 
vasodilated to supply the increased needs of an hypertrophied left ventricle. The 
inability of these vessels to further vasodilate in response to increased demand would 
make the hypertrophied part of the left ventricle most at risk from further ischaemic 
attacks. (Kalkman et a l, 1997)
Vascular function -  summary:
1) Impairment of either (or both) stimulated and basal release of EDRFs are common 
observations in blood vessels of all sizes from animals and humans with heart 
failure irrespective of aetiology.
2) Extent of dysfunction is proportional to severity of heart failure. Generalised 
hyporeactivity to vasoconstricting factors and impaired smooth muscle cell 
relaxation pathways, are probably more common in severe heart failure.
3) Vascular dysfunction is highly heterogeneous between vascular beds, dysfunction 
occurs in isolated vessels and so is related to local defects, not just to elevation in 
systemic neurohormonal mechanisms.
1.4.19 Vascular structure in heart failure
Vascular structural alterations in heart failure are mild and not always apparent. This is 
surprising considering the well-defined vascular remodelling observed in hypertension, 
and the higher levels of neurohumoral factors present in heart failure. For example, 
noradrenaline, Angll, endothelin, ANP and NO can all affect vascular growth and 
apoptosis.
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Ill data obtained after CAL in the rat, large conduit vessels have been reported to have a 
reduced medial CSA and decreased media-to-lumen ratio i.e. inward hypotrophic 
remodelling. This has been described in the thoracic aorta, abdominal aorta, renal 
artery, superior mesenteric artery and carotid artery (Heeneman et a l,  1995). However, 
studies are just as likely to show no change in these vessels, at least in the thoracic 
aorta, which has been most extensively studied (Stassen et a l,  1997b; Richer ei a l, 
1992; Ceiler et a l, 1998).
In the resistance arteries the picture is not any clearer. For the mesenteric resistance 
arteries, a number of studies have found no change in media CSA or media-to-lumen 
ratio for a wide range of time points from one day to one year post-infarct (Mulder et 
a l,  1996; Stassen et a l, 1997b). Negative results have also been obtained in femoral 
resistance arteries (Mulder et a l , 1996), myocardial resistance arteries (Kalkman et a l ,
1996) and in human subcutaneous resistance arteries (Stephens et a l,  1998). Only two 
studies report structural alterations in the mesenteric resistance ai'teries. In both, medial 
CSA remains close to normal while lumen diameter increases, resulting in a lower 
media-to-lumen ratio (Heeneman et a l, 1995; Buus et a l, 1999). Therefore, there is no 
change in quantity of material, but remodelling of existing material around a slightly 
enlarged lumen.
In summary, vascular structural alterations in heart failure are borderline and may only 
be observed dependent on severity and time course of failure. A fine balance of 
vasoactive factors may contribute to maintaining the status quo. For example, in normal 
rats, infusion of Angll increases blood pressure and results in vascular hypertrophy. An 
identical infusion in rats after CAL has neither of these effects. Flowever, co-infusion 
of Angll + NOS inhibitor in CAL rats, still does not increase blood pressure, but 
vascular hypertrophy is observed. This suggests that during heart failure NO counters 
the mitogenic effects of Angll (Fleeneman et a l, 1997).
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2. Methods
This chapter describes general laboratory practice and details teclmiques that are 
common to more than one chapter. The experimental protocols for each group of 
experiments are described in the relevant chapters, along with techniques applicable 
only to that chapter.
2.1 General laboratory Practice
All experiments were performed using the highest quality reagents available and using 
the appropriate level of safety as prescribed in the Control of Substances Hazardous to 
Health regulations i.e. lab coat, safety goggles, mask or fume cupboard where 
appropriate.
Animal strains
All rat work was undertaken in accordance with the Animals (Scientific Procedures) Act 
1986 under the project licence “Spontaneously Hypertensive Studies” 60/1982, held by 
Prof. Dominiczak.
Animals were provided by an in-house breeding programme of SHRSP and WKY rats. 
Inbred colonies of these strains have been maintained in Glasgow by brother-sister
mating since 1991, when 6 males and 7 females of each were gifted by Dr. D.F. Bolri’
from the Department of Anatomy and Cell Biology at the University of Michigan, USA. 
The original breeding stock was obtained over 15 years previous from the National 
Institutes of Flealth, Bathseda, USA. In order to preserve the hypertensive versus 
normotensive phenotype, only adult animals with the following characteristics are 
selected as breeders. Male SHRSP with systolic blood pressure 200-23 OmniHg, and 
females with 170-190mmHg and WKY males 130-150mmHg, females 100-130mmHg. 
All rats were kept in a controlled environment for temperature (2UC) and humidity, 
with a 12-hour light/dark cycle. Normal rat chow (rat and mouse No.l maintenance 
diet. Special Diet Services) and water was available ad libitum. Individuals were 
housed with siblings in same sex groups until on procedure, when they were housed one 
per cage.
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Body M>eight and tibial length measurements
Body weights of animals were taken immediately prior to all manipulations and 
procedures using a Ohaus Lume-O-Gram balance. Animals undergoing surgery also 
had external tibial length measured with Mitutoyo digital calipers (Jencons Scientific 
Ltd.).
Blood pressure measurement
Systolic blood pressure was measured by taiLcuff plethysmography (Evans et a l, 
1994). In order to fully dilate the vessels in the tail, rats were pre-warmed to 36°C in a 
well-ventilated polystyrene box containing familiar bedding to minimise stress. The 
animals were then wrapped in a cloth to keep them placid while an inflation cuff was 
placed around the tail. The cuff was controlled by a Hartman & Braun type 2 
current/pressure transducer, capable of delivering ImmHg steps over a range of 0- 
300mmHg. A piezoceramic transducer was incorporated for pulse detection over this 
range of pressures, and interfaced to an IBM-compatible personal computer. The 
pulsation signal was displayed as a function of pressure to enable automated estimation 
of the systolic blood pressure. A minimum of three such readings were made for each 
rat, and the average taken as the blood pressure for that sitting.
Tissue harvest & blood sampling
Where blood samples were required, these were collected by cardiac puncture. Animals 
were deeply anaesthetised using halothane 5% in Og, and the chest wall quickly opened. 
A 10ml syringe with green 21G needle was rinsed with heparin sodium (1000 units/ml) 
and used to withdraw blood directly from the still beating left ventricle. A quantity of 
between 4 and lOiul of blood could be extracted per animal. This was transferred to 
heparinised tubes and stored on ice. The blood was fractionated by centrifugation at 
2500 revolutions per minute, 4°C for 10 minutes (Centra-7R, International Equipment 
Company). The plasma supernatant was collected and stored at -20°C until required.
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Neuroendocrine measurements
Plasma renin activity was measured using an antibody-trapping method adopted for use 
with rat plasma (Morton & Wallace, 1983). Plasma aldosterone were analysed using a 
commercial radioimmunoassay (Peninsula Laboratories, California, USA).
Rat ANP was measured in plasma by radioimmunoassay, after prior extraction on C l8 
Sep-Pak columns, with a modification of the method of Richards et al. (1987). The 
antibody cross-reacted 100% with rat ANP. Rat BNP was measured with a 
radioimmunoassay kit (RIK 9103, Peninsula Laboratories) again after prior extraction.
2.2 Preservation of tissues & RNA extraction
Tissue harvest and general laboratory practice
Where rat hearts were collected for Northern blot analysis, both atria were removed and 
approximately 25% of the left ventricular free wall proximal to the mitral valve. Tissue 
was inunediately snap frozen in liquid N^, and stored at -70°C until required. Dissection 
was rapid to minimise degradation of RNA by endogenous RNAases.
To protect the samples from RNAases present in the environment, all work was 
performed using RNAase-free technique. This involved wearing gloves at all times, and 
changing them frequently to prevent se lf  contamination. All work surfaces and 
equipment were cleaned with a 3% solution of hydrogen peroxide, and all solutions 
were made using a 0.1% solution of the RNAase inhibitor diethyl pyrocarbonate 
(DEPC) in distilled water followed by autoclaving. At all times during processing, 
samples were kept on ice to slow down any degradation. By strict adherence to these 
principles, no problems due to RNA degradation were experienced.
RNA extraction
To isolate RNA, each tissue sample was removed from the freezer and dropped into a 
test-tube containing 4ml of chilled RNAzol B (Biogenesis), then homogenised using a 
Kinematica polytron homogeniser (Philip Harris Scientific, Aberdeen, UK). To each 
sample was added 400p,l chloroform followed by vortexing for 15 seconds, and left on 
ice for 5 minutes. Tubes were then spun at 4‘^ C in a centrifuge at 2500 revolutions per 
minute for 10 minutes (Centra-7R, International Equipment Company). The
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supernatant containing RNA was transferred by sterile Pasteur pipette into 15ml glass 
test-tubes. Care was taken not to disturb the interface between layers to prevent 
contamination with DNA. An equal volume of isopropanol was added and the tube 
mixed by inversion before being allowed to precipitate on ice for at least 30 minutes. 
After RNA precipitation, tubes were spun in a centrifuge at 4°C and 10000 revolutions 
per minute for 15 minutes (Model J2-21, Beckman). After discarding the supernatant, 
the resulting pellet was washed with 2ml of 70% ethanol to dissolve salts, followed by 
vortexing, and a ftu'ther 15 minutes of centrifugation at the same settings. Ethanol was 
then removed using a sterile Pasteur pipette, and the pellet left on ice to dry. The pellet 
was re-suspended with 100-200pl of DEPC H^O, and stored in a sterile Eppendorf tube 
at -70°C.
Agarose gel electrophoresis
Integrity of the RNA solution was then checked using agarose gel electrophoresis. A 
1% agarose gel was made with tris-acetate (TAE) buffer and incorporating Ipl ethidium 
bromide. This was placed in an electrophoresis tank and immersed in TAE buffer. To 
each well was added 2pi of the RNA solution to be tested, 3 pi DEPC HjO, and Ipl of 
agarose gel blue loading dye (6x strength). One well was reserved for running 
molecular weight markers created by the restriction enzyme X Hind III (Promega). The 
gel was then run by applying a potential difference of 5 volts per cm until the loading 
dye had migrated two thirds of the way down the gel. RNA was then visualised under an 
ultraviolet (UV) transilluminator (UVP). Good quality RNA samples showed clear 
strong bands of 28S, 18S and 5S ribosomal RNA and a light smear representing the full 
range of mRNAs which are present only at low concentrations. An example is shown in 
Figure 2.1.
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28S. 18S‘ 
5S.
Figure 2.1 Example of 1% agarose gel incorporating ethidium bromide for checking 
integrity of total RNA. Each lane contains sample RNA from the left ventricle of either 
WKY or SHRSP animals. The three distinct bands in each lane represent the high 
abundance 28S, 18S and 5S ribosomal RNAs which are approximately 5000, 2000 and 
160 nucleotides long respectively. The final lane has been loaded with the digest 
product of the restriction enzyme IHind III.
RNA quantification
RNA concentration and purity was measured by spectrophotometry. A quartz UV 
transparent cuvette was filled with 1ml of DEPC HjO and the absorbance zeroed on 
spectrophotometer (Ultrospec 2000, Pharmacia Biotech, St. Albans) at a wavelength of 
260nm. RNA solution was then added to the cuvette in 2pl and 4pl volumes to give 
dilutions of 1 in 500 and 1 in 250 respectively. The use of two different dilutions 
provided an internal check that the measured absorbance was in a linear relationship 
with the concentration of RNA. Measurements were repeated at a wavelength of 
280nm.
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The optical density (OD) or absorbance was used to determine the purity of the RNA 
sample. The optical density at 260imr (ODjeo) is a measure of RNA concentration, 
whereas the OD280 reading corresponds to the protein concentration. A ratio of these 
values, OD2Go:OD28o, in the range 1.8 to 2.3 was taken to be indicative of a satisfactory 
level of purity.
The OD260 value was further used to calculate the concentration of single strand RNA 
(ssRNA) in the sample solution. Since an OD2Ü0 of 1.0 is equivalent to 40pg of ssRNA 
in a 1 OOOpl sample, it was calculated that,
ssRNA concentration of sample (pg/ml) = ODjgo x 40 x dilution factor
(Sambrook et a l, 1989)
2.3 Northern blot analysis (see Appendix for solution recipes)
A quantity of sample containing lOpg total RNA was mixed in an Eppendorf with 3 
volumes of 100% ethanol, and 1/10th volume of 3M Sodium Acetate, then stored 
overnight at -70°C.
The next day, samples were defrosted and pelleted by centrifugation at 14000 
revolutions per minute for 30 minutes at 4°C (Eppendorf 5402). The supernatant was 
removed and pellet washed with 180pl of 70% ethanol before re-spimiing for 15mins. 
Again the supernatant was removed and samples left on ice to dry.
A 1% (w/v) agarose gel was made incorporating 10% lOx denaturing gel buffer 
(Ambion), without ethidium bromide. Pelleted samples were re-suspended in 5 pi 
DEPC H2O and 15 pi northern sample loading dye (Ambion) then incubated for 15 
minutes at 65°C to denature secondary structure. The samples were loaded on the gel, 
with one lane containing 5pi DNA fragments from X Hind III as size markers. The 
electrophoresis tank was filled with Ix denaturing gel buffer (Ambion) and run at a 
potential difference of 5 volts per cm until the loading dye had migrated two thirds of 
the way down the gel.
Capillary transfer
The size fractionated RNA was transferred from the gel to a positively charged nylon 
membrane (BoeMnger 1417240) by capillary transfer. A perspex bridge was placed in 
a tray containing 20x SSC solution, and covered by 3 layers of Whatmami 3MM paper
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which had been soaked in 20x SSC. Assemblage was such that both ends of the paper 
were in the 20x SSC solution, and so could act as a wick. The gel was placed on top of 
the bridge and then the nylon membrane cut to size and soaked in 2x SSC. A further 3 
layers of Whatmann 3MM paper soaked in 2x SSC were cut to the same size as the gel 
and added, and finally a 2 inch thick bundle of tissue paper which was weighted down 
with a 500g weight. At all stages, care was taken to remove air bubbles between layers. 
Contact between upper and lower layers, except through the gel, was prevented by 
cai'efully sealing around the gel with Parafilm. The transfer assembly was left 
overnight.
The next day the transfer system was disassembled and the membrane rinsed in 6x SSC, 
air dried for 30 minute, then baked in an oven for 30 minutes at 80°C to deglyoxylate 
the RNA. Cross-linldng to the membrane was achieved by irradiating with 2400 joules 
ultraviolet light (Stratalinlcer 2000, Stratagene Ltd., Cambridge). The lane containing 
DNA molecular size markers was cut off and visualised by staining for 5 minutes in
0.04% (w/v) methylene blue in 0.5M NaOAc (pH 5.5), followed by washing for 20 
minutes in distilled H^O.
Hybridisation
The membrane was placed into a hybridisation flask (Techne) containing 10ml per 
lOOcnf pre-hybridisation solution (Ambion) and washed for 1 hour at 42°C in a 
hybridisation oven (Hybidiser HB-1, Teclme).
In the meantime, the DNA probe was radiolabelled. In all experiments the blot was 
initially hybridised with a cDNA fragment of glyceraldehyde phosphate dehydrogenase 
(GAP). In an Eppendorf, 2pl GAP fragment (15ng/pl) and 43pi distilled H^O were 
mixed then denatured at 95°C for 3 minutes (Griffin block heater) and placed on ice for 
2 minutes. The contents of the Eppendorf were used to re-suspend Ready to Go DNA 
labelling beads (Pharmacia Biotech 27-9240-01), to which was added 5pi radioactive 
dCT^2p (Amersham Pharmacia Biotech.) followed by incubation at 30°C for 30 minutes. 
To purify the probe, a Nick column (Pharmacia Biotech) was washed tluough with 3ml 
TE solution, the probe was added followed by 400pl TE, which was collected in an 
Eppendorf and discaided. A second 400pl TE solution was added to the column and 
collected in a clean Eppendorf, this aliquot contained the purified radiolabelled probe.
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demonstrated by high radioactive counts on a Geiger counter. Again, DNA was 
denatured at 95°C for 3 minutes followed by cooling on ice for 2 minutes. The 
radiolabelled probe was added to hybridisation solution (10ml per lOOcnf of blot, 
Ambion) and replaced the pre-hybridisation solution in the hybridisation flask. The 
probe was incubated with the membrane overnight at 42°C with continuous turning. 
Subsequent hybridisation e.g. for ANP, BNP or iNOS, followed the same protocol for 
radiolabelling, but with a comparative quantity of appropriate cDNA substituted for 
GAP.
Blot washing & visualisation
The next day, the blot was washed to remove non-specific radioactivity using the wash 
protocols and solutions detailed in appendix I. The blot was then wrapped in cling film 
and placed in a cassette with two enliancement screens for autoradiography using high 
performance autoradiography film at -70°C (Hyperfilm, Amer sham). Initial exposure 
time was for 24 hours, when film was developed using a Kodak X-OMAT automated 
developer. If necessary the blot was re-exposed for a length of time dependent on the 
signal intensity and signal-to-noise ratio.
Densitometry and analysis
Developed blots were scamied using a Fluor-S Mutilmager (Bio-Rad) and analysed on a 
personal computer using Multi-Analyst Version 1.1 software (Bio-Rad, Hercules, USA). 
Measurements of optical density were made on-line by using the freehand drawing tool 
to draw round individual bands on the blot. Background readings of optical density 
were also taken, and the optical density (OD) of a given band calculated as -
O .D . =  “ ODb,eUg,oun.i) X Area of band
This allowed for comparison of relative abundance of RNA between lanes on a single 
blot. The molecular sized markers were used to check that the observed RNA band was 
at the expected size for that gene product e.g. 1.8 kb for GAP.
If blots were to be re-probed for visualising other gene products, then the blot was 
stripped by repeated washing in a solution of 0.1% SDS w/v at lOO'^C.
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Preparation o f  cDNA for hybridisation
Complimentary DNA (cDNA) was used as the hybridisation probe. Probes for GAP 
and ANP Northerns were available from previous work in this lab. The cDNA for BNP 
was prepared utilising the reverse transcriptase-polymerase chain reaction (RT-PCR) to 
produce multiple copies of the region of interest. Forward and reverse primers were 
designed based on the Imown sequence for rat BNP (Brosnan et a l,  1999), and were 
synthesised by Oswel DNA service (Southampton, UK). The nucleotide sequence was 
as follows,
Forward primer AGACAAGAGAGAGCAGGACAC
Reverse primer AGACTGTCGGTAAGGTAGAGG
The amiealing temperature for these primers was estimated from the GC content as 
59°C. It was calculated that the product would be approximately 750 base pairs long 
and so would require a longer than normal cycle time for elongation. Therefore, the 
conditions for PCR were set at 1 minute at 94°C, followed by 1.5 minutes at 59°C for 
annealing, then 2 minutes elongation time at 72°C. This cycle was repeated 30 times.
In a 96-well tray, the following components were added to give a final volume of 20pi 
in each of 12 wells.
5 pi of 20ng/pl WKY genomic DNA
5pi of IpM  primers solution to give final concentration of 0.25pM
lOpl Mastermix (Promega) containing dNTPs, lOx buffer, dUgO, lOx Mg^' (final Mg^’
concentration of 1.5 inM, and 0.375 units of Taq DNA polymerase (Promega).
This reaction mixture was covered by a drop of mineral oil to prevent evaporation. 
Before adding the Mastermix the DNA and primers were given a hot start of 4 minutes 
at 94°C to denature secondary structure. Water blanlcs were run in two of the wells in 
which WKY genomic DNA was replaced with dHgO in order to check for 
contamination by foreign DNA.
After 30 cycles of PCR, the contents of the wells were combined, mixed with 6x loading 
dye, and run on a 1.5% agarose gel together with the water blanlcs and IH ind III 
molecular weight markers. The agarose gel incorporated Ipl ethidium bromide to 
enable visualisation and so check that the product was the expected size (Figure 2.2).
82
23130
b 2 0 -,
Sample migrated 12mm 
= 10^ ®^  or 741 bp
15 -
10 -
O)
2.5 3.0 3.5 4.0 4.5 5.0
Molecular weight (Log bp)
Figure 2.2 Panel (a) shows BNP PCR products run on a 1.5% agarose gel. Lane 1 
was loaded with A.Hind III molecular weight markers with size of fragments in base 
pairs (bp) indicated on the left-hand side. Lanes 2 and 4 contain 1 pi samples of PCR 
product, and lanes 3 & 5 contain water blank controls. Panel (b) is a standard curve of 
migration distance against molecule weight for the molecular weight markers. The PCR 
samples migrated 12mm, which corresponds to a molecular weight of 741 base pairs.
To prepare a solution of the cDNA, the band obtained from the agarose gel was cut-out 
and placed into a small section of dialysis tubing that had been pre-soaked in distilled 
water. The tube was filled with a few millimetres of Ix TAB and sealed, taking care to
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remove air bubbles from the bag. The dialysis tubing was placed in an electrophoresis 
tanlc orientated such that the band of gel was orientated towards the negative electrode. 
A current of 80 volts was then applied for 30 minutes in order to electrophorese the 
DNA out of the gel and into solution. Purification of the cDNA was by standai'd phenol 
and chloroform extraction. The cDNA was then radiolabelled prior to hybridisation as 
described earlier in section 2.3.
2.4 Confocal microscopy
Confocal microscopy for imaging rat mesenteric resistance arteries is utilised in 
hypertensive rats (Chapter 4) and in rats after coronary artery ligation (Chapter 5). The 
methodology applied to each was identical, and was based on a technique developed in 
this laboratory (Arribas et a l, 1996; McGrath et a l, 1995; Arribas et a l, 1997).
A large section of the mesenteric arcade was dissected from an area supplying the 
jejunum, and bathed in PPS while fine dissection of 3"' order mesenteric resistance 
arteries was performed. The basis for artery selection is described in Figure 2.3. 
Arteries were mounted on a perfusion myograph and fixed with formal saline under 
pressure (Living Systems Instrumentation). Vessels for Chapter 4 were fixed at half the 
systolic blood pressure measured in vivo by tail-cuff plethysmography. Since blood 
pressure data was not available for heart failure rats, vessels from these animals were 
fixed at 50mmHg, which had been calculated from wire myography experiments to be 
90% of in vivo lumen diameter.
Nuclei were stained by incubation with lOpmol/L propidium iodide for 1 hour, then 
washed for 3 hours. Vessels were visualised following the method of Arribas et a l 
(1997) with an Odyssey Real Time Laser Scanning Confocal Microscope (Noran 
instruments), using excitation at 488nm from an argon ion laser, and emission at 515nm 
with a slit size of 15pm. The lumen was visualised with a lOx air objective through the 
widest section of the vessel. A 40x water immersion objective was used for wall 
thiclmess measurements, when the plane was focused in the middle of the artery and 
1pm z-axis segments were taken through the vessel wall. Metamorph software 
(Universal Imaging Corporation) was used to make calibrated measurements from a 
minimum of tlnee lumen images and two wall thiclaiess stacks per vessel.
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Figure 2.3 Anatomical selection of 3'"' order mesenteric resistance arteries. Typical 
internal diameter ranges from 150-250pm. Panel A indicates the position of 3"' order 
vessels in the mesenteric arcade. Panels B & C illustrate methods employed for 
differentiating arteries from veins. Wlien depressed with forceps, blood contained in 
arteries (but not veins) will retimi to the area of depression due to the muscular walls 
(panel b). The junctions in arteries also differ from veins (panel c).
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The arrangement of the imaging plane perpendicular to the artery is demonstrated in 
Figure 2.4. Multiple imaging planes were talcen along the z-axis, probing deeper into 
the vessel wall in 1pm increments. The scale diagram indicates that the width of the 
imaging plane at 102 pm is wide enough that some curvature should be expected in these 
small vessels if the artery in cross-section remains perfectly round. It therefore becomes 
important to adopt a protocol to ensure that curvature does not result in an 
overestimation of the wall thickness when measuring between the most distant points of 
the inner and outer surfaces. Fortunately, the effects of curvature are easy to identify, 
for instance, when endothelial cells are visible in the centre of the image, with smooth 
muscle cells occurring in bands above and below. In these cases, only cells included 
within the central band were used to calculate dimensions, while all cells were counted 
for cell number data. A computerised counting system was utilised to ensure cells were 
not double counted in error.
The following data are measured directly, wall thiclaiess, adventitial, medial and intimai 
thickness and cell numbers. The method for identification of cell types is shown in 
Figure 2.5. Other parameters such as cross-sectional area (CSA) or volumes are 
calculated as outlined below. The assumptions made in these calculations are that 
vessels are of uniform thickness and composition along their length and circumference, 
and that they form a perfect circle in cross-section.
We know from calihration of the microscope the area of each plane (image) in the stack, 
which remains constant tlu'oughout the experiments.
Area of image = 10404 pm  ^ = 0.010404 mm^
The number of endothelial cells (nEC) is comited from a set of 4 -  8 images and 
calculated as endothelial cell number per m n f.
iiEC/mm^ = Total nEC / (Area of image x Number of images) Equation 1
The external diameter was not measured directly, but was simply calculated as,
External diameter = lumen diameter + (2 x wall thickness) Equation 2
Using this, the cross-sectional area (CSA) was calculated assuming the cross-section to 
form a circle, such that area = % r ,^ where r = radius of circle. The CSA using the 
internal dimensions could then be subtracted from CSA of external dimensions to obtain 
the area of each layer of interest.
Vessel wall CSA = [71 (External diameter/2)^] -  [7t(lumen diameter/2)^] Equation 3
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Adventitial CSA was calculated using equation 3 by including medial and intimai 
thickness with lumen radius when calculating internal dimensions. Media and intima 
CSAs were calculated in a similar way.
z-axis 1pm steps
g
102pm
►53pm 181pm
lumen
Figure 2.4 Schematic representation of a resistance artery in cross-section 
indicating the relationship between imaging plane and vessel wall. Diagram is drawn to 
scale based on data from hypertensive SHRSP using a x40 objective. Optical sections 
are taken along the z-axis in 1pm steps, while each imaging plane occupies a 
102x102pm square.
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A measurement of volume could then be obtained by multiplying CSA by length of 
vessel, assuming the vessel to have a cylindrical shape. For the purposes of simplicity, 
a standard segment length of 1mm was chosen, such that CSA in m nf was equal to 
volume of a 1mm segment in m n f.
The volume of a stack was calculated as.
Volume of stack mm  ^= Area of image x Wall thickness Equation 4
N.B. Conversion from pm^ to mm^ requires multiplication by 1x10 ^
Since we laiow both the volume of the stack and the number of smooth muscle cells 
(SMC) contained within it, then it is possible to calculate the total number of SMC in a 
1mm segment of artery by determining the number of stacks required to represent that 
artery.
Number of stacks / Imm^ = Wall volume / Volume of stack Equation 5 
Total nSMC = (Number of stacks / Imm^) x (nSMC in stack) Equation 6
Finally, cell density was calculated by correcting total cell number for volume of the 
appropriate layer.
SMC density (n/mm^) = Total nSMC / Media volume Equation 7
The equivalent parameters for adventital total cell number and density were calculated 
in an identical fashion.
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Figure 2.5 Extended focus 
views through the vessel wall 
o f a mesenteric resistance artery 
using laser scanning confocal 
microscopy. Nuclei have been 
stained with propidium iodide. 
ABC is a 3-D reconstruction 
through the entire wall. It can 
be optically dissected according to 
cell type to give images A, B & C. 
Image A shows endothelial cells 
in the intimai layer. These lie 
oriented in the same plane as 
blood flow through the vessel. 
Image B shows the smooth muscle 
cell layers, which lie perpendicular 
to flow.
Image C shows adventitial cells, 
which are typically rounded, and 
stain brightly.
This type o f optical dissection 
allows cellular quantification o f 
arterial component parts.
/  «
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3. Assessment of Left Ventricular Structure and Function by 
Echocardiography in the Rat
3.1 Introduction
Ultrasound as a body imaging technique has been used clinically for several decades, 
and has become increasingly important in the diagnosis and assessment of prognosis in 
hypertensive heart disease, cardiac hypertrophy and heart failure (Savage et a l,  1987). 
It is only in the last 10 years that teclmology has advanced sufficiently to allow imaging 
of small, fast moving objects such as the rat heart. Since the rat is the most common 
animal used to model cardiovascular disease, there are obvious benefits in studying left 
ventricular (LV) parameters in these animals using echocardiography. Previously, 
larger mammals such as dogs had to be used for non-invasive studies evaluating LV 
function and geometry.
The main problems in using ultrasound in the rat are the small size o f cardiac structures, 
and the much higher heart rate. In addition, the formulae for calculating 
echocardiographic (echo) parameters such as ejection fraction and left ventricular mass, 
were derived in man. Wlien applied to a different species and scale, the assumptions 
made in these calculations may no longer be true, especially since all estimations of LV 
mass make assumptions about cardiac geometry. Since there have only been a handful 
of studies validating the use echocardiography in the rat, it is necessary to determine 
whether the assumptions made in calculating these parameters are still valid for the 
WKY and SHRSP strains. It also represented an opportunity to establish baseline data 
for a variety of cardiac parameters in the Glasgow WKY and SHRSP strains.
The specific aims of this chapter are as follows,
1. To validate echocardiographic calculation of LV mass with LV mass measured
at post-mortem in SHRSP and WKY.
2. To determine the accuracy of echo derived LV mass in detecting LVH in rats.
3. To determine baseline characteristics of dimensions, geometry and function and
establish how these differ between WKY and SHRSP.
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4. To determine the reproducibility of echo derived parameters for its application 
in future longitudinal studies.
To answer these questions requires some knowledge of the principles of ultrasound 
diagnostics, in particular, those that impose technical restraints on the use of 
echocardiography in the rat. To this end, this chapter will discuss ultrasound 
technology, teclmiques, methods of calculation and sources of variability, with 
particular emphasis to its adaptation in rats.
Principles o f  ultrasound
Ultrasound is high frequency sound above the 20kHz tlneshold of human hearing. The 
clinically useful range is found between 1.5 and 7.5MHz. The transducer both 
generates ultrasound and receives the echo reflected from the surface of objects. From 
this a grey scale image is produced on a monitor based on the strength of these 
reflections. The transducer consists of a piezoelectric crystal that oscillates at a 
determined frequency when a potential difference is applied across it. These oscillations 
produce the alternating compression and rarefaction of the sound wave. The thiclaiess 
of the piezoelectric crystal determines the wavelength of the ultrasound, with crystals 
manufactured to be one half wavelength of the desired ultrasound frequency 
(Monaghan, 1990). Therefore to produce an ultrasound transducer that operates at a 
frequency of 7.5MFIz, the piezoelectric crystal would have to be cut 0.1mm thick, since 
the wavelength would be 0.2mm. This is because wavelength is inversely proportional 
to frequency and vice versa, such that,
X, = V / f  Equation 1
Where X = wavelength (m), V = velocity of sound (m/s) in soft tissues such as the heart 
this is 1540m/s, f  = frequency (Hz : number of wavelengths per second).
It is an advantage to have a high frequency, low wavelength ultrasound, since the 
wavelength is an important determinant of resolution. Therefore, a high frequency 
transducer improves the ability to resolve small cardiac structures. However, the 
downside is that high frequency sound is more easily absorbed and diffracted by tissue 
interfaces, making penetration of the beam poorer (Monaghan, 1990). This makes the
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highest ultrasound frequencies unsuitable for use in adult humans, but is not a problem 
in rats where the path length is only a few centimetres, and so the highest frequency 
transducer available is generally used.
The transducer generates ultrasound as pulses. As the pulse travels tlirough tissue a 
proportion is reflected back towards the transducer as an echo each time it crosses a 
material interface e.g. as the sound wave travels between myocardium and blood. The 
remainder will be transmitted imtil the next interface, and so on. The amount of 
ultrasound reflected (the strength of echo), is dependent on the difference in densities 
between the two materials, known as the acoustic impedance. For example, the strong 
reflection at the tissue/air interface is responsible for the high level of noise produced by 
the lung. To prevent high levels of reflection from the contact between transducer and 
tissue ruining image quality, a water-based gel is applied to the surface to replace any 
trapped air, and so reduce acoustic impedance.
The reflected sound is detected by the piezoelectric crystal, which mechanically vibrates 
at the same frequency as the incoming ultrasound. This generates a potential difference 
across the crystal that is proportional to the energy of the returning ultrasound. This can 
be measured by the electrodes, and represented as a grey scale on the monitor. By 
measuring the time taken from transmission of the ultrasound pulse until receiving its 
echo, it is possible to determine the distance travelled, since,
D =  y  X  Vz t Where D = distance from transducer to reflecting interface (m)
V = velocity of sound (m/s)
Equation 2 t = time from pulse transmission to return (s)
The velocity of sound is the same for the forward and return journeys, but the time 
taken is halved, to determine the distance for one direction only (Marshall et a l, 1992).
Since the same crystal is used to transmit and receive ultrasound, the somid is generated 
in pulses. The pulses are short, at only a few wavelengths, as this maintains good 
resolution (if the pulse is longer than the distance between two interfaces, then the echo 
from these will merge and be detected as one). This also allows a fast sampling rate of
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around 1000 measurements/second allowing visualisation of moving structures 
(Monaghan, 1990).
Resolution
Echocardiography in rats requires the imaging of very small structures in the mm range. 
For this reason, particular attention should be paid to understanding the factors 
governing resolution of the system. When discussing resolution above, this referred to 
the axial resolution, that is, the ability to differentiate between two points lying along 
the same path of the sound beam. However, in 2-D echocardiography we also deal with 
lateral resolution, the ability to differentiate between two points lying side by side 
relative to the beam path. The lateral resolution is dependent on beam width, for if two 
objects lying side by side fall within the same beam path, they will appear as one. It is 
only when the distance between these objects straddles two or more beam paths that 
both objects will be resolved. In turn, the beam width is dependent on depth, power 
output, receiver gain and the focal point. The lateral resolution is never as good as the 
axial resolution, and may be several mm. It is for this reason that the M-mode is the 
preferred format for taking measurements from, as it relies purely on axial resolution 
(Marshall et a l, 1992).
M-mode echocardiography
M-Mode or time-motion echocardiography is a single beam path expressed as a 
function of time. An example of a rat M-mode echocardiogram is shown in Figure 3.1. 
The advantages of taking measuiements in M-mode are the improved resolution and 
edge definition. It also has greater temporal resolution than 2-D images, due to the high 
sampling rate. This makes it particularly suited to following wall motion, the correct 
identification of end systole and end diastole or identifying cardiac arrhythmias. This 
gains importance in the fast beating rat heart (Litwin et al., 1994).
Two-dimensional echocardiography
The second major viewing mode is 2-D echocardiography. The ultrasound beam is 
moved through a 30°- 90° arc to capture the heart in two dimensions. This is achieved 
by either 1) mechanical means, whereby the transducer is physically swept through an 
arc containing >100 scan lines, or 2) using a phased-array system where the
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piezoelectric crystal has been divided into 64 or 128 individual elements, each with a 
separate electrical connection (Monaghan , 1990).
Two-dimensional echocardiography is the display of the full arc of beams as a cross- 
sectional moving image of the heart (example in Figure 3.2). Multiple beam paths are 
required to form one picture, and so the frequency at which a single point is revisited 
decreases in proportion with the number of beam paths. For this reason, the sampling 
rate is much lower in two-dimensional echocardiography, 30-126 frames per second 
compared to 1000 samples/sec for the M-mode format (Marshall et a i, 1992). Two- 
dimensional echocardiography is useful for checking the anatomical orientation of the 
M-mode, and most modern machines combine M-mode and 2-D on one screen for this 
purpose. It is considered superior for determination of ejection fraction as it takes into 
consideration asymmetries that may be present in the ventricle (Wallerson & Devereux, 
1987). It is also easy to detect wall motion abnormalities and akinetic regions.
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Figure 3.1 M-mode echocardiogram showing the heart of a SHRSP rat. Movement 
of the line cursor on the 2-D image (left-hand side) selects the beam path of interest. 
The wave motion on the M-mode represents the cardiac cycle, as points in the beam 
path move inwards and outwards during systole and diastole.
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Diastole Systole
Figure 3.2 Two-dimensional echocardiogram of a SHRSP rat heart. The image is a 
short-axis view at the level of the papillary muscles, taken through the parasternal 
window. On the left side the heart is in diastole, and on the right in systole. The 
papillary muscles can be seen protruding into the LV cavity during diastole.
Imaging windows
Obtaining an echocardiographic image of the heart is hampered by the rib cage. Bone is 
a very poor transmitter of ultrasound, and when the lungs are filled with air, almost all 
the ultrasound is reflected. For this reason there are only 4 main imaging windows that 
afford unimpeded views of the heart. The positions of these relative to the heart are 
shown in Figure 3.3. The dominating position of the sternum necessitates imaging to 
occur either above it, in the suprasternal notch, or below it, termed subcostal. Two 
windows are available to the left of the sternum, imaging between the 3^*^ and 5^  ^
intercostal spaces. These are the parasternal view, and the apical view (Marshall et al., 
1992).
Any particular window can afford a multitude of imaging planes through the heart. For 
example, the parasternal view can obtain sections transversing anywhere from the mitral 
valve to the apex. In order for measurements to be reproducible and comparable 
between subjects, the same plane of enquiry should be imaged at every 
echocardiographic examination. To aid this the heart is described as having a long and a 
short axis. The long-axis of the heart runs down through the centre of the heart from 
mitral valve to apex, while the short-axis runs perpendicular to this from the anterior 
wall to the posterior wall (Figure 3.4). Images can then be obtained from a determined 
point along the selected axis e.g. the papillary muscles in a parasternal short-axis view. 
By using the papillary muscles as a landmark, it is hoped to avoid errors of oblique 
angulation of the beam.
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Suprasternal
Subcostal
Figure 3.3 Positions of the four echocardiographic imaging windows shown in 
relation to the rib cage.
Since the M-mode only measures in one dimension, measurements taken from the short- 
axis view make the assumption that both short-axis dimensions are equal i.e. in Figure 4 
that the dimensions from a to b (anterior-posterior) and from a to c (interventricular 
septum- posterior) are equal.
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Figure 3.4 Orientation of the two imaging planes referred to in this thesis. In a 
parasternal view, the transducer would be imaging from above. The short-axis plane 
runs through the heart from a to b, while the long-axis images a plane from e to f. LV : 
left ventricle; RV: right ventricle; LA : left atrium; RA : right atrium; PA : pulmonary 
artery; AO : aorta.
Measurement ofLVdimensions
Wall thickness and LV cavity dimensions are often measured from the M-mode. To 
standardise how measurements are made, various conventions have been advocated. 
All of these were derived for humans, and include the National Institutes of Health 
(NIH), American Society of Echocardiography (ASE), and the Penn conventions. The 
earliest o f these was the 1973 NIH convention, which stated that measurements should 
be taken from the centre o f the line that defines the interface. This has since been 
superseded by the other two conventions, as it fails to standardise at what point in the 
cardiac cycle parameters should be measured, and there is no supportive evidence from 
post-mortem validation studies (Wallerson & Devereux, 1987). The Penn convention 
was empirically derived from autopsy validation by Devereux & Reichek (1977). This 
method does not include the thickness of the endocardial interface when measuring wall 
thickness, instead including it in the measurement of end diastolic diameter. The Penn 
convention has never been validated in rats, and indeed there was shown to be no 
advantage over ASE when taking measurements in rabbits (Young et a i,  1986). The 
ASE or leading edge convention is the most commonly used, and defines measurements 
to be taken from the leading edge of one interface to the leading edge of another. This
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removes error inherent in the echo system associated with display of thin lines (Sahn et 
a i,  1978). It was selected on the basis of reproducibility between sonographers, and 
has since been validated by autopsy in man and rat (de Simone et al., 1990; Pawlush et 
al, 1993). It provides good correlation with post-mortem LV mass, but may 
systematically overestimate it, requiring use of a correction factor (Devereux et al. 
1986). Examples of ASE and Penn methodologies are shown superimposed on a 
representative M-mode in Figure 3.5. Whichever convention is used, LV dimensions 
should be measured from at least three consecutive cycles on the M-mode tracings, to 
allow for beat-to-beat variation. In subjects where respiration has not been controlled, it 
has been suggested that measurements be made from six cardiac cycles, in order to 
include all phases in the respiratory cycle (Wallerson & Devereux, 1987).
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Figure 3.5 M-mode echocardiogram showing methods for measurement of cardiac 
dimensions; anterior wall thickness (AWT), posterior wall thickness (PWT), end 
diastolic diameter (EDD), and end systolic diameter (shown in white). The left hand 
side indicates defined interfaces of the American Society of Echocardiography (ASE), 
while the right side indicates the same measurements using the Penn convention. 
Adapted from Devereux and Reichek (1977).
LV mass determination
Echocardiographic estimation of LV mass provides important information concerning 
cardiac hypertrophy without the need for invasive or terminal studies, and with greater
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accuracy than electrocardiography (Liebson et ah, 1987). There are numerous methods 
available, and these are outlined below. All of these techniques are concerned with 
calculating the volume of the LV myocardium, from which LV mass can be determined 
by multiplying by the specific gravity of myocardium, 1.04 g/ml (Troy ei a l,  1972). 
Major assumptions are made in the calculation of LV mass, most notably on cardiac 
geometry. In general, three-dimensional events are being extrapolated from 
measurements made in one or two-dimensions.
1. Cubed formula -  The simplest method assuming the heart dining diastole forms 
a prolate ellipsoid, and the long-axis dimension is twice that of the short-axis. 
This may not be a fair assumption, especially in hearts exhibiting LV dilatation. 
Nevertheless, this method can produce good correlation with post-mortem LV 
mass in man and rats (Devereux & Reichek, 1979; Pawlush et a l, 1993).
LV mass = 1.04[(EDD + PW T + AWT)^ -  EDD^] Equation 3
Where, EDD = end diastolic dimension; PWT = posterior wall thickness; AWT 
= anterior wall thickness (de Simone et a l, 1990). Essentially, this calculation 
estimates the volume of the whole left ventricle from a single M-mode 
dimension, by cubing the short-axis external diameter. It then subtracts the 
volume of the LV cavity, to obtain LV myocai’dial volume. Great care is 
required when taking measurements using the cubed formula, since errors are 
greatly magnified by the cubed function, and it has a tendency to over-estimate.
2. Modified cube formula -  gains in accuracy by incorporating long-axis length at 
diastole as a 2"  ^ dimension, (e.g. Isgaard et a l, 1997). This depends on being 
able to obtain an accurate long-axis view, which is not always possible in the rat 
due to the thoracic anatomy and high heart rate (de Simone et a l, 1994). In the 
authors experience a clear long-axis view is available in only a few exceptional 
animals.
3. Simpson’s rule -  this also requires the long-axis dimension and multiple short- 
axis images, which are treated as a series of disks of laiown thickness along the 
long-axis. The summation of these disks is used to calculate myocardial
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volume. The greater the number of disks, the higher the degree of accuracy in 
the determination. It is the only method that truly takes account of three- 
dimensional cardiac geometry, and as such, is the only method truly suited to 
estimates of LV mass after myocardial infarction (Pai & Shah, 1995). 
Simpson’s rule forms the hasis for the algoritlims used in modern automated 
three-dimensional echocardiography, where the spatial positioning of the 
transducer (and hence the short-axis disks) is automatically described relative to 
the long-axis. This allows a 3-D computer-generated image of the heart to be 
constructed (Gopal et a l, 1997). Unfortunately, the accuracy of the transducer 
positioning system is not sufficient for imaging the rat heart. It is also very 
difficult to consistently obtain multiple short-axis images along the long-axis of 
the rat, which is around 12mm in length. A view shared by Litwin et a l (1994).
4. Ellipsoidal method -  this was the method advocated by the first paper in rats to 
determine LV mass and compare it with necropsy validation (de Simone et a l , 
1990). It assumes the heart at diastole to form a prolate ellipsoid. The authors 
recognised the difficulty of directly measuring long-axis length in the rat, and in 
a second paper suggested a modified method for the empirical estimation of 
long-axis fi om a learning series of rats, using body weight, fractional shortening, 
and posterior wall thickness in systole (de Simone et a l, 1994).
As with all these methods, accuracy is often improved by modelling the correlation line 
to a theoretical perfect of y = x, via a correction factor. This involes multiplying values 
by the reciprocal of the slope, and correcting for the y-axis intercept (Litwin et a l, 
1994).
There are also numerous methods to estimate LV mass using 2-dimensional 
echocardiography. These include modifications of Simpson’s rule, approximation to a 
cylinder, an ellipsoid, or a bullet shape (Wyatt et a l, 1979). The advantages are a 
potentially smaller standard error in the estimation, and the fact that some aecomit is 
taken of changes in geometry in the short-axis view (Reichek, 1987; Schiller, 1987). 
However, 2-D imaging may over-estimate myocardial cross-sectional area, and has not 
proved itself to be superior to M-mode echocardiography (Reichek, 1987). Since some 
of these techniques require an apical view, and all require the long-axis dimension, they
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have never been applied to LV mass evaluation in the rat, and will not be discussed 
further in this thesis.
For the purposes of this thesis, the cubed formula was selected for calculating LV mass 
as this requires only one imaging plane, and so is likely to work for all animals. 
Preliminary data using the modified ellipsoidal method showed that it was no more 
accurate at estimating LV mass than the much simpler cubed method.
To obtain an index of myocar dial mass independent of assumptions concerning three- 
dimensional shape, some researchers calculate myocardial cross sectional area (CSA) 
(de Simone et a l, 1990).
CSA (mm^) = ir[(EDD + PW T + AWT)/2]^ -  7t(EDD/2)^ Equation 4
This, like all the M-mode methods above, still makes the assumption that the 
myocardial cross-sectional area is circular in shape.
Measurement o f  LV  function
Ejection fraction is defined as the volume of blood leaving the LV with each heartbeat 
(stroke volume) expressed as a percentage of the total LV volume at diastole. The 
derivation is as follows:
SV = EDV -  ESV Equation 5
EF — SV/EDV Equation 6
Where, SV = stroke volume (ml); EDV = end diastolic volume (ml); ESV = end systolic 
volume (ml); EF = ejection fraction (%). For the purposes of estimating ejection 
fraction using echocardiography, the equivalent calculation for two-dimensional cross- 
sectional area is often applied:
EF = (EDA — ESA) / EDA Equation 7
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Wliere, EDA (mm^) and ESA (mm^) are the cross-sectional areas of the LV cavity 
measured at diastole and systole respectively (Pai & Shah, 1995). This assumes that 
contractility is identical at all levels of the left ventricle. This is likely to be true for all 
normal and concentrically hypertrophied hearts, but is unlikely to hold for infarcted 
hearts.
Cardiac output (CO) may also be calculated if the heart rate (HR) is known, since:
CO (ml/min) = SV (ml) x HR (beats/min) Equation 8
The heart rate can be calculated from the number of cardiac cycles appearing on the M- 
mode. However, this Figure may be highly variable in the rat and should be treated 
with caution, due to the depressant effect of all anaesthetics and sedatives on heart rate. 
Cardiac output will therefore depend on depth of anaesthesia.
Doppler cardiac output
Some groups have been able to obtain an apical 5-chamber view in the rat to determine 
LV outflow velocity using Doppler flow measurements. This means that by measuring 
the diameter of the ascending aorta, and heart rate, it is possible to calculate cardiac 
output, as follows;
C O. = velocity time integral x [ tt (LV outflow diameter / 2) ]^ x heart rate
Equation 9 (Litwin c/n/., 1994)
Echo Doppler may also be used to look for mitral regurgitation by placing the sample at 
the leaflets of the mitral valve, just inside the left atrium, and looking for back flow. 
Although one group have attempted this technique in the rat, they comment on the 
difficulty of imaging the aortic root which was often unobtainable due to difficulties 
with the imaging window (Pawlush et al., 1993).
Sources o f Error in Echocardiography
Sources of error in echocardiography were elucidated in a paper by Kuecherer et al. 
(1991), and are relevant to both 2-D and M-mode. They identified a variety of sources 
of variability contributing to the total variability of a given measurement.
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Subject variability - is the vaiiation that occurs within a subject echoed on two different 
occasions. It includes parameters such as difference in body position or autonomic 
tone. This is obviously important in protoeols that demand serial evaluation, and can be 
quantified by measuring the same subject a few days apart.
Technical variability - describes variation arising from image aeqiiisition and 
quantification. It includes inter- and intra- operator variability. Variability includes 
differences in selection of the correct imaging plane between two different operators, 
and between the same operator on different days.
Inter- and intra- reader variability - is a measure of variability in digitising and 
measuring recordings e.g. use of the leading edge method. It also includes beat-beat 
variability in measuring over a number of cardiac cycles. Intra-reader variability can be 
quantified by a blinded re-measuring of images
Kuecherer and colleagues showed determination of LV mass to have the greatest total 
variability of any echo parameter tested, and that teclmical variability was the largest 
contributor to this. Specifically, variability in measuring the short-axis dimensions was 
particularly high (understandably since using the cubed formula). There are obvious 
hazards in interpreting small changes in LV mass as significant, especially if based on 
single readings by only one operator. However in animal studies there is the option of 
increasing sample size to increase the power of the observation. The most reliable 
parameter measured was ejection fraction, where subject variability was the largest 
contributor to total variability. The conclusion is that ejection fraction is suitable for 
serial evaluation studies.
Problems specific to the rat
An important consideration for accuracy that occurs in the rat, but is not a problem in 
humans, is the very high heart rate in these animals. The heart rate of the anaesthetised 
rat is approx. 350-400 beats per minute. This means that ultrasound machines with a 
low sampling rate will only have a few images to represent the full cardiac cycle. It is 
therefore possible that end diastole and end systole can not be identified correctly, 
leading to errors in measurement. A sample rate of 25Hz (the minimum required to
103
depict moving images) would only deliver around 4 frames for every cardiac cycle. The 
Medison machine used in this study has a sampling rate of 126Hz i.e. a temporal 
resolution of -8ms. It can therefore record -20 frames per cardiac cycle, making it easy 
to accurately select end diastole and systole. However, even on this modern machine, 
the sample rate falls dramatically to as low as 18Hz if multiple functions are used 
simultaneously e.g. colour doppler with M-mode. Another approach is the use of 
simultaneous electrocardiography, such that representative images can be selected on 
the basis of synchrony with cardiac electrical activity. For example, diastolic 
measurements at the onset of the QRS complex in the ASE convention (Sahn et a l, 
1978), or at the peak of the R wave in the Penn convention (Devereux & Reichek, 
1977).
The other major difference between rat and human echocardiography is one of scale. 
Imaging a rat is technically very difficult as it requires measurement of structures as 
small as 1mm, close to the limit of spatial resolution. However, with due care, and the 
use of high frequency transducers, accurate results can be obtained. Indeed, 
echocardiography in mice has recently been described using the same teclmiques 
described here, but utilising a 15MHz transducer (Harada et a l,  1998; Yang et a l, 
1999).
The final consideration when performing echocardiography in rats is the inability to 
control the respiration rate. The act of inspiration and expiration may cause problems 
due to lateral movement of the heart, or air-filled lungs reflecting ultrasound. A human 
subject can be requested to hold their breath, however, the rat has a resting respiration 
of 60-100 breaths per minute, making interference a common problem. Fortunately, 
these movements are easy to identify in an M-mode, and can be corrected for by always 
taking measurements at the same point in the respiration cycle. The problem can also 
be minimised by using only light sedation during the procedure, this ensures that the 
animals’ breathing remains shallow.
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3.2 Methods
Animal characteristics
Growth curves for LV mass against age and body weight were constructed from a total 
of 104 rats consisting of 54 SHRSP (24 males, 30 females) and 50 WKY (29 males, 21 
females). A subset of these rats (n=75) were examined by echocardiography up to 24 
hours before euthanasia, and these data are presented in the LV mass validation study. 
There were 42 SHRSP, 20 males and 22 females (M:F ratio 0.91), and 33 WKY, 
consisting of 16 males and 17 females (M:F ratio 0.94). Ages ranged from 52 days to 
446 days old, and body weight between 102-494g. Since the male to female ratio was 
similar between groups, and the data normalised to body weight, echocardiographic 
parameters have been presented as combined data for males and females.
Echocardiographic examination 
Equipment.
Two ultrasound machines were used in this study. The first 30 animals were imaged 
using an Acuson 128 ultrasound scanner and 7MHz paediatric probe, with images 
recorded on Super-VHS tape for analysis off-line. With the purchase of an ultrasound 
machine dedicated to animal work, the remaining animals were examined using a 
Medison Sonoace SA8800 (Diagnostic Sonar, Livingston, UK). This was interfaced to 
a JVC Super-VHS video recorder for continuous recording of moving images. In 
addition, this system had a scrolling memory that allowed review and selection of the 
best quality images, which were saved in digital format as bitmaps on a 650Mb PD 
drive (Panasonic). The transducer was a 7.5MHz, 128 line phased-array system, with an 
adjustable 60° imaging angle and a 2cm footprint. This provided a more than adequate 
image depth of 7.5cm, and 10% accuracy in measuring distances between 1 -  60mm. 
When measuring time in M-mode, at a sweep speed of 126MHz, accuracy was 5% for 
the range 0.01 -  8 seconds. All images were obtained at x2 magnification.
Imaging technique
Animals were lightly anaesthetised with Halothane 1 -2% in oxygen (flow rate 2L/min) 
and the left side of the chest closely shaved. A copious quantity of ultrasound gel was 
used to dispel any pockets of air trapped in the fur. With the rat lying in the left lateral
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position, short-axis 2-dimensional B-mode and corresponding M-mode images were 
taken tlnough the left parasternal window at the level of the papillary muscles. All 
images were adjusted to obtain the optimal dynamic range of the displayed image. LV 
cavity was selected to appeal* black, and the myocardium a mid grey with special 
attention given to endocardial definition.
Each echo exam lasted between 5 and 15 minutes and consisted of 3 sets of 2-D images 
and a minimum of 3 independent M-mode images. In 2-D mode, end diastolic images 
were selected for good edge definition, a round cross-section, and the largest thinnest 
section of left ventricle. M-mode images were guided using information from 
simultaneous 2-D images, allowing the centre of the cross-section to be selected as the 
plane of interest. Care was taken to avoid measuring directly tlirough the papillary 
muscles, as this would give the impression of a thicker wall. Similarly, the anterior wall 
may also appear thicker if imaged at the junction between septum and right ventricle. 
The M-mode was selected for good edge definition when both the epicardial and 
endocardial surfaces of the anterior and posterior walls were clearly visible, and when 
there was a regular cardiac cycle with little change in dimensions from beat to beat.
In 11 animals, a different anaesthetic was used to determine if there was a measurable 
effect of anaesthetic choice on echocardiographic parameters. These animals were 
lightly sedated using an intraperitoneal injection of 0.04-0.1ml Hypnorm. All other 
aspects of the examination were identical.
At the end of the echo exam (or within 24 hours) animals were euthanased by an 
overdose of halothane anaesthetic. The heart was immediately removed by 
thoracotomy, blotted and weighed. The right ventricle was carefully dissected from the 
left, the great vessels and atria removed, and the component parts blotted and weighed 
(Mettler Toledo PB302 balance). The left ventricle was defined as the combined left 
ventricular free wall and interventricular septum up to the level of the mitral amiulus. 
The same operator weighed all hearts.
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Data analysis.
Video recordings were digitised using a Ulead multimedia video card and software 
(Hauppage Ltd.), and analysed on a PC running the Metamorph version 2.75 program 
(Universal Imaging Corporation). However, wherever possible, measurements were 
taken from the digital stills, due to the greatly improved clarity of image obtained by 
bypassing digital-analogue-digital conversions. For analysis of 2-D images, 3 
measurements at systole and diastole were made for each of the 3 data sets, providing 
data on 9 cardiac cycles. The endocardial border was traced onto the screen aided by 
the use of a calibrated ellipsoid for automatic calculation of cross-sectional area (CSA). 
These were used to derive an estimation of ejection fraction (Equation 10), and the data 
averaged.
Ejection Fraction (%) = End diastolic CSA -  End systolic CSA (Pye et a l, 1996)
End diastolic CSA
Equation 10
A minimum of 3 independent M-mode images were acquired at each exam for 
measurements of wall thiclaiess. LV dimensions were measured using the American 
Society of Echocai'diography leading-edge method from six consecutive cardiac cycles 
on each of the M-mode tracings (Salm et a l , 1978). This data was averaged and used to 
calculate left ventricular mass assuming a cubed model (Devereux & Reichek, 1979). 
Therefore a total of 24 measurements were taken and averaged for each dimension.
LV mass = 1.04[(EDD + PWT + AWT)^ -  EDD^]
Where PWT = Posterior wall thiclaiess (mm)
AWT = Anterior wall thiclaiess (mm)
EDD = End diastolic dimension (mm)
The following measurements were taken from the M-mode, AWT, PWT, EDD, ESD, 
PWTs. Where PWTs is posterior wall thickness measured at systole. The positioning 
of these in the echocardiogram are shown in Figure 3.5. The posterior wall was 
identified as having the steepest slope (Pawlush et a l, 1993).
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End diastolic volume (EDV) and end systolic volume (ESV) were calculated from the 
M-mode using the teclmique of de Simone et al (1990) which assumes the ventricle to 
have an ellipsoidal shape.
EDV = 7t/6 EDD^ [2(EDD + 2PWT) -  I.IPWT] Equation 11
ESV = 71/6 ESD^ [2(ESD + 2PWTs) -  l.lPW Ts] Equation 12
Stroke volume (SV) = EDV -  ESV Equation 13
Fractional shortening (FS) was also calculated as a measuie of cardiac function 
calculated from the M-mode as follows,
FS (%) = [(EDD-ESD) / EDD] xlOO Equation 14
(Pawlush et a l,  1993)
Repeatability study.
The intra-observer repeatability of echo derived parameters was quantified in 18 rats 
according to the methods of Bland & Altman (1986). These animals underwent an echo 
exam as above, with a second examination within two days. For any given 
measm'ement, the difference in values between study 1 and study 2 was calculated, 
together with the mean difference. A perfectly reproducible study will have a mean of 
differences equal to zero. Provided the mean of differences was not significantly 
different from zero, then the standard deviation of the differences was calculated. The 
co-efficient of repeatability is defined as twice this value (2SD) and represents the range 
within whieh 95% of differences occur. The co-efficient of repeatability can therefore 
be used to determine echo-derived parameters are accurate enough to be useful in serial 
studies.
All echocardiographic studies in this thesis were performed and measured by the same 
operator, and so no effort was made to ascertain the inter-operator or inter-reader 
variability.
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Statistical analysis
All results are displayed as mean ± standard deviation (SD) unless otherwise stated. 
Measurements between WKY and SHRSP animals were compared using an unpaired 
Student’s / test. A P value < 0.05 was considered significant. LV mass by 
echocardiography was compared with actual LV mass by linear regression. The P value 
for this parameter tests the null hypothesis that the overall slope is zero.
3.3 Results
For the purposes of the validation study it was necessary to include a variety of animals, 
male and female, exhibiting a wide range of body weights and ages, in order to ensure a 
large range of LV mass for linear regression analysis. Therefore, when comparing 
echo-derived parameters of LV mass between WKY and SHRSP it is important to be 
comparing like with like. The standard method is to normalise to body weight, but 
other methods such as normalisation to tibial length, brain weight or body surface area 
may be applied. For any of these methods, it is assumed that rate of growth of the left 
ventricle is directly proportional to the rate of growth of the chosen denominator, 
tlnoughout the range of values observed. This may not always be true, especially when 
the animal reaches full maturity and one factor continues to change. For example, 
normalisation to body weight would not be valid if the animals became obese, or lost 
weight due to surgical procedures. However, body weight is the preferred 
normalisation factor, due to ease of measurement and the ability to measure in live 
animals for use in serial studies. In addition, the SHRSP has a lower body weight at all 
ages, and so requires correction for this. To determine whether normalisation to body 
weight was a valid transformation in this population of rats, growth curves of LV mass 
against body weight were constructed from necropsy data, and are shown in Figure 3.6.
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Figure 3.6 Growth curves for LV mass against body weight constructed from 
autopsy data. Panel (a) shows data with linear regression for male WKY and SHRSP, 
while panel (b) shows the same data for females. The linear relationships indicate that 
LV mass increases in direct proportion to body weight, tluoughout the range of body 
weights used in this study.
All four data sets shown in Figure 3.6 produced excellent correlation coefficients by 
linear regression analysis, ranging between r = 0.90 to 0.97. These linear relationships 
indicate that LV mass increases in direct proportion to body weight throughout the 
range of body weights used in this study. Therefore, normalisation to body weight is an 
appropriate method in these animals. It is interesting to note that the rate of LV growth, 
as measured by the slope of the regression line, is almost identical within the foiu 
groups: SHRSP males m=0.0030, SHRSP females m=0.0030, WKY males m=0.0023,
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WKY females m=0.0030. WKY males may be slightly lower due to the inclusion of 
one animal with very low body weight.
In light of this data, all echocardiographic parameters were normalised to body weight, 
with the obvious exception of ratio and percentage values. In the interests of simplicity, 
data has been analysed as males and females together. Normalising to body weight 
adequately accounts for any sex differences, as once data has been transformed, sex 
differences are indistinguishable (data not shown). In addition, there is no bias when 
comparing WKY and SHRSP in this way as the ratio of males : females are almost 
identical between the two groups.
In the validation experiments, LV mass was calculated using the cubed method 
(Equation 3). A modified cubed method using the long-axis as a second dimension was 
also considered. Figure 3.7 shows a parasternal long-axis view from a SHRSP rat, 
however, it was not possible to consistently obtain these views in all but a handful of 
animals, and this method was abandoned.
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Figure 3.7 Parasternal long-axis view in a SHRSP rat. Long-axis measurements are 
taken from the mitral valve to the apex.
The correlation of calculated LV mass (from the echocardiogram) against actual LV 
weight measured at autopsy is shown in Figure 3.8. Linear regression of data from 75 
animals measured, yields the equation of the line y = 0.92x + 0.08, r = 0.86, standard 
deviation of the residuals (Sy.x) = 0.13, P<0.0001. This approximates well with the 
theoretical y = x, and to improve accuracy, was modelled to this line using the 
correction factor x = (Cubed method -  0.08)70.92 (Figure 3.8, panel b).
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Figure 3.8 Correlation between LV mass estimated by echocardiography and actual 
LV mass measured at autopsy. Raw data shown in panel a, equation of the line y = 
0.92x + 0.08, n = 75, r = 0.86. Panel b shows the same data with correction factor 
approximating to y = x. The co-efficient of repeatability for comparison between echo- 
derived and LV blotted weight is 0.26g.
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The ability of echocardiography to accurately determine between animals with and 
without LV hypertrophy was examined by calculating sensitivity and specificity for this 
test. Since WKY rats do not exhibit LV hypertrophy, the highest value in this group 
was defined as the limit of normality. Therefore a LV mass to body weight ratio of 
greater than or equal to 2.86 g/Kg was adopted as the definition of “true” hypertrophy, 
and all animals below this as hypertrophy negative. Sensitivity was calculated to be 
92%, and represents the probability of an animal with “true” hypertrophy giving a 
positive test. The specificity was 64%, which is the probability of an hypertrophy 
negative animal giving a negative test. The predictive (diagnostic) value was 78% i.e. 
78% of rats giving a positive test actually have LV hypertrophy, or in other terms, a 
false-positive rate of 22%. The false-negative rate was only 14%. Thus, 
echocardiography could identify rats exliibiting LV hypertrophy with an acceptable 
degree of accuracy.
Of the animals used for the validation study, 54 had systolic blood pressure measured 
by tail-cuff plethysmography on at least two occasions. A comparison of mean systolic 
blood pressure is detailed in Figure 3.9, with 13-14 animals in each group. Blood 
pressure was compared by one-way ANOVA with Bonferroni’s correction for multiple 
comparisons. SHRSP males had a significantly higher blood pressure, 178±20 mmHg 
when compared to any other group (all P<0.001). In turn, SHRSP females at 147±16 
mmHg were significantly more hypertensive than either WKY males at 129±9 mmHg 
(P<0.01), or WKY females at 120±5 mmHg (P<0.001). There was no significant 
difference when comparing WKY males with females. There were no differences in 
heart rate measured at this time, with the mean heart rate being in the range of 440-460 
beats per minute for all groups.
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Figure 3.9 Systolic blood pressure measui'ed by tail-cuff plethysmography in male 
(m) and female (f) SHRSP and WKY rats. The solid line represents the mean value in 
each group.
The relationship between cardiac hypertrophy and hypertension was examined by 
plotting autopsy LV mass (normalised to body weight) against systolic blood pressure, 
and performing linear regression analysis (Figure 3.10). No correlation was apparent 
for either WKY or SHRSP animals.
A large range of parameters were calculated from echocardiograms, describing LV 
dimensions, volmne, cross-sectional area and mass (Table 1). All 75 animals used in 
the validation study were included, 33 WKY and 42 SHRSP. Data are presented as 
mean value ± standard deviation, and comparison between WKY and SHRSP is by 
unpaired Student’s /-test, with the P value reported. Where possible all values are 
represented as both raw data, and normalised to body weight.
The extent of LV hypertrophy was very pronounced in the SHRSP, and was 
significantly higher even before normalisation to body weight. At post-mortem there 
was on average 28% higher LV mass to body weight ratio in the SHRSP, and this was 
only slightly over-estimated at 31% using the cubed method. Right ventricular weight 
was also significantly higher in the SHRSP after normalisation to body weight 
(P<0.0001). These differences were mirrored by myocardial cross-sectional area, which 
was again highly significant between groups. Thicker left ventricular walls appear to be 
the culprit. Both anterior and posterior aspects exhibited hypertrophy in the SHRSP. 
The difference in anterior wall thickness was greatest at 23% higher than the WKY,
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compared to 17% for the posterior wall. This was reflected in the AWT: PWT ratio, 
suggesting that the SHRSP anterior wall is slightly more prone to hypertrophy than the 
posterior wall.
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Figure 3.10 Lack of relationship between LV mass normalised to body weight and 
systolic blood pressure measured by tail-cuff plethysmography in (a) WKY and (b) 
SHRSP. Data from 13-14 each of male and female SHRSP and WKY.
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Table 3.1 Echocardiographic derived parameters in WKY and SHRSP rats.
WKY n =33 SHRSP 11=42
Mean ±SD Mean ±SD P value
Body weight Kg 0.245 0.073 0.230 0.066 0.40
LV mass post-mortem g 0.621 0.198 0.730 0.219 0.046
g/Kg 2.513 0.177 T228 0.498 <0.0001
LV mass cubed method g 0.612 0.254 0.750 02:64 0.04
g/Kg 2.507 0.684 3.296 0.585 <0.0001
RV mass post-mortem g 0.170 0.05 0.138 0.03 <0.0001
g/Kg 0.577 0.105 0.668 0.117 <0.0001
Myocardial CSA mm^ 425 10.2 49.4 9.7 0.006
m nf/Kg 180.1 38.5 222.5 37.3 <0.0001
Dimensions
AWT mm 1.64 0.32 1.89 0.25 0.0006
mm/Kg 7.06 1.74 8.67 1.98 0.001
PWT mm 2.05 0.29 2.24 0.26 0.007
mm/Kg 8.84 1.95 10.30 2.43 0.011
AWT : PWT ratio 0.803 0.090 0.840 0.055 0.02
PWTs mm 2.63 0.37 2.86 0.43 0.02
mm/Kg 11.22 2.61 12.93 2.70 0.01 ?
EDD mm 5.37 0.68 5.51 0.82 0.42 :
mm/Kg 23.42 5.15 25.43 5.69 0.14 y
ESD mm 3.31 0.56 3.51 0.76 0.21
mm/Kg 14.39 3.43 16.18 4.26 0.07 [
Fractional Shortening % 38.57 4.38 36.71 6.5 0.18
LV  lumen characteristics
Cavity CSA diastole mm^ 20.86 5.55 22.48 8.64 0.39
mm^/Kg 87.9 19.7 96.8 2A8 0.13 X
Cavity CSA systole mm^ 7.36 2.66 11.82 5.2 0.0001
m nf/Kg 30.9 10.9 52.9 21.4 <0.0001
EDV ml 0.263 0.093 0.277 0.095 0.52
ml/Kg 1.118 0.304 1.253 0.325 0.09
ESV ml 0.086 0.039 0.108 0.062 0.09
ml/Kg 0.365 0.139 0.469 0.204 0.02
Stroke Volume ml 0.177 0.057 0.186 0.068 0.55
ml/Kg 0.753 0.191 0.825 0.214 0.16
Ejection Fraction % 66.1 5.6 47.8 7.6 <0.0001
All values aie mean ± standard deviation. AWT represents anterior wall thiclaiess; 
PWT, posterior wall thickness; EDD, end-diastolic diameter; ESD, end-systolic 
diameter; CSA, cross-sectional area; EDV, end-diastolic volume; ESD, end-systolic 
volume.
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There was no significant difference in LV cavity geometry when measuring one­
dimensional end-diastolic diameter (EDD) by M-mode, or in two-dimensions by cavity 
cross-sectional area from a 2-D image. It is not possible however; to say whether there 
was any difference in long-axis dimension, as long-axis views were not obtained in 
most animals. End diastolic volume (EDV) was calculated assuming there was no 
change in relationship between long-axis and short-axis dimensions, and although 
showing a tendency to be larger in the SHRSP, failed to reach statistical significance.
L V function
Large differences were observed in LV function as measured by ejection fraction. 
Representative 2-D images are shown in Figure 3.11.
Figure 3.11 Sample 2-D echocardiograms from the parasternal short-axis view. Top 
panels are from a WKY rat at diastole (a) and systole (b); lower panels are from SHRSP 
diastole (c) and systole (d). Note thicker walls in the SHRSP.
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In WKY rats, ejection fraction was 66.1±5.6%, but only 47.8±7.6% in SHRSP rats 
(P<0.0001). When graphed on a scatter plot to examine the spread of this data, there 
was a very clear difference between groups, with a few SHRSP exhibiting very low 
ejection fractions (Figure 3.12). This large difference is surprising, and is reminiscent 
of the mild LV dysfunction observed in coronary artery ligated rabbits (see Chapter 7).
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Figure 3.12 Ejection fractions for WKY and SHRSP rats. The solid line represents 
the mean value in each group. Comparison of means by Student’s f-test, P<0.0001,
In addition, although there was no significant difference in fractional shortening, it was 
very low in both groups at around 38%, compared to published data in the rat of 56% in 
normal animals (Pawlush et a l, 1993). Taken together, these results suggest that 
measurement of LV function in the present study may be grossly under-estimating 
contractility. No attempt was made to validate ejection fraction by comparing 
measurements with other techniques, so the question could not be addressed directly. 
However, it was decided to examine the effects of the anaesthetic on contractility, as the 
cai'diac depressant effect of halothane was a prime suspect.
To perform an echocardiographic examination on rats without an anaesthetic would 
require months of animal training, and it is difficult to objectively assess depth of 
anaesthesia in the rat. Therefore, the effect of halothane exposure time on contractility 
was examined as a inaiker of its cardio-depressant effect. Ejection fractions from 24 
animals (12 SHRSP, 12 WKY) were calculated at 3-4 different time points after
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induction of anaesthesia. With each time point representing the mean of three cardiac 
cycles. No baseline was available (i.e. without halothane) and so the first ejection 
fraction for each animal was obtained within 5 minutes of induction of anaesthesia. 
This value was defined as unity and all subsequent measurements were expressed as a 
ratio of this value, to provide an index of contractility change with time of exposure to 
halothane (Figure 3.13). Where animals share a time point, data has been meaned.
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Figure 3.13 Effect of length of halothane exposure on cardiac contractility as 
measured by ejection fraction. All values are expressed as a ratio of the first 
measurement, and meaned with data from other animals sharing that time point. The 
number of animals at each time point therefore ranges from 1 to 8. All values are mean 
± standard error of the mean.
It is clear that from 3 minutes up to 24 minutes after induction of anaesthesia, halothane 
had no effect to systematically decrease contractility. However variability in the 
measurement does seem to increase after 10 minutes exposure, although this is partly 
due to fewer animals composing the time points in this range (most echo exams took 
less than 15 mins). Unfortunately, it was not possible to rule out an immediate (< 3 
minutes) effect of halothane on contractility. The only way to determine this was by 
comparison with another anaesthetic. For these purposes a small number of animals 
were lightly sedated with 0.1ml Hypnorm® I.P., and ejection fraction measured. 
Ejection fraction was higher in both groups, at 77.9±2.5 for WKY and 76.7±2.4 for 
SHRSP, such that an inter-group difference was no longer discernible. This suggests
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that halothane depresses contractility in both strains, but by an unlaiown mechanism 
affects the hypertrophie SHRSP heart to a greater degree.
Halothane anaesthesia, did not appear to affect measurements of LV dimensions, 
volume, or mass, as the values for these in Hypnorm sedated animals mirror the values 
obtained with halothane. Hypnorm was used for all subsequent echocardiographic 
examinations in this thesis.
Reproducibility
The stated aim of adapting echocardiography to the rat was to allow serial studies 
examining changes in echo parameters with time or treatment. In order to ascertain if 
real changes are being observed with time, it is necessary to determine the repeatability 
of measurements made a few days apart. The co-efficient of repeatability was 
calculated for 18 rats that had a repeat echocardiogram within 48 hours of the first. The 
data was analysed as the difference between and 2"^ ' studies expressed in terms of the 
mean for both values. A graphical representation of this is given in Figure 15 as an 
example. The mean value between measurements is shown as the line of identity, with 
±2SD (co-efficient of repeatability) on either side of this line. Values in future studies 
exceeding 2SD are likely (P<0.05) to belong to a different population, and cannot be 
explained simply due to variability in the measurement process (Bland & Altman, 
1986). Data was analysed in this way for a range of parameters, and the mean value ± 
standard deviation are given in Table 3.2. Data normalised to body weight has been 
calculated in the same way to allow comparison of co-efficient of repeatability on this 
scale.
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Figure 3.15 Assessment of repeatability between echocardiographic measurement of 
myocardial cross-sectional area measured on two separate occasions within 48 hours. 
This indicates the relationship between difference in measurements and the mean 
measurement for individual rats (n=18). The mean of differences and co-efficient of 
repeatability (2SD) are indicated by dashed lines.
The co-efficient of repeatability gives some indication of the reliability of 
measiu’ements comparing WKY and SHRSP made earlier in this chapter (Table 3.1). 
Wliere the co-efficient of repeatability is smaller than the difference between WKY and 
SHRSP, we can confidently say that the difference is real and not due to variability in 
measurement. Therefore, the most reliable measurements when dealing with 
differences between WKY and SHRSP are, LV mass (g/Kg), myocardial CSA (g/Kg), 
AWT (g/Kg), and ejection fraction. Of course, other parameters can be useful if the n 
number is sufficiently high. The usefulness of any given pai'ameter will depend on the 
difference you would expect to observe between groups, and whether this is biologically 
significant.
1 2 1
Table 3.2 Vaiiability between two sequential echocardiographic studies 48 hours 
apart performed in 18 rats.
Study 1 Study 2 Mean of 
Differences
Co-efficient of 
Repeatability
LV mass “cubed” mg 
g/Kg
0.769±0.267
3.15±0.50
0.7904=0.29
3.204=0.38
-0.021
-0.051
0.165
0.72
Myocardial CSA nim^ 48.5±1L8 49.14=12.2 -0.60 7.4
mni^/Kg 209±34 210=432 -1.46 32.8
AWT 111111 1.824=0.37 1.804=0.27 0.01 0.31
mm/Kg 7.94=1.7 7.84=1.6 0.03 1.3
PWT 111111 2.174=0.33 2.194=0.32 -0.01 0.36
mm/Kg 9.484=1.89 9.54=42.05 -0.05 1.69
EDD 111111 5.634=0.61 5.64=40.41 0.01 1.01
mm/Kg 25.7=46.1 25.6=45.3 0.20 4.5
ESD 111111 3.494=0.49 3.53=40.44 -0.02 0.92
mm/Kg 15.6±4.4 15.64=3.5 0.10 4.49
Cavity CSA mni^ 22.54=4.7 21.74=5.2 0.76 10.1
Diastole mni^/Kg 97.94=24.7 93.4=420.4 4.47 48.0
Cavity CSA nini^ 10.34=4.2 10.4=44.6 -0.13 7.4
Systole ninf/Kg 44.7±19.0 43.8=413.7 0.91 30.9
Stroke volume ml 0.194=0.05 0.19±0.04 0.007 0.07
ml/Kg 0.874=0.20 0.84=40.12 0.035 0.30
Ejection fraction % 56.2=411.0 54.8=49.7 1.34 12.6
All values are mean ± standard deviation. AWT represents anterior wall thiclaiess; 
PWT, posterior wall thiclaiess; EDD, end-diastolic diameter; ESD, end-systolic 
diameter; CSA, cross-sectional area.
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3.4 Discussion
All images were obtained using standaid clinical ultrasound machines with paediatric 
probes. No modifications were required. The technique was well tolerated with zero 
mortality or morbidity regardless of the anaesthetic regime used. This was true of all of 
the 300+ echocardiographic examinations reported in this thesis. The best quality 
images were obtained with the rats lying in the left lateral position, with the chest fur 
closely shaved and using copious amounts of ultrasound gel. Care should be taken not 
to press too hard with the transducer against the thorax, as this was found to limit 
respiration and deform cardiac geometry.
The groups used in this study were fairly comparable with regards age range, body 
weight and sex ratio. However, the exception was SHRSP males, which tended to be 
younger and clustered around one age, with the oldest being 226 days old, compared to 
the 440 days in the other groups. This is because after 6 months of age male SHRSPs 
become much more likely to die of stroke, making it unusual to encounter an animal 
more than one-year-old (Okamoto et a l, 1974). There was a cluster of rats at around 
100 days old, as this is the age that animals are most commonly used in this lab. 
Animals have reached maturity by this age, and the blood pressure of the SHRSP has 
attained its maximum (Davidson et a l,  1995). To avoid killing animals unnecessarily 
this study mostly used untreated rats that were being euthanased for other studies, or 
that were being culled as excess to requirements. Normalisation to body weight 
corrected for differences in body mass and sex (Figure 3.6).
Post-mortem validation ofLV m ass calculation
In human studies, there is still some debate concerning the relative benefits of M-mode 
and two-dimensional methodologies, and in choice of formulae for calculation of left 
ventricular mass (Liebson et a l, 1987). Flowever, in the rat the situation is much 
clearer as technical considerations often dictate which methods can be used. One major 
constraint is the difficulty of reliably obtaining any views other than the parasternal 
short-axis. Although a parasternal long-axis view is shown in Figure 3.7, this was very 
much an exception rather than the rule. Indeed a number of groups have commented on 
the teclmical problems of obtaining an accurate long-axis view in the rat (Nakamura el 
a l,  1992; de Simone et a l, 1990). This severely limits choice of formulae, with the
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cubed method being the most widely supported, and hence the method used in this 
study.
Table 3.3 summarises LV mass validation data from all published studies in the rat. 
From the correlation co-efficient comparing echo LV mass with autopsy LV mass, this 
study is in good agreement with the published data. As mentioned above, most groups 
have used the cubed method for calculating LV mass, due to the difficulty of obtaining 
a reliable long-axis view in the rat. The one exception to this has been de Simone et al. 
(1990 & 1994), who used the long-axis view as a second dimension in the ellipsoidal 
method, and in doing so gained in accuracy. However, in that study the long-axis view 
was not obtainable in all animals. The standard error of estimate in the present study is 
very low, and this simply reflects the large number of animals used (n=75) for the 
correlation. The accuracy of this study was calculated as sensitivity 92% and specificity 
64%, which is again comparable to published data in the rat, and indeed to echo 
detection of LV hypertrophy in man (sensitivity 88% and specificity 84% using M- 
mode, Kucherer & Kuebler, 1992). The Penn convention has not been validated in the 
rat, with all groups choosing to follow the American Society for Echocardiography 
methodology. It is possible that the application of the Penn convention to echo 
measurements, may be beneficial in rats as it tends to result in lower estimations of LV 
mass than those obtained by ASE methods (Devereux & Reichek, 1977). For example, 
in studies using ASE convention and the cubed formula in man, the over-estimation of 
LV mass has been as large as 20% (Devereux, 1987). However, the present study had 
an echo/necropsy mass ratio of 1.05, indicating a relatively modest 5% over-estimation 
of LV mass, and by employing a simple correction factor this ratio was reduced to 1.00, 
such that systematic over-estimation was no longer a problem.
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Accuracy in detecting cardiac hypertrophy
The decision of where to set the upper limit of normality when describing LV 
hypertrophy will obviously have a pronounced effect on the calculations of accuracy, 
and it would be desirable to have an agreed value of what represented hypertrophy in 
the rat. It is not possible to compare this limit in the work of Pawlush et al (1993) as 
they normalise LV mass to tibial length. The only directly comparable studies, are 
those of de Simone et a l (1990 & 1994). In their 1994 paper, the critical value for LV 
hypertrophy was set at 1.62g/Kg. This is much lower than even the lowest 
measurement for WKY in this study, which can be explained by the fact that they 
normalised to body weight when using rats up to 763g in weight. In the 1990 paper, de 
Simone et a l set limits depending on body weight range. The critical value is 3.2g/Kg 
for animals between 100-299g body weights, dropping to 2.2g/Kg in animals with body 
weight between 300-499g. These are in rough agreement with the 2.86g/kg value in 
this study, and demonstrate that such limits can only be compared within a well-defined 
population. The limit is only likely to apply as long as the heart weight is increasing in 
direct proportion to the body weight, as observed in the growth curves (Figure 3.6). In 
humans, the Framingham heart study noted different limits for cai'diac hypertrophy in 
men and women, even when normalised to body weight (Devereux, 1987). However, in 
a smaller study of normal subjects no sex difference was noted (Gardin a/., 1987). As 
with the present study in rats, correction for body weight apparently accounted for any 
sex difference.
When assessing echocardiography as a diagnostic test in this way we are looking for a 
“yes” or “no” answer to the presence of hypertrophy. However, the population of rats 
in the current study does not lend itself well to this question, as it includes young 
SHRSPs that represent a continuous range of LV mass from normal to hypertrophied. 
Indeed, this is the same situation that occurs clinically in man, where, although it is 
possible to set a value for LV mass over which we define “hypertrophy”, there is some 
concern that patients in the upper range of “normality” may have an increased clinical 
risk, despite a negative test (Liebson et a l, 1987). One reason why other groups appear’ 
to have a superior accuracy compared to this study is that they have greater polarity 
between normal and hypertrophied groups. If there is not a continuous range of values, 
but a clear difference between normal and hypertrophied (e.g. by age and sex matching),
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then improved levels of accuracy are only to be expected. Another important 
consideration is that only one group reported the predictive value of the test, i.e. the 
number of true cases among all positive results, and the false-negative rate. These 
parameters give a better indication than sensitivity and specificity of the usefulness of a 
test where prevalence of the condition is known (Daly et a l, 1991).
Comparison o f WKY M>ith SHRSP
The blood pressme data for this study gives lower values for SHRSP animals than has 
been reported previously in this laboratory (Davidson et al., 1995). The reason for this 
is the inclusion of a wide variation of ages, including young animals that may not yet 
have attained full hypertensive status. These were not excluded from this study as they 
provide the range of hypertensive / hypertrophic states important for the validation 
exercise. In contrast, Davidson et a l (1995) made standardised measurements at a 
constant age confirmed by telemetry. However, in this study, clear statistical 
differences were still observed between male and female SHRSP, and between both 
sexes of SHRSP and WKY.
There was no positive correlation between cardiac hypertrophy and systolic blood 
pressure in either WKY or SHRSP animals (Figure 3.10). This is a common finding in 
hmnan and animal studies. In man, single measurements of systolic blood pressure are 
only weakly related to echo LV mass, with correlation co-efficients ranging from 0.24 
to 0.45 (Devereux et a l, 1987). In the SHR, LV weight continues to rise for months 
after blood pressure has reached its maximum level (Pfeffer et a l,  1979), and may even 
be elevated before blood pressure begins to rise (Yamori ei a l, 1979). Therefore, 
elevated blood pressure is only one of many factors that probably influence LV 
hypertrophy, such as, environmental, endocrine, or genetic differences. For example, in 
a genetic analysis that including SHR and SFIRSP, Tanase et a l (1982a) estimated that 
65-75% of variability in LV mass was attributable to genetic causes.
Table 3.1 indicates differences observed between WKY and SHRSP in echo-derived 
parameters. Wlren normalised to body weight, the SHRSP heart had a significantly 
greater LV mass and myocardial cross-sectional area. This was due to a thickening of 
both aspects of the ventricular wall. There was no significant evidence for remodelling 
of the LV cavity, as only small increases were observed in end-diastolic dimension and
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end-diastolic volume. This suggests that the increased wall thickness of the SHRSP 
models outwardly, as there is no encroaclrment into the LV lumenal space. The 
hypertrophic response is not perfectly concentric as there was a small but significant 
difference between AWT:PWT ratio in WKY and SHRSP, indicating the anterior wall 
to exhibit a greater degree of hypertrophy.
In man, left ventricular wall thiclmess can show considerable regional variation. Wall 
thickness gets progressively less the closer measurements are made to the apex, and the 
anterior wall tends to be thicker than the posterior wall (Reichek, 1987). In this study 
the AWT:PWT ratio was less than 1, indicating a relatively thicker posterior wall, 
unlike in man. Why this should be so, is not entirely clear. It may in part be due to 
poor differentiation between inter-ventricular septum and anterior wall. In the rat it is 
difficult to define exactly which section of the wall is being measured, as the right 
ventricle is not usually visualised. Another confounding factor is the difficulty in 
obtaining good epicardial definition in the anterior wall, which in the rat, lies very close 
to the transducer and therefore not in the zone of optimal focus.
A further study in rats not included in Table 3.3 is concerned with the determination of 
stroke volume in male Wistar rats (Nakamura et a l, 1992). In this study, the ability to 
estimate stroke volume from short-axis measurements using a cubed formula was 
compared with simultaneous measurement using a pulsed Doppler flow meter placed 
around the aorta. The authors report very good correlations between measurements 
when a range of values were created either by atrial pacing (r ^  0.84) or saline infusion 
(r = 0.91). The method of calculating stroke volume is very similar to that employed in 
the present study, and suggests that at least in the non-hypertrophied heart, the value 
obtained may be fairly accurate.
As a word of caution, care should be taken when comparing data from WKY and 
SLIRSP, as any differences observed do not represent remodelling of the heart, since 
there is no evidence to suggest that SHRSP hearts were ever identical to WKY rats at 
any stage of development. The differences indicated are between a normotensive and 
hypertensive strain, and remodelling can only be said to occur when following 
longitudinal changes in the same animals.
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It would have been useful to calculate LV wall stress in these animals, as pressure 
overload is thought to cause concentric LV hypertrophy by elevation of systolic wall 
stress (Kucherer & Kuebler, 1992). To measure this non-invasively requires the 
simultaneous measurement of blood pressuie and LV dimensions by echo cardiography 
(Fouad-Tarazi & Liebson, 1987). This could be achieved by continuous blood 
pressrne monitoring after surgical implantation of a radiotelemetry probe. There is 
considerable experience of telemetric recording in this laboratory, and the combination 
with echocardiography may be investigated in the future.
Measurement o f  LV function
When using halothane anaesthetic, ejection fraction was consistently and significantly 
attenuated in the SHRSP (Figure 3.12). The decrease in function observed in this study 
was clearly contributable to the use of halothane, as although length of exposure was 
not an important determinant of function (Figure 3.13), changing anaesthetic to 
hypnorm greatly improved LV function in both WKY and SHRSP (78% versus 77% 
respectively), when the difference between groups was no longer apparent. Flowever, 
the results from the halothane studies are interesting because it shows that in rats with 
severe cardiac hypertrophy, large differences in LV function may become unmasked 
under situations where the heart is suitably stressed.
Halothane was originally chosen as the anaesthetic in these studies due to practical 
considerations. A suitable vaporiser was available in the animal unit, and because 
induction and recovery are very rapid at between 1 -3 minutes, the total anaesthetic time 
for each animal could be kept to an absolute minimum. However, halothane does have 
Imown depressant effects on the cardiovascular system, with a reduction in cardiac 
output and peripheral vasodilatation, resulting in a degree of hypotension. It also has a 
dose-dependent effect to depress respiration (Fleclmell, 1996). Since almost all 
anaesthetics have some cardiac depressant effects it was hoped that WKY and SHRSP 
would be affected to a similar' extent. In humans, the depressant effects of halothane 
may be more pronounced in infants, where it has been shown to decrease heart rate, 
fractional shortening, velocity of circmnferential fibre shortening and cardiac index 
(Wodey et a l, 1997). The interaction between cardiac hypertrophy and halothane has 
been examined in rabbits after aortic coarctation to induce LV hypertrophy (Rooke & 
Su, 1992). Using an in vitro set-up of skinned myocardial fibre bundles, both normal
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and hypertrophied samples showed a dose-dependent effect of halothane to decrease 
contractility in response to maximal calcium concentration. Also, no difference was 
detected in the ability of halothane to inliibit calcium storage by the sarcoplasmic 
reticulum. The authors concluded that calcium sensitivity and storage are not the cause 
of the interaction between the cardiac depressant effects of halothane and hypertrophy. 
The mechanism remains to be elucidated.
Wlren choosing a replacement anaesthetic, hypnorm was selected, as small doses are 
sufficient to produce sedation in the rat for echocardiographic examination. Thus, a 
much lighter depth of anaesthesia could be used, resulting in cardiac depressant effects 
that were much less pronounced. This worked well with an intraperitoneal dose of 0.04 
-  0.1ml producing light sedation while major reflexes remained intact e.g. response to 
painful stimuli, righting reflex.
Even when using hypnorm, ejection fraction was around 75-80%, which although high 
in human terms is lower than 91-94% obtained in the study by Pawlush ei a l (1993). 
This may represent differences due to anaesthetic or strain, they used pentobarbital in 
Sprague-Dawley rats, or it may be inherent in the variability in measurements. 
However, it is important to remember that we are not trying to obtain absolute values 
for ejection fraction, rather to achieve reproducible measurements that can be compared 
to baseline data in longitudinal studies.
Use o f  echocardiography for serial evaluations.
The co-efficient of repeatability was determined for a range of echo-derived parameters 
using the method of Bland & Altman (1986). It would be wrong simply to use 
correlation co-efficient as a measurement of strength of relationship in this case, as we 
do not laiow the true value, and want to compare the agreement of two measurements. 
The correlation co-efficient will be high if the values lie on any straight line, but may 
not reflect actual agreement between values e.g. if one set of measurements incorporates 
a systematic error.
Wlien using the co-efficient of repeatability to measure agreement between studies, it is 
first necessary to determine if any systematic error has affected either of the 
measurements. Calculating the mean of differences is used for this purpose. Normally
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distributed data should be spread evenly above and below the mean, such that the mean 
of differences approximates to zero. If the mean of differences is significantly not zero, 
then this technique is not appropriate unless some consideration is given to correcting 
for the systematic error. As can be seen from Table 3.2, the mean of differences is close 
to zero for all parameters when compared to the mean values.
The co-efficient of repeatability can also be described as a percentage of the mean value 
obtained in the measurements, i.e. the percentage change in that parameter representing 
two standard deviations. This is similar to the method for deriving the co-efficient of 
variability described by Clark et al. (1980), and used in some studies. However, it 
should be noted that the co-efficient of repeatability incorporates two standard 
deviations, while the co-efficient of variability reports just one. Either method allows 
comparison between measurements to determine the most reproducible parameters, and 
hence the most useful for serial evaluations. Values for these are shown in Table 3.4, 
calculated from data in Table 3.2.
Table 3.4 Co-efficient of repeatability for echocardiographic parameters measured 
48 hours apart, expressed as percentage change from the mean.
Echo-derived measurement. Co-efficient of repeatability. 
Percentage of mean.
LV mass 21%
Myocardial CSA 15%
Anterior wall thickness 17%
Posterior wall thickness 16%
End diastolic dimension 18%
End systolic dimension 26%
Cavity CSA diastole 44%
Cavity CSA systole 71%
Stroke volume 37%
Ejection fraction 23%
This means that an observed change in LV mass of >21% would represent a shift of 
more than two standard deviations from the mean, such that there is a 95% chance that 
the change is real and not due to variability in measurement. This compares favourably
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with the only other study in rats which used this methodology, which obtained a co­
efficient of repeatability for LV mass of 32% (Jones et a l, 1992). The data in Table 3.2 
indicates that the M-mode in rats is superior to two-dimensional imaging, as the 
repeatability of cavity cross-sectional areas, which are measured from 2-D, are very 
poor. In contrast, one-dimensional measurements from the M-mode such as anterior 
and posterior wall thiclaiess and end diastolic dimension are much more reproducible. 
However, it is interesting to note that ejection fraction, as the ratio of these 
measurements, has a much improved co-efficient of repeatability. It is evident that for 
any given measurement the changes in CSA during diastole and systole retain the same 
relationship. The poor repeatability may be due to large subject variability, potentially 
exacerbated by use of halothane anaesthetic. Alternatively, problems in obtaining the 
identical short-axis imaging plane in both studies may be to blame. Angulation of the 
transducer beam away from the true short-axis may result in over-estimation of LV 
dimensions, or imaging too low down the heart may result in measurement of smaller 
dimensions. In human studies of serial echocardiography, positioning of the transducer 
was the most important technical consideration affecting reproducibility of the 
measurement (Wallerson & Devereux, 1987). However, since the plane for M-mode is 
selected from two-dimensional images, we would expect the same variability to be 
present in LV dimensions using this teclmique, which clearly there is not. The high 
variability in two-dimensional measurements is therefore most likely due to a 
combination of high intra-subject variability and less reliable measurements in 2-D 
mode, for example, due to poor edge definition.
The most reproducible, and therefore the most useful, measurement is myocardial cross- 
sectional area. Why this should be less variable than its individual component parts is 
probably due to the averaging out of errors incurred in measuring very small distances. 
In a study by Nakamura et al. (I99I) post-mortem validation of myocardial CSA with 
echo-derived CSA gave very good correlations in Wistar (r = 0.91) and SHR (r = 0.84) 
rats, confirming the suitability of myocardial CSA as a marker of hypertrophy in its own 
right. As soon as we attempt to extrapolate into three dimensions we lose a good deal 
of repeatability, as can be seen by the higher co-efficient of repeatability for LV mass 
and stroke volume.
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The repeatability of ejection fraction is not as good as expected. In the chapter on heart 
failure in rats, repeatability of ejection fraction in sham animals seems to be much 
improved. This may simply represent a learning curve for making echo-derived 
measurements. The heart failure data was collected at a time when the sonographer had 
a much greater experience (>200 examinations in rats).
For the use of echocardiography in serial studies it is concluded that where clear 
differences are expected, for example of the magnitude observed between WKY and 
SHRSP, most of the parameters studied will he useful. Appropriate power calculations 
can be performed to determine the number of animals required to show significant 
changes. However, for smaller incremental changes, more reliance should be placed on 
measurements from the M-mode, in particular individual wall thickness, myocardial 
cross-sectional area, and end-diastolic dimensions.
Sources o f  variability
The use of simultaneous two-dimensional imaging is probably of some considerable 
benefit in selecting the appropriate M-mode, but appears to be highly variable when 
taking measurements. The superior edge definition and temporal resolution of the M- 
mode makes it the most reliable in the fast moving rat heart, and this is borne out by the 
much lower co-efficient of repeatability for M-mode measurements in this study.
One major advantage of the M-mode that has already been mentioned is its high 
temporal resolution, which is vitally important with the high heart rate in the rat. 
Increasing heart rate may have an influence on accuracy of LV dimensions in serial 
measui'ements. One study in normal humans has shown a linear decrease in end- 
diastolic dimension when the heart rate was raised in 10 beats/min increments 
(Wallerson & Devereux, 1987). This decrease was small at 2.7%, and it is not known 
how this may relate to measurements in the rat. However, it follows that the effect of 
particular anaesthetics in lowering heart rate may have implications for accuracy of LV 
dimension in the rat.
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Quality control
Although this study included criteria for choosing the best echocardiograms from which 
to take measurements, no criteria were adopted for rejecting unsatisfactory images. In 
human studies, it is common for patients to be excluded due to poor quality 
echocardiograms. For example, in the Framingham heart study, out of 6148 patients 
examined, only 80% had acceptable quality images when assessed against strict 
exclusion criteria. In addition, the authors describe a significant learning curve, with the 
acceptance rate as low as 28% in the first 5 months, rising to a high of 96% after 2 years 
(Savage et a l, 1987). Again, in the present study, as with all other studies in rats, no 
consideration was given to inclusion criteria or to the learning curve. This does not 
mean that it is easier to obtain acceptable images in the rat, rather that measurements are 
attempted regardless of the quality of the echocardiogram. Error introduced due to this 
will be accounted for within the calculations of accuracy, and it may be that these would 
be improved by adopting criteria for the rejection of images, as occurs in clinical 
studies.
A further problem relating to variability is that of systematic observer bias. This may 
occur when any clue is available as to the identity of the subject being measured. In this 
study, despite the reader being blinded as to whether rats were WKY or SHRSP, it was 
often easy to identify at a glance those animals exhibiting cardiac hypertrophy (see 
Figure 3.11 for example). Thus, a certain amount of bias may be unavoidable, 
depending on how easily groups can be differentiated. This is also true in data from the 
heart failure rats reported in Chapter 5, where it was often possible to visualise the 
infarct area or wall motion abnormalities, that would give away the operational status of 
the animal.
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3.5 Conclusions
Despite the technical limitations in imaging small objects such as the rat heai't,
echocardiography has been shown to have sufficient accuracy and repeatability to be
useful in serial studies in determining LV structure and function (where function is
comparative not absolute). In particular,
• The SHRSP has been confirmed as a good model of severe cardiac hypertrophy with 
on average 28% greater LV mass to body weight ratio when compared to WKY.
• The extent of differences in cardiac mass and dimensions are such that it is suitable 
for detection by echocardiography using an unmodified machine.
• Cardiac hypertrophy does not correlate well with single point measurement of blood 
pressure.
• The SHRSP is much more susceptible to the cardiac depressant effects of halothane 
when compared to WKY (halothane unmasks LV dysfunction in the SHRSP). 
However, when using hypnorm sedation, LV function in the SHRSP is not 
compromised when compared to WKY.
• The use of echocardiography to determine LV mass in rats provides a good 
correlation with LV mass at post-mortem.
• The presence of cardiac hypertrophy in this strain of rats can be defined as a LV 
mass / body weight ratio of >2.86g/Kg.
• The accuracy for determining cardiac hypertrophy by echocardiography is 
comparable to that for the same technique in man, with sensitivity 92% and 
specificity 64%.
• The most reliable measurements for longitudinal studies are LV mass, myocardial 
cross-sectional area, and wall thiclaiess.
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4. Prevention of Cardiac and Vascular Hypertrophy in a 
Model of Genetic Hypertension
4.1 introduction
As discussed in Chapter 1, the ability of antihypeitensives to control complications of 
prolonged blood pressure elevation such as cardiac and vascular- hypertrophy are 
thought to be important in preventing decline of cardiac function in the long-term. In 
this chapter, the ability of irbesartan, an angiotensin II type 1 receptor (AT;) antagonist, 
was tested in preventing these complications in the stroke-prone spontaneously 
hypertensive rat (SHRSP), a severe model of genetic hypertension. Irbesartan treatment 
fi-om 6 weeks of age was compared to untreated control SHRSP, as well as rats given an 
equihypotensive dose of hydralazine + hydrochlorothiazide (H+H). The hypothesis was 
that blockade of AT; receptors provides additional benefits over and above the blood 
pressure lowering effect.
Prevention of left ventricular (LV) hypertrophy was quantified by trans-thoracic 
echocardiography before and during treatment. In addition, natriuretic peptide gene 
expression in the LV was assessed, since ANP and BNP have been suggested as 
molecular markers of LV hypertrophy (Kawakami et a l, 1996). The influence of 
irbesartan on medial hypertrophy of resistance arteries was studied, for the first time, 
using laser scanning confocal microscopy (LSCM). This allowed the quantification of 
vascular wall thiclaiess and of cell number, in order to evaluate the relative importance 
of hypertrophy and hyperplasia.
Hydralazine + hydrochlorothiazide was chosen for this study as previous work in this 
laboratory has shown a dose of 4mg/Kg/day of each to be as effective as the ACE 
inliibitor perindopril in lowering blood pressure in the SHRSP (Devlin ei a l, 1995). 
Hydrochlorothiazide is a thiazide diuretic and therefore inhibits sodium reabsorption in 
the early distal convoluted tubule, its antihypertensive action also involves direct 
vasodilatory effects. Hydralazine is classed as a vasodilator and probably acts directly 
on the smooth muscle, but its mechanism of action is poorly understood, and may
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involve modulation of intracellular calcium handling or a direct interaction with the 
contractile appaiatus (Jacobs, 1984).
Irbesartan pharmacology
Irbesartan (BMS-186295 or SR 47436) is an angiotensin II type 1 receptor antagonist 
(AT]RA). It is one of four ATiRAs currently licensed in the UK to treat hypertension, 
the class leader being losartan (BNF No.38 September 1999). ATiRAs interact with the 
renin-angiotensin system, which has a central role in regulating blood pressure and 
electrolyte balance (discussed in Chapter 1). In this respect they are similar to ACE 
inhibitors which inliibit angiotensin-converting enzyme, preventing the conversion of 
angiotensin I to angiotensin II (Angll). ACE inhibitors represent the gold standard in 
this area and have been used clinically to treat hypertension and heart failure with 
considerable success for many years. Theoretically, Angll receptor antagonism may 
offer several advantages over ACE inliibition by providing a more complete blockade of 
the RAS. This is because inliibiting the angiotensin-converting enzyme does not 
prevent the production of Angll by non-ACE pathways, whereas antagonism of the 
Angll receptor will block the effects of all Angll, whatever the source. In addition, 
inhibition of ACE can result in accumulation of bradykinin since ACE also 
masquerades as kininase II, which inactivates bradykinin. Excess bradykinin in the 
bronchial mucosa may be responsible for the persistent cough, which is a common side 
effect of ACE inhibitors. This is not a problem with ATiRAs (Powell et al., 1998).
It is the angiotensin type 1 receptor (ATi) which mediates the deleterious effects of 
Angll such as vasoconstriction, cellular hypertrophy, sodium retention and increased 
aldosterone release. Blockade of the ATi receptor in the juxtaglomerular apparatus 
leads to an increase in plasma renin activity and therefore a rise in circulating Angll. 
This rise in Angll ( 1 .5 - 2  fold for irbesartan) does not interfere with the inliibition of 
ATI receptors, as antagonism by irbesartan is insurmountable. Furthermore, the 
increased activity of Angll at AT2 receptors may contribute to the beneficial effect of 
ATiRAs since the AT% receptor is thought to mediate an antiproliferative effect on 
coronary endothelimn and to inhibit growth in vascular smooth muscle. (Powell et a l, 
1998). Flowever, the clinical importance of these ATz-mediated effects have not been 
firmly established.
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Irbesartan is highly potent, in radioligand binding studies it has ten times the affinity 
over losartan for ATi receptors in rat liver membranes and vascular smooth muscle cells 
(IC50 = 1.7nM). It is selective for AT, with a greater than 10000 times lower affinity for 
AT2 receptors, and no affinity for a-adrenergic, serotonin, bradykinin, or vasopressin 
receptors or calcium chamiels at concentrations up to 30pM (Powell et a l, 1998). It has 
the advantage over losartan of not requiring transformation to an active metabolite to 
attain its full effect.
The pharmacokinetics of irbesartan are favourable. After oral administration, 
absorption is rapid with a high bioavailability of 60 -  80%, unaffected by food. The 
elimination half-life in healthy volunteers is between 11 and 15 hours with no gender 
differences, allowing for once daily dosing. At the clinical doses of 150 and 300mg 
daily, steady state is attained after 3 days and there is no significant accumulation. 
Higher plasma concentrations of irbesartan are observed in hypertensive females, but 
this does not affect half-life or accumulation, nor does renal or hepatic insufficiency 
(Powell et a l, 1998).
From trial data in 2600 patients, irbesartan also appears to be well tolerated with a 
frequency of adverse reactions similar to placebo. The incidence of first dose 
hypotension is also equivalent to placebo (Powell et a l, 1998).
Before starting this study there had only been a handful of papers published on 
irbesartan in hypertensive rat model. Initial reseai'ch showed that a single oral dose of 
irbesartan could abolish the pressor response of angiotensin II in normotensive rats, and 
a dose of 30mg/Kg almost totally abolished the rise in blood pressure (Cazaubon et a l,
1993). In another dosing study by the same group, oral and intravenous administration 
of irbesartan was examined in a wide range of hypertensive models including renal 
artery-ligated rats, 2-kidney 1-clip Goldblatt rats, and DOC A treated rats. In the SHR, 
acute oral administration with lOmg/Kg significantly reduced mean arterial pressure 
(MAP) within l ‘A hours and peaked at 3 to 5 hours with a reduction of 16mmHg. This 
effect lasted 8 hours, and at 24 hours the treated animals were still lOmmHg lower, 
although this was not statistically significant. After 2 weeks treatment at the same dose, 
a small but consistent reduction in MAP of 17mniHg was observed (Lacour et a l.
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1994). These studies showed the potential for once daily dosing, but that doses of 
30mg/Kg would be required for significant lowering of blood pressure in the rat.
The response to irbesartan clearly depends on the underlying aetiology of the model. In 
rats with pressure-overload due to aortic banding a dose of 50mg/Kg could only reduce 
systolic blood pressure by 8mmHg over a 15-week period. In addition, there was no 
effect of treatment on cardiac hypertrophy with left and right ventricular weights 
remaining elevated, as did myocyte cross-sectional area. It is not surprising that there 
was no improvement in survival despite a small decrease in LVEDP and normalisation 
of LV ACE mRNA levels (Weinberg et a l, 1995). The bottom line is that aortic 
banding does not produce a high renin dependent model, and so is less susceptible to 
modulation by Angll antagonists.
In male Wistar rats made hypertensive by administration of 50mg/Kg/day L-NAME, 
irbesaiian (lOmg/Kg/day) reduced but did not normalise blood pressure. Despite the 
low dose, irbesai'tan had a more profoimd effect on cardiac hypertrophy and in 
controlling inflammatory changes. It prevented the increase in heart to body weight 
ratio, and cardiac fibrosis and cell infiltration. It also prevented the inflammatory 
response in aortic smooth muscle, preventing the rise in protein and gene expression of 
iNOS, ICAM-1 and VCAM-1 (Luvara et a l,  1998).
In a prevention study similar to the one reported here, SHRs were treated orally with 
60nig/Kg/day from 4 to 20 weeks of age. Animals treated with irbesartan had a 
consistently lower systolic blood pressure by around 40mniHg. Diastolic pressure was 
also lowered at all time points. Post-mortem cardiac morphology showed a decrease in 
heart weight, LV cross-sectional area and collagen content in the treated group, 
consistent with a reduction in cardiac hypertrophy. From 14 weeks of treatment 
onwards the aorta of treated rats exhibited a reduced media thickness and collagen 
content, while nuclear density was increased. These effects persisted for 8 weeks after 
cessation of irbesartan (Vacher et a l, 1995)
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The aims of the present study were to examine in more detail the ability of irbesartan to 
prevent hypertension and its associated cardiac and vascular complications. The 
specific research questions were as follows,
• Is irbesartan effective in preventing blood pressure rise in the SHRSP?
• Will irbesartan prevent cardiac hypertrophy in the SHRSP? Can this be measured 
by serial echocardiography? Wliat is the temporal relationship between rise in blood 
pressure and development of cardiac hypertrophy?
• Does irbesartan alter other markers of cardiac hypertrophy such as gene expression 
of ANP and BNP?
• Is irbesartan able to prevent vascular hypertrophy of resistance arteries associated 
with prolonged hypertension?
To what extent are these effects reliant on blockade of angiotensin II receptors 
compared to maintaining low blood pressure per sel This will be achieved by 
comparing results with a non-angiotensin II mechanism using hydralazine + 
hydrochlorothiazide.
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4.2 Methods
Protocol
A  total of 24 SHRSP rats were used in this study with 8 (4 males and 4 females) in each 
of the tliree treatment groups, control, irbesartan and hydralazine + hydrochorothiazide 
(H+H). Drug treatment began shortly after weaning at between 6 and 7 weeks of age 
and continued daily at the same time each day for the entire 8 weeks of the study. 
Blood pressure was measured twice weekly by tail-cuff plethysmography from one 
week before entry until euthanasia. Echocardiographic examination was performed at 
baseline and then at study week 4 and 8. After 8 weeks of drug treatment animals were 
euthanased by an overdose of halothane anaesthetic, blood removed by cardiac puncture 
and the left ventricle weighed. At this time a small portion of the left ventricle was 
frozen in liquid nitrogen for subsequent isolation of RNA and Northern blot analysis for 
ANP and BNP. A section of jejunum with mesenteric arteries attached was placed in 
cold physiological salt solution and later fixed for study of mesenteric resistance arteries 
by laser scanning confocal microscopy.
Drug dosing
The normal method for delivering drugs in the rat is by dissolution in the drinking 
water. However, several properties of irbesartan make it less than ideal for this. Firstly 
it is only poorly water-soluble. To prepare a solution of appropriate strength and pH the 
manufacturers suggest dissolving the powder in a highly alkaline solution such as 
tribasic sodium phosphate. This requires the preparation of two buffer solutions and 
sonification may be necessary. This would not be a problem if large quantities could be 
prepared in advance. However, the stability of a 7mg/ml stock solution of irbesartan 
prepared in this way is very poor, with only 93% of the initial drug concentration 
remaining after 3 days at room temperature. There is also a high possibility of drug 
precipitation during storage as the solution is supersaturated. This would require 
solutions to be prepared and used on a 24-hour basis (Personal communication, Bristol- 
Myers Squibb).
For this reason, another system was required for delivering the drug. It was decided to 
create a simple suspension of drug in a small quantity of chocolate mousse. Animals 
were weighed weekly and the quantity of drug to provide 16mg/Kg/day of irbesartan or
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4mg/Kg/day each of hydralazine and hydrochlorothiazide was calculated. Daily doses 
of the drug were weighed out several days in advance and stored in the dark until 
required. Immediately prior to administration, the dose was mixed with 1ml of 
chocolate mousse to form a suspension of drug. Control animals received 1ml mousse 
containing no treatment. The flavouring of the mousse was chosen to be most palatable 
to the rats, while disguising the taste of the drug. The drug-mousse mixture was almost 
always eaten immediately on introduction to the cage. The mousse was a commercial 
brand of chocolate pudding marketed for infants (H.J. Heinz Co. Ltd., Uxbridge, UK). 
The ingredients were as follows: skimmed milk (76%), water, cornflour, sugar, 
vegetable oil, fat reduced cocoa powder (1%) and natural flavouring. It contained no 
added preservative, artificial flavours, artificial colours, and no added salt. The 
nutritional status of the mousse is provided below, with the relative quantities provided 
for a 1ml daily intake.
Nutrition Information Per lOOe Per 1ml
Energy 77kcal O.Skcal
Protein 2.9g 32mg
Carbohydrate 13.2g 145mg
(of which sugars) (8.7g) 96mg
Fat 1.4g 15mg
(of wliich saturates) 0.2g 2.2mg
Fibre 0.3g 3.3mg
Sodium O.lg 1.1 mg
The dose of irbesartan was chosen at 60mg/Kg/day, as this dose has been shown to 
prevent hypertension in the SHR (Vacher et al., 1995). The dose of H+H has been used 
previously in this lab, and was effective at normalising blood pressure in the SHRSP 
(Devlin et a l, 1995).
TaiUcuffplethysmography
Measurements of systolic blood pressmo and heart rate were performed twice weekly 
(48 hours apart) by tail-cuff plethysmography. The mean of these two independent 
readings was used to represent systolic blood pressure for that week for each individual 
animal. Method was as described in chapter 2.
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Echocardiography
Method is as described in Chapter 3, using the Medison Sonoace SA8800 ultrasound 
machine interfaced to a 7,5MHz transducer. Light sedation was with 0.04 -  0.1ml of 
intraperitoneal hypnorm.
Northern analysis & Laser scanning confocal microscopy 
Both as detailed in Methods chapter.
Statistics
Comparisons between groups were performed using one-way ANOVA corrected for 
multiple comparisons using the Newman-Keuls test, adopting a significance level of 
P<0.05.
Spearman correlation was used where sample size was eight animals, since this is a non- 
parametric test and so does not assmne a Gaussian distribution. For this sample size, a 
correlation co-efficient of r > 0.71 is considered significant (P<0.05).
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4.3 Results
Blood pressure
There were no differences between treatment groups as regards age, sex ratio or body 
weight at the start of this study (Table 4.1 ). All data are presented as the mean value for 
both males and females. Systolic blood pressures for the duration of the study are 
shown in Figure 4.1.
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Figure 4.1 Systolic blood pressure measured by tail-cuff plethysmography in 
control and treated SHRSP. Week 6 refers to baseline measurements before treatment, 
with data shown until euthanasia at week 14. All data points are the mean ± sem for 8 
rats, each with two independent measurements performed 48 hours apart. Comparison 
between means using one-way ANOVA with Newman-Keuls correction for multiple 
comparisons, *** Denotes P<0.001 and ** denotes P<0.01 for both control vs. 
irbesartan and control vs. H+H.
Before treatment, there was no significant difference in systolic blood pressure (BP) 
between groups: 113, 121, 118mmHg for control, irbesartan and H+H respectively. By 
four weeks into the study, BP in the untreated control group had risen significantly 
(P<0.01) compared to both treatment arms, and continued to rise until a maximum of 
166mmHg at 8 weeks compared to 127mmHg in irbesartan and ISlmmHg in H+H
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animals. There were no differences in BP between irbesartan and H+H treated groups 
throughout the duration of this study.
Cardiac hypertrophy
Echocardiograms were taken at baseline, 4 and 8 weeks of treatment, when LV mass 
was confirmed by post-mortem examination. Figure 4.2 shows the LV mass to body 
weight ratio for all three groups throughout the study. The full range of results 
including LV dimensions and function is shown in Table 4.1 for baseline data. Table 4.2 
for 4 week data, and in Table 4.3 for data obtained at 8 weeks immediately prior to 
sacrifice. In all tables, data are presented as absolute values since the groups are closely 
matched as regards age, body weight and sex ratio throughout the study. Similar results 
are obtained if normalised to body weight (data not shown), with the exception of LV 
mass when a difference between irbesartan and H+H groups is unmasked. For this 
reason Figure 4.2 shows data for LV mass normalised for body weight.
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Figure 4.2 Left ventricular mass measured by echocardiography and normalised to 
body weight at baseline (before treatment), 4 weeks and 8 weeks of treatment. LV mass 
measured at post-mortem at 8 weeks is presented in the final column for comparison. 
All data are mean ± sem, comparison by ANOVA with Newman-Keuls correction for 
multiple comparisons. *** Denotes P<0.001; ** P<0.01; * P<0.05; n.s., difference not 
significant.
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There were no significant differences between groups for any of the measured 
parameters at entry to the study (Table 4.1). However, by 4 weeks, control animals had 
a significantly increased LV mass when compared to either treatment (P<0.05). As 
shown in Table 4.2, this difference was not just significant for LV mass, but was also 
highly significant for posterior wall thiclaiess (F=10.7, P=0.0006) and myocai’dial cross- 
sectional area (F=12.6, P^O.0003). The trend was also observed in anterior wall 
thiclaiess but just failed to reach significance (F=3.15, P=0.06). In all these 
measurements, control hearts had the largest diniensions, followed by H+FI then 
irbesartan animals, wliich consistently had the smallest measurements for LV 
dimensions. In none of the parameters was the difference between irbesartan and H+H 
groups shown to be significant. Despite the greater wall thiclaiess in control animals, 
no differences were observed in LV cavity dimensions (EDD & ESD), or in cardiac 
function as measured by fractional shortening.
Table 4.1 Echo-derived LV measurements obtained at baseline.
Baseline Control Irbesartan H+H P value
Age (days) 5 1 ± 6 49 + 3 51 + 3 n.s.
Body weight (g) 100+14 98 + 20 110+18 n.s.
EDD (mm) 3.6 ± 0.6 3.5 + 0.7 3.9+ 0.1 n.s.
ESD (mm) 1.3 ±0.5 1,3 + 0.4 1.4+ 0.1 n.s.
PWT (mm) 1.5 ± 0.1 1.6+ 0.2 1.4+ 0.1 n.s.
AWT (mill) 1.3 ±0.2 1.3 + 0.2 1.2 + 0.1 n.s.
Myocardial CSA (iiuif) 22.2+1.3 22.0 + 3.6 21.7+1.6 n.s.
LV mass (mg) 228 + 31 225 + 50 233 + 22 n.s.
Fractional shortening (%) 65 + 7 64 + 8 66 + 6 n.s.
All values are mean ± standard deviation. EDD represents end-diastolic dimension; 
ESD, end-systolic dimension; PWT, posterior wall thickness; AWT, anterior wall 
thiclaiess; CSA, cross-sectional area and n.s., not significant.
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Table 4.2 Echo-derived LV measurements obtained at 4 weeks of treatment.
4 weeks Control Irbesartan H+H P value
Age (days) 80 ± 6 79 + 2 78+ 1 n.s.
Body weight (g) 185 + 28 175 + 35 183 + 31 n.s.
EDD (mm) 4 .0+  0.3 4.0+  0.6 4.1 + 0.5 n.s.
ESD (mm) 1.3 + 0.2 1.4+ 0.4 1.4+ 0.2 n.s.
PWT (mm) 2.14 + 0.14 1.75 + 0.26^=^* 1.80 + 0.13** 0.0006
AWT (mm) 1.65 + 0.13 1.42 + 0.27 1.46 + 0.15 0.06
Myo CSA (m nf) 35.2 + 2.8 27.1 + 4.4*** 29.4 + 2.3** 0.0003
LV mass (mg) 428 + 53 322 + 69** 347 + 42** 0.0024
FS (%) 68 + 4 66 + 8 66 + 4 n.s.
All values are mean ± standard deviation. EDD represents end-diastolic dimension; 
ESD, end-systolic dimension; PWT, posterior wall thickness; AWT, anterior wall 
thiclaiess; Myo CSA, niyocai*dial cross-sectional area; FS, fractional shortening. 
denotes P<0.001 versus control group, P<0.01 versus control group and n.s., not 
significant.
The differences observed at 4 weeks were still present at 8 weeks and LV mass was 
confirmed by autopsy (Table 4.3). Both drug regimes significantly prevented cardiac 
hypertrophy when compared to control animals, however they were not equipotent in 
this respect. Irbesartan treated animals also had a significantly lower LV/body weight 
ratio when compared to H+H, indicating an additional effect over and above the ability 
to lower blood pressure. This was observed in the autopsy data, but was not significant 
in the echo-derived data, probably due to the variability of this method. As with data 
collected at 4 weeks, significantly smaller LV dimensions were observed with both drug 
treatments e.g. posterior wall thickness (F=20.3, P<0.0001), myocardial CSA (F=8.31, 
P=0.002) and this time anterior wall thiclaiess (F=8.22, P=0.002). The ranlc order for 
LV dimensions was control»>H+H>irbesrtan. Again, there were no significant 
differences in LV cavity dimensions or function, which was confirmed by measurement 
of ejection fraction from two-dimensional echocardiograms. Representative M-mode
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echocardiograms are shown in Figure 4.3 indicating the thicker left ventricular walls 
observed in untreated control animals.
Table 4.3 Echo-derived LV measurements obtained at 8 weeks of treatment and 
LV and RV mass at autopsy.
8 weeks Control Irbesartan H+H P value
Age (days) 106 + 5 105 + 3 107 + 3 n.s.
Body weight (g) 217 + 37 204 + 49 214 + 37 n.s.
EDD (mm) 4.4+  0.4 4.5+  0.3 4.7 + 0.4 n.s.
ESD (mm) 1.3+ 0.1 1.4 + 0.1 1.5+ 0.2 n.s.
PWT (nun) 2.41+0.15 1.93 + 0.17*** 2.00 + 0.17*** <0.0001
AWT (nun) 2.06 + 0.13 1.70 + 0.22** 1.81 + 0.19* 0.0023
Myo CSA (mm^) 46.8 + 5.7 36.3 + 5.6** 39.3 + 4.5* 0.002
LV mass (mg) 645 + 121 474 + 98** 530 + 83* 0.0096
FS (%) 70 + 2 68 + 2 68 + 2 n.s.
EF (%) 74 + 4 72 + 4 7 1 + 5 n.s.
LV mass actual 636+ 103 461+ 104** 548 + 78 0.0058
LV mass (g/Kg) 2.95 +0.17 2.27 + 0.13*** 2.57 + 0.12***# <0.0001
RV mass 151+25 145 + 34 144 + 29 n.s.
All values are mean ± standard deviation. EDD represents end-diastolic dimension; 
ESD, end-systolic dimension; PWT, posterior wall thiclaiess; AWT, anterior wall 
thiclaiess; Myo CSA, myocardial cross-sectional area; FS, fractional shortening; EF, 
ejection fraction. *** denotes P<0.001 versus control group, ** P<0.01 versus control 
group, * P<0.05 versus control group, # P<0.001 H+H versus irbesartan and n.s., not 
significant.
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Figure 4.3 Sample M-mode echocardiograms of the left ventricle from control (A), 
irbesartan (B) and hydralazine/hydrochlorothiazide (C) treated rats obtained 
immediately before sacrifice at 8 weeks. The anterior wall is uppermost in these 
images, with the posterior wall below. Wall measurements are superimposed in white. 
Note the significantly thicker walls in the untreated control animal (A).
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There was no relationship between LV mass/body wt. and systolic blood pressure in any 
of the groups (Figure 4.4, panel a). This was true irrespective of how blood pressure 
was expressed, for example, as mean blood pressure over whole 8 weeks, blood 
pressure readings at 4 or 8 weeks, or maximum attained blood pressure (data not 
shown). Although still poor, the best correlation was obtained by plotting change in LV 
mass with change in systolic blood pressure (Spearman correlation, r = 0.38) i.e. the 
difference between 8 week and baseline values (Figure 4.4, panel b). There was also no 
relationship between LV mass/body wt. and systolic blood pressure at entry to the study 
for all the animals combined (Figure 4.4, panel c), or for males and females only.
Gene expression o f ANP and BNP
Cardiac mRNA expression of atrial & brain natriuretic peptides were compared as 
independent markers of cardiac hypertrophy. The Northern blot and mean data for 
ANP are shown in Figure 4.5. The size of the labelled mRNA was checked against 
molecular weight markers and atrial RNA was used as a positive control. Atrial tissue 
is known to have a very high concentration of ANP mRNA (Ogawa et a l, 1991), and as 
can be seen in panel A this is confirmed in this analysis. Untreated control animals had 
significantly greater gene expression than either treatment group (F=15.4, P<0.0001) 
and there was a non-significant trend for H+FI to have a higher expression than 
irbesartan animals. This pattern is identical to that observed with the LV mass results 
from echocardiography. Flowever, when the correlation was drawn between ANP gene 
expression and LV mass for control animals the correlation co-efficient was not 
significant (Figure 4.7, panel a). A much better relationship was observed between ANP 
and blood pressure (r = 0.90, Figure 4.7, panel b), which was significant at P=0.005. 
Due to the small sample size, non-parametric Spearman correlation was utilised. A 
correlation co-efficient >0.71 was considered significant.
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Figure 4.4 Correlation between LV mass and systolic blood pressure. Panel (a) 
indicates no positive correlation in control and treated animals at 8 weeks. Panel (b) 
shows the poor correlation between change in LV mass with change in systolic blood 
pressure between baseline to 8 weeks in control animals. Panel (c) indicates a lack of 
correlation for all animals at entry to this study (6-7 weeks of age).
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Figure 4.5 Panel (a) Northern blot indicating relative gene expression of GAP 
(1.8kb) and ANP (0.9kb) in the left ventricle o f the SHRSP after 8 weeks o f drug 
treatment. The first four lanes in each group are males, the latter four females. Lane A 
is atria from a control animal. Panel (b) shows the same data after quantification by 
densitometry. ANP expression has been normalised to GAP to correct for differences in 
loading of total RNA between lanes. Data are mean ± sem, *** denotes P<0.001 when 
analysed by one-way ANOVA with Newman-KeuTs correction for multiple 
comparisons.
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Figure 4.6 Panel (a) Northern blet indicating relative gene expression of GAP 
(1.8kb) and BNP (0.9kb) in the left ventricle o f the SHRSP after 8 weeks of drug 
treatment. The first four lanes in each group are males, the latter four females. Panel 
(b) shows the same data after quantification by densitometry. BNP expression has been 
normalised to GAP to correct for differences in loading of total RNA between lanes. 
Data are mean ± sem, ** denotes P<0.01 when analysed by one-way ANOVA with 
Newman-Keul’s correction for multiple comparisons. There is no significant difference 
between expression in control and H+H groups.
153
o<(D
a.
<
3-,
2-
1 -
0 .
2.50
O
O OO
O
O O
O
2.75 3.00 3.25 3.50
LV mass (g/Kg)
b
I
I
CL
I
3-,
2 -
1 -
O
%O
O
oo
o
130 140 150 160 170 180 190
Blood Pressure (mmHg)
200
Figure 4.7 Correlation between mRNA expression of ANP in the left ventricle with 
(a) left ventricular mass (Spearman correlation, r = 0.67, P = n.s.) and (b) blood pressure 
(r = 0.90, P = 0.005) in control animals measured at 8 weeks.
Left ventricular gene expression of BNP is indicated in Figure 4.6. There was no 
significant difference in expression of BNP mRNA between control and H+H treated 
animals, however both these groups had significantly higher BNP expression than the 
irbesartan group (F = 8.8, P = 0.002). Lowering of blood pressure by H+H had almost 
no impact on the gene expression of BNP in the left ventricle. It is therefore not 
surprising that BNP expression does not correlate well with systolic blood pressure 
(Figure 4.8, panel b). However, milike ANP, there is a strong positive relationship 
between BNP gene expression and LV mass (panel a, r = 0.98).
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Figure 4.8 Correlation between mRNA expression of BNP in the left ventricle with 
(a) left ventricular mass (Spearman correlation, r = 0.98, P=0.0004) and (b) systolic 
blood pressure (r = 0.62, P = n.s.) in control animals measured at 8 weeks.
Caution should be used in interpreting the correlation results due to the small sample 
size. However, obvious trends are apparent.
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Figure 4.9 Change in heart rate during treatment from baseline values. Baseline 
was the mean of 2 measurements per animal, while treatment was the mean of 15 -  16 
measurements per animal (n = 8 per group). There is no significant difference between 
groups by ANOVA (P = 0.06).
Heart rate
Heart rate was measured during tail-cuff plethysmography twice weekly for the duration 
of the study. Baseline data are the mean of two measurements per animal. The “during 
treatment” data represents mean heart rate for the entire period of treatment i.e. an 
average of 15 -  16 measurements. The rationale for this is that individual heart rate 
readings are highly variable and we want to detect long-term changes in heart rate in 
order to determine the effect on long-term responses such as LV mass and cardiac gene 
expression.
During treatment, H+H animals at 487+19 beats/min had a higher heart rate than either 
irbesartan or control groups, which were almost identical at 451+28 and 448+19 
respectively. However, before starting the study, H+H animals were already slightly 
higher. To account for this, the change in heart rate from baseline was calculated, and is 
shown in Figure 4.9. There is a trend for treatment with H+H to result in an increase in 
heart rate, although this just failed to reach significance (P=0.06).
To determine if the higher heart rate in H+H treated animals was significantly affecting 
LV mass or gene expression of natriuretic peptides, correlations between heart rate and
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LV mass and ANP & BNP mRNA levels were calculated. A significant positive 
Spearman correlation was not obtained for any of these parameters (LV mass, r = 0.61; 
ANP, r = -0.60; BNP, r = 0.30). However, this does not rule out a more subtle effect of 
raised heart rate on these factors.
Plasma Renin <& Aldosterone
Plasma concentrations of renin and aldosterone were measured from blood samples 
taken at sacrifice and are shown in Table 4.4. Adequate samples were not available 
from all animals, and so sample size is given in parenthesis. There was no significant 
difference between groups for either parameter; however, there was a trend for 
irbesartan animals to have elevated plasma renin concentrations. Although mean 
aldosterone concentration was higher in H+H rats, this could be entirely explained by 
one outlier with very high values. The remaining animals in this group had 
concentrations comparable to control and irbesartan animals.
Table 4.4 Plasma concentrations or renin and aldosterone at sacrifice.
Renin Aldosterone
Control 3.4 ± 1.2 (n=7) 32.0 ± 6.4 (n=6)
Irbesartan 8.6 ±2.0  (n=8) 29.4 ±8.1 (n=8)
H+H 5.7 ± 0.8 (n=7) 46.0 ± 13.7(11=7)
Data are mean ± sem 
Vascular hypertrophy
The presence of vascular hypertrophy was determined in order mesenteric resistance 
arteries using LSCM. Arteries from all twenty-four animals were measmed, with the 
exception of the irbesartan group, where one was discarded after being identified as a 
vein under the confocal microscope. Arteries from control animals had significantly 
thicker vessel walls than either drug treatment (P=0.02). Wlien this was broken down 
into the vessel component parts, there were no significant differences in adventitial or 
intimai thiclaiesses, but a significantly thicker media layer in the untreated controls 
(P<0.01, Figure 4.10). The relationship of these dimensions when applied to a cross- 
section of the artery are indicated in Table 4.5, with a significantly higher medial cross- 
sectional area (CSA) in control animals. There were no significant differences in cell
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number in either adventital, medial or intimai layers between any of the groups. 
However when expressed as smooth muscle cell (SMC) number normalised to medial 
volume, both treatment groups have a higher SMC density due to the same number of 
cells being arranged within a smaller volume. Lumen diameters were comparable, 
although tended to be lower in H+H animals. For this reason, wall/lumen and 
media/lumen ratios in the H+H group were closer to that of untreated controls. 
Representative cross-sections of the vessel wall are shown in Figure 4.11 to illustrate 
the greater thickness observed in untreated control animals.
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Figure 4.10 Relative thickness of the component parts of the arterial wall as 
measured by LSCM. All data are mean ± sem, n=8 except irbesartan where n=7. * 
denotes P<0.05 for control versus irbesartan treated; ** P<0.01 for control versus H+H. 
There were no significant differences between treatment groups, and no significant 
differences between any groups for adventita and intimai thickness.
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Table 4.5 Measurements of 3“^^  order mesenteric resistance artery dimensions and 
cell numbers using LSCM.
Control Irbesartan H+H P value
n=8 n=7 n=8
Wall thielaiess pm 53 ± 7 43 + 8 44 + 7 0.02 *#
A. thickness pm 14 + 4 12 + 3 14 + 3 n.s.
M. thickness pm 27 + 6 20 + 3 2 1 + 4 <0.01 *##
I. thickness pm 13 + 3 1 1 +4 10 + 3 n.s.
Wall CSA p n f 39146 + 7453 30444 + 6075 28729 + 8551 0.03 *#
A. CSA pm^ 11194 + 3331 9753 + 2813 9887 + 2115 n.s.
M. CSA pm^ 19518 + 3539 14162 + 2388 13185 + 4459 0.005
I. CSA pm^ 8433 + 2858 6529 + 2232 5656 + 3071 n.s.
Lumen dia. pm 181 + 38 185 + 28 160 + 43 n.s.
Wall/lumen % 31 + 10 24 + 6 29 + 8 n.s.
Media/Lumen % 16 + 8 11 + 3 14 + 4 n.s.
External dia. pm 288 + 37 270 + 26 249 + 47 n.s.
A. cell number 19.5 + 4.3 17.6 + 4.4 15.4 + 2.5 n.s.
SMC number 49.1 + 8.0 44.5 + 5.9 49.5 + 4.9 n.s.
EC number/mm2 1583 + 591 1718 + 572 1493 + 333 n.s.
nA cells/A volume 126560+30059 135109+66356 98416+30727 n.s.
nSMC/M. volume 179858+40561 218632+49465 238921+39122 0.04#
All data are derived fiom one vessel per animal and is presented as mean ± SD. A., 
adventitial; M., medial; I., intimai; CSA, cross-sectional area; dia., diameter; SMC, 
smooth muscle cell; EC, endothelial cell. Using one-way ANOVA with Newman-Keuls 
test to correct for multiple comparisons, * and denote P<0.05 and P<0.01 
respectively for control versus irbesartan; # and ##, P<0.05 and P<0.01 respectively for 
control versus H+H group; n.s., not significant. There were no significant differences 
between irbesartan and H+H groups.
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Figure 4.11 Representative cross-sections through the 3'^ ‘^ order mesenteric resistance 
artery wall from control (A), irbesartan (B) and hydralazine /hydrochlorothiazide (C) 
treated rats at 8 weeks. Images are 3-dimensional reconstructions of the vessel wall in 
cross-section. Vessels were fixed at half-systolic blood pressure by laser scanning 
confocal microscopy. Note the increased thickness of the vessel wall in untreated 
control animals (A).
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There was no relationship between media thickness and systolic blood pressure in 
control SHRSP (Figm'e 4.12). This was true when looking at mean blood pressure 
tlii'oughout treatment or blood pressure at week 8.
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Figure 4.12 Lack of relationship between media thielaiess in mesenteric resistance 
arteries and mean systolic blood pressure in untreated control SHRSP.
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4.4 Discussion
The addition to standard rat chow of 1ml chocolate mousse containing only trace 
amounts of fat and sodium does not represent a significant departure from the normal 
diet. In fact, the extra sodium intake of 1.1 mg per day is less than half the 2.3mg extra 
sodium per day that would have been ingested if the irbesartan was forced into solution 
according to the manufactiu’ers instructions. This is based on calculations for a 150g rat 
drinking 20ml daily, receiving 60mg/Kg/day irbesartan in drinking water that had been 
buffered using sodium phosphate. To put it in perspective, most commercial rat chow 
contains around 1% NaCi, and a minimum of 0.13% is required for normal growth 
(Rapp, 1987). The mousse contains only 0.1% sodium.
The use of chocolate mousse had a number of advantages over dissolution in drinking 
water. For example, in the ease of preparation: aliquots of dry powder could be 
weighed several days in advance without risk of degradation, such that admixture with 
the mousse could be performed by animal house staff minutes before administration. 
The mousse was highly palatable, even with large concentrations of drug. Although 
often cautious in the first few days of treatment, rats soon learnt to eagerly await their 
next dose, which was usually devoured within seconds. This gave the added advantage 
o f allowing quick visual inspection that the full dose had been ingested, rather than 
calculating daily water intake. It also circumvents problems of variability in water 
intake that could occur on initiating treatment with irbesartan, as Angll is thought to 
regulate thirst via a central action (Morton et a l,  1982). That sufficient quantities of the 
drug were bioavailable in this formulation is evidenced by the convincing blood 
pressure effect. It could be concluded that creating a suspension in small quantities of 
infant mousse is a simple and effective way of delivering poorly soluble drugs in the rat.
Systolic blood pressure
By 4 weeks into the study, both treatment arms had significantly and consistently lower 
BP compared to the control group, and the 35 -  40mmHg difference by week 8 was 
almost identical to that observed in an irbesartan prevention study in the SFIR (Vacher 
et a l, 1995). The blood pressure of the treatment groups remained within the 125 -  
130mniHg range observed in the adult WKY (Figure 3.9, Chapter 3), and this was
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firmly within the normotensive range. At these doses irbesartan and H+H appear to be 
equipotent at preventing the rise in systolic BP associated with genetic hypertension. 
Drug treatments were given as once daily doses in the afternoon, while blood pressure 
was measured in the morning. Thus, both irbesartan and H+H effectively lowered 
blood pressure for at least 20 hours of every day.
LVfunction
Ejection fraction and fractional shortening were within normal values for all rats at all 
time points, indicating that systolic function was not compromised by left ventricular 
hypertrophy. This suggests well compensated hypertrophy in agreement with that 
observed in aortic-banded rats 4-5 weeks after surgery (Pawlush et a l,  1993) and in the 
6 month old SHR (Pfeffer et a l, 1979).
Cardiac hypertrophy
A similar picture was observed in the prevention of cardiac hypertrophy, with both drug 
groups preventing the increase in LV mass observed in untreated controls. Significant 
differences between treated and control groups were apparent at 4 weeks corresponding 
with the rise in blood pressure, which also became significant at 4 weeks. The 
hypertrophic response occurred fairly rapidly after the increase in blood pressure, which 
is consistent with the dynamic response to exogenous Angll (Kim et a l, 1995) or after 
myocardial infarction (Reiss et a l, 1993). The question remains whether the LV mass 
differences at 4 weeks are real, and not due to variability in echo measurements. 
However, the observed differences at 27% and 22% for irbesartan and H+H 
respectively, were greater than could have been explained by variability of the method 
alone. The differences are also observed when looking at the raw data, or other 
measures of hypertrophy with lower co-efficient of repeatability, such as posterior wall 
thielaiess or myocardial CSA. Between baseline and 4 weeks the LV/Body weight ratio 
actually got smaller in all 3 groups (Figure 4.2). However, on examining raw LV mass 
data, LV mass actually increased by 73%, 43% and 53% in control, irbesartan and H+H 
respectively over those 4 weeks. It appears that over this time, body mass increased to a 
greater extent.
At week 8 (Table 4.3), differences in LV dimensions remained pronounced, and anterior 
wall thickness was also significantly smaller in both treatment groups. For all 
measurements of anterior and posterior wall thielaiess, myocardial CSA and LV mass
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made at 4 and at 8 weeks, H+H treated animals were consistently, but not significantly, 
greater than those treated with irbesartan. The only time that this difference became 
significant was for autopsy LV mass normalised to body weight.
According to the defined limits in Chapter 3, cardiac hypertrophy is present in this 
population of rats when LV/body weight ratio exceeds 2.86g/ICg. Thus, none of the rats 
had actual cardiac hypertrophy at 4 weeks, but by week 8 all but one control animal 
exhibited hypertrophy by this criterion. In contrast, none of the rats from either 
treatment group had a ratio above 2.86g/Kg.
There was no relationship between LV mass/body wt and systolic blood pressure in 
control animals or treatment groups (Figure 4.4, panel a). Normalisation to body weight 
was used as in Chapter 3, as this was shown to correct for sex differences. As discussed 
in the introduction, this is a common finding in animals (Pfeffer et a l,  1979) and 
humans with established hypertension (Devereux et a l, 1987), and indicates the 
importance of other trophic factors over and above blood pressure. In older animals, 
this lack of correlation is not surprising, considering that LV mass continues to rise for 
many months after maximum blood pressure has been attained (Pfeffer et a l, 1979). 
This suggests that blood pressure is not a major determinant of LV mass maintenance, 
yet it may still be important in the development of LVFI. In the present study, there was 
a close temporal relationship between the rise in blood pressure and LV mass. By using 
serial echocardiography to determine LV mass, this allowed the determination of 
change in LV mass in relation to blood pressure change. Although this did provide a 
better correlation, the correlation co-efficient was still poor (Figure 4.4, panel b). 
Finally, baseline LV mass/body wt. was compared to blood pressure to determine if 
there was any relationship prior to the study at 6-7 weeks of age. SHRSP and SHR are 
reported to have a higher LV mass compared to WKY as young as 30 days (Yamori ei 
a l, 1979). Again, any early differences are not heavily dependent on blood pressure 
(Figure 4.4, panel c).
However, as this study did not include normotensive controls, the presence of LVFI on 
entry to the study was not determined. Therefore, the improved ability of irbesartan 
compared to H+H in preventing the increase in LV mass may be due not only to 
prevention of hypertrophy, but also to an increased ability to regress any LVFI that was
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already present. In regression studies of established hypertension, losartan has been 
shown to regress LVH in the SHRSP (Kim et a l,  1996), while hydralazine alone has no 
effect in the SHR (Yamori et a l, 1979). In a regression study from this laboratory, 5 
month old SHRSP treated with H+H or the ACE inliibitor perindopril provided a similar 
result to the present study with both drugs reducing LV mass compared to controls, but 
perindopril treatment being significantly more efficacious (Devlin et a l, 1995). This 
suggests that similar mechanisms are governing development and maintenance of 
cardiac hypertrophy.
In summary, untreated control animals exhibited significantly larger LV wall thielaiess 
and mass at 4 and 8 weeks when compared to either irbesartan or H+H treated animals. 
Treatment with either drug regimen prevents cardiac hypertrophy in the SHRSP, and 
produces a LV mass/body weight ratio normally observed in WKY rats. Despite 
preventing the rise in blood pressure to a similar extent, treatment with irbesartan tends 
to be better at preventing cardiac hypertrophy.
Gene expression o f  ANP & BNP
ANP gene expression in the left ventricle was significantly higher in untreated controls 
when compared to either treatment group. As with LV mass, the rank order was 
control»>H+H>irbesartan, although the difference between treated groups failed to 
reach significance. Several groups cite ANP gene expression as a marker for cardiac 
hypertrophy (Kim et a l, 1996; Harada et a l, 1998), however, there is only a poor 
correlation with LV mass in these animals (Figure 4.7, panel a) in contrast with renal 
hypertensive rats (Kawakami et a l, 1996). However, a good positive correlation 
between ANP gene expression and systolic blood pressure was observed (r = 0.90; 
Figure 4.7, panel b), and this is consistent with ANP release occurring in response to 
atrial and left ventricular stretch due to pressure overload (Sadoshima et a l, 1993). 
Good correlates between plasma ANP concentration and blood pressure are also 
observed in renal hypertensive rats (Garcia et a l, 1987).
As with LV mass, there was a trend for ANP gene expression to be lower in irbesartan- 
treated animals compared to H+H rats, despite both treatments lowering blood pressure 
to an identical degree. This disparity cannot be explained by differences in blood 
volimie status between treated groups. Hydrochlorothiazide will result in fluid 
depletion due to its diuretic effects, and ANP release is known to be sensitive to blood
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volume (Levin et a l, 1998). However, reduced volume would result in lower 
expression of ANP, not more. Another possibility is that ANP gene expression may 
also depend on Angll, as there was an additional benefit associated with blocking ATi 
receptors. The implication is that Angll may be involved in regulating the hypertrophic 
response and perhaps the expression of ANP. This is in agreement with in vitro systems 
where Angll can increase ANP gene expression independent of blood pressure 
(Molkentin et a l , 1998).
A slightly different pictui-e was observed for left ventricular BNP gene expression 
where irbesartan treated animals had a much lower mRNA expression than either 
control or H+H groups. The ranlc order was control=H+H»>irbesartan. Despite the 
fact that treatment with H+H decreased cardiac hypertrophy and normalised blood 
pressure, it had absolutely no effect to alter levels of BNP gene expression.
The relationship between BNP and systolic blood pressure in control animals was not 
significant, and yet there is an excellent positive correlation with LV mass (Figure 4.8). 
Since expression of BNP mRNA is known to be elevated in the hypertrophied heart of 
the SHRSP (Ogawa ei a l, 1991), and H+H treatment prevented LV hypertrophy, we 
would expect it also to affect BNP expression, and yet it does not. As with ANP gene 
expression, it would be expected that diuretic treatment would reduce blood volume and 
thereby reduce stretch, and decrease BNP levels in the heart. The fact that it does not, 
may suggest an AT \ dependent mechanism for control of BNP gene expression in the 
left ventricle of the SHRSP, since H+H had absolutely no effect on BNP gene 
expression despite lowering blood pressure and LV mass, while irbesartan was highly 
effective. This is consistent with studies in cultured cardiomyocytes where the BNP 
promoter is activated in response to the transcription factor NF-AT, a known 
intracellular mediator of Angll-induced hypertrophy (Molkentin et a l,  1998). 
However, other pathways must also control BNP gene expression as BNP mRNA is up 
regulated in the left ventricle of mice after aortic banding, despite lacking AT i receptors 
(Harada et a l, 1998). Another possible mechanism is that ATz-receptors are mediating 
some of the beneficial effects of irbesartan. Blockade of ATi-receptors results in 
elevated Angll levels that could have an unopposed effect on the ATz-receptor. In rats 
with heart failure, AT]-antagonists can reduce LVH and myocyte CSA, and this can be 
prevented by co-administration of an ATi-receptor antagonist (Liu et al., 1997).
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However, an ATi-, but not an AT2- antagonist, can prevent the increase in ANP gene 
expression associated with pressure-overload hypertrophy (Sadoshima et a l,  1993). 
What is evident, is that ANP and BNP gene expression in the left ventricle are 
differentially regulated, and that both involve factors in addition to hypertrophy or 
blood pressure.
Another explanation of why irbesartan was more effective would be if PI+H treatment 
had trophic effects on the myocai’dium, independent of blood pressure lowering. We 
know from echo data (Table 4.3) that there is no difference in systolic function that 
could explain differences in LV mass and gene expression. Reflex activation of the 
sympathetic nervous system could account for these differences and increased exposure 
to noradrenaline causes myocyte hypertrophy in vitro (Bishopric et a l,  1987). Heart 
rate was used as a marker for sympathetic activation, and there was a non-significant 
trend for elevated heart rate during treatment in the H+H rats (Figure 4.9). Could this 
be the cause of the higher LV mass and gene expression of natriuretic peptides? 
Probably not, correlations of LV mass, ANP or BNP with heart rate in H+H animals 
failed to show any significant relationship. Thus, the modest elevation in heart rate 
observed during treatment with H+H probably does not explain differences in LV mass 
and cardiac gene expression. However, treatment with this dose of H+H (4mg/Kg/day 
of each) has been shown to increase plasma Angll levels in the SHRSP (Devlin et a l , 
1995), and elevated Angll is capable of inducing hypertrophy in myocytes independent 
of blood pressure (Sadoshima et a l,  1993). The slightly higher LV mass and natriuretic 
peptide expressions may be due to a direct hypertrophic effect of AngIL In the present 
study, Angll was not measured directly, but plasma renin and aldosterone 
concentrations were not significantly elevated in the H+H group (Table 4.4). Also 
arguing against this is that both drug treatments were equally effective at preventing 
medial hypertrophy in resistance arteries, which would also be sensitive to an increase 
in circulating Angll. However, changes in local tissue RAS can not be excluded. The 
LV is known to have a local tissue RAS that is up-regulated in hypertensive animals, 
and myocardial Angll levels coiTelate with extent of hypertrophy (Yamazaki & Yazaki, 
1997; Jolmston, 1994).
Regardless of whether the differences observed between irbesartan and H+FI are due to 
activation of the RAS by H+H, both drugs lowered blood pressure to comparable levels.
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Thus, the difference in LV mass and gene expressions between treatments are consistent 
with Angll having a role in regulating LV mass independent of its pressor effects. This 
is in agreement with other pharmacological studies that have shown an additional 
benefit on LV hypertrophy of blocking the RAS, greater than can be expected due to 
lowering blood pressiue alone (Baker et a l, 1990; ICim et a l, 1996). This also appears 
to be true in human essential hypertension, where in a recent meta-analysis, ACE 
inliibition was found to be more effective at regressing LV hypertrophy than Ca^ "^  
chamiel blockers, dimetics or (3-blockers (Sclimeider el a l, 1996).
Vascular hypertrophy
The LSCM technique used for studying resistance artery morphology and cell number 
was developed in this laboratory, and was fully validated in a study by Arribas et a l 
(1997). In that study, the effect of fixation on measured parameters was quantified by 
examining vessels before and after fixation with 10% formal-saline. Fixation resulted 
in a 13% reduction in lumen diameter, but had absolutely no effect on wall thickness 
measui'ements in any of the component parts, adventitia, media or intima. It has the 
advantage over histological methods of providing objective measurements in intact 
arteries.
The confocal microscopy results clearly indicate that the vessel wall of mesenteric 
resistance arteries is thicker in untreated hypertensive animals (Table 4.5). This 
difference resides within the medial layer, which has approximately 28% greater 
thickness than either treatment group. As there are no differences in cell number, this 
suggests a role for hypertrophy rather than hyperplasia. Either there is more comiective 
tissue in the media of these animals, or the smooth muscle cells are larger. Confocal 
microscopy does not answer this question as propidium iodide is a nuclear dye, and so 
differences in cell size were not apparent.
Having one less animal in the irbesartan group is luilikely to have affected the results 
other than to slightly reduce the power of the study to detect significant differences. 
This is probably the reason that SMC density achieved significance in the H+H, but not 
in the irbesartan group. The missing animal was a female, which may have biased the 
results in favour of a male phenotype. However, sex differences were not observed in
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any of the groups, and there appeared to be no relationship between sex and wall 
thickness, external or internal dimensions (data not shown). This is further supported 
by the lack of correlation between vessel thickness and systolic blood pressure, which 
does exhibit sex differences (Figure 4.12).
Both drug regimes appeared to be equally effective in preventing vascular hypertrophy 
in the SHRSP. This suggests the balance of variables mediating LV mass and medial 
hypertrophy of resistance arteries are not the same, as there was no additional benefit 
observed with blockade of ATi receptors. However, the greater wall/lumen ratio 
observed in H+H animals when compared to irbesartan allows for a second 
interpretation. It could be argued that the smaller lumen diameter indicates that 
hypertrophy of the vessel wall has encroached into the lumenal space i.e. inward 
remodelling. This seems unlikely as the wall dimensions are not thickened when 
compared to irbesartan animals, and there is no correlation between increased wall 
thielaiess and a smaller lumen diameter in this group. It is the author’s experience that 
lumen diameter is highly variable even between two branches of the same artery within 
the same animal. It is therefore likely that the small difference in lumen diameters is due 
to natural variation and not differences in remodelling. However, since this study 
represents a snapshot of the artery at 8 weeks, with no baseline data to determine the 
type of remodelling that has occurred, such differences cannot be ruled out.
Differences in morphology between order mesenteric resistance ai'teries in WKY and 
SHRSP have previously been quantified in this laboratory using identical methodology 
(Arribas et a l, 1997). The only difference was in the age of the animals, which were 8- 
10 months old in the Arribas study, and 14-15 weeks old in the present study. 
Compared to WKY, SHRSP animals had a decreased lumen diameter, increased wall 
thickness due to hypertrophy in the medial layer, with no increase in cell number in the 
media i.e. inward hypertrophic remodelling. This is in agreement with untreated 
SHRSP in the present study, with the treated animals being similar to the WKY results. 
However, several other differences were noted such as an increase in adventitial cell 
numbers (almost double) in the SHRSP, and a large decrease in the number of 
endothelial cells in the intima. These factors, along with lumen diameter, were not 
altered by either treatment in the present study. If they are also present in the 14 week 
old SHRSP, then the inability of antihypertensive treatment to modify lumen diameter
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or numbers of adventitial and endothelial cells may represent treatment failure. It is 
possible that such subtle changes may develop regardless of treatment, or are already in 
place in the young SHRSP before 6 weeks of age.
If a reduction in endothelial cell number remained with antihypertensive treatment it is 
easy to speculate how this might significantly affect function. The endothelial layer is 
responsible for flow-mediated vasodilatation via the release of nitric oxide (Joannides et 
al., 1995), and by responding to circulating vasoactive agents, controls lumen diameter. 
Indeed, fewer endothelial cells could explain why treatment failed to improve lumen 
diameter in this study. The endothelium may also have a direct role in hypertrophic 
growth as nitric oxide has anti-proliferative effects in vascular smooth muscle cells 
(Garg et a l, 1989) and is open to modulation by circulating trophic factors. An increase 
in adventitial cell number may also have an important role in remodelling or vascular 
function. Little is known about the influence of adventitia on function, but in rat aorta 
stimulated with lipopolysaccharide, vessels with intact adventitia produced 3.5 times 
more nitrite and nitrate than those with adventitia removed, with a resultant 
hyporeactivity to noradrenaline (Kleschyov et a l, 1998). This suggests the ability of 
the adventitia to produce bio active nitric oxide at least in certain pathological 
conditions. Further characterisation of these changes in young and treated animals 
deserves further study.
The pattern of medial hypertrophy observed in the study of Arribas et al. (1997) is 
common to other models of hypertension. Third order mesenteric resistance arteries 
from renal hypertensive WKY (1 kidney, 1 clip) have increased smooth muscle cell 
volume but not cell number (Korsgaard & Mulvany, 1988), and increased medial 
hypertrophy is also observed in subcutaneous resistance arteries from patients with 
essential hypertension (F alio on & Heagerty, 1994). In contrast several studies in the 
SHR (reviewed in Heagerty et a l, 1993) have indicated a relative increase in smooth 
muscle cell number, with a minor role for hypertrophy. The reason for this disparity is 
not obvious, but may include methodological reasons, as cell number is seldom counted 
directly as in the present study and that of Arribas et a l (1997).
Further up the vascular tree, studies in conduit arteries have also emphasised the 
importance of hypertrophy over hyperplasia. Owens & Schwartz (1982) showed that 
the thoracic aorta of 5-month-old SHR had increases in smooth muscle cell volume
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density, medial cross-sectional area and nuclear volume density compared to age- 
matched WKY. The percentage of polyploid cells was greater than WKY from 3 
months onwards and increased with age and blood pressure. The number of DNA 
copies (ploidy) was directly related to the mass of the cell. The authors concluded that 
the increase in aortic smooth muscle cell mass in the SHR could be fully accounted for 
by cellular hypertrophy without hyperplasia.
As with the relationship for blood pressure versus LV mass, smooth muscle cell 
hypertrophy is probably controlled by other trophic factors such as Angll. For example, 
in a further study by Owens using the same technique, treatment with captopril 
decreased polyploidy more than would be expected for blood pressure lowering effect 
alone, while propranolol had no effect on polyploidy despite lowering blood pressure 
(Owens, 1987). Similarly, in SFIRSP with established hypertension, perindopril 
treatment reduced smooth muscle cell polyploidy in the aorta to WKY levels. An equi- 
hypotensive dose of H+H was ineffective in this regard (Devlin ei a l, 1995). Likewise, 
resistance artery hypertrophy can be regressed by ACE inhibitors, but not hydralazine 
(Stryker-Boudier et a l, 1990), and infusion of Angll results in hypertrophy of 
mesenteric resistance arteries (Daemen et a l, 1995). In addition, a direct trophic effect 
of Angll has been demonstrated in smooth muscle cell cultures (Owens, 1989). Further, 
there is evidence for a local RAS in conduit and resistance arteries, which can alter local 
and downstream fimction, and presumably therefore structure (Flenrion et a l, 1997). 
Given the strong evidence for Angll involvement in vascular hypertrophy, it is an 
important finding of the present study that irbesartan and H+FI were equally effective in 
preventing medial hypertrophy. This suggests that in the mesenteric resistance arteries 
of the SHRSP, Angll does not play an important role in the hypertrophy of the vascular 
wall.
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4.5 Conclusions
This study examined the ability of irbesartan (60mg/Kg/day) and hydrochlorothiazide +
hydralazine (4mg/Kg/day of each) compared to a control group (all delivered in
mousse) in preventing cardiac and vascular remodelling in the SHRSP. The main
findings are:
• A suspension of drug in infant mousse is a convenient and effective method of 
delivering poorly soluble drugs by the oral route in the rat.
• By 14-15 weeks of age the SHRSP develops concentric LVH that is well 
compensated with no change in systolic fimction.
• There is no correlation between systolic blood pressure and LV mass even when 
expressed as unit change of these values.
• Irbesartan is as effective as LI+H at preventing the elevation of blood pressure 
observed in the young SHRSP.
• Irbesartan prevents the subsequent increase in LV mass and associated left 
ventricular gene expression of ANP and BNP with greater efficacy than H+H 
despite identical blood pressure lowering effect. This indicates an additional benefit 
of blocking ATi receptors, which may represent a role for angiotensin II in the 
hypertrophic response.
• ANP and BNP mRNA expression in the left ventricle are differentially regulated. 
ANP correlates with blood pressure, while BNP correlates with LV mass. In 
addition, H+H treatment had no effect on BNP gene expression suggesting a role for 
the AT I receptor pathway for mediating BNP mRNA.
• Irbesartan and H+H were equally effective in preventing medial hypertrophy in 3"^  ^
order mesenteric resistance arteries, with no change in smooth muscle cell number 
or in adventitial or intimai cells. This argues against a local trophic effect of Angll 
in mediating hypertrophy in these vessels.
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5. Cardiac and vascular remodelling after
coronary artery ligation in the rat.
5.1 introduction
The alterations that occur in the heart and blood vessels after myocardial infarction (MI) 
determine the onset and severity of heart failure, and therefore outcome, in man and 
animal models. To study this process, rat models have commonly been used where the 
left descending coronary artery is permanently occluded. The haemodynamic and 
neurohormonal consequences of this have been discussed fully in Chapter one. Such a 
model of coronary artery ligation (CAL) is described in this chapter for the WKY rat, 
and comparisons are made with sham-operated controls.
Confirmation o f heart failure
Due to the variability in infarct size in CAL rats, it is necessary to attempt to quantify 
LV dysfunction and recognise congestive heart failure on an individual animal basis. 
Even in rats with large infarcts, clinical signs such as peripheral oedema, respiratory 
distress or poor grooming are seldom apparent (Pfeffer el a l, 1979). Although it has 
been claimed that a conscious respiratory rate greater than 100 breaths per minute is 
indicative of “clinical” heart failure in the rat (Latini el al., 1998), in practice, it is 
difficult to make these observations without the presence of an observer influencing 
respiration. Objective measurements are therefore essential.
A number of studies have indicated that infarct size is in itself a good indicator of 
myocardial function (Pfeffer et a l, 1979; Pfeffer el al., 1984). However, histological 
measurements may only be made post-mortem, and do not provide direct evidence of 
dysfunction. Many groups have made use of LV catheterisation to gain detailed 
information on haemodynamics and function. There is a typical haemodynamic profile 
after CAL in the rat which mirrors that observed in human heart failure (see Figure 1.5, 
Chapter 1). However, this is an invasive procedure and is often a terminal end-point. 
Echocardiography is being increasingly used to study cardiac function in rodent models 
of heart failure. The obvious advantage is its non-invasive nature, which in theory 
allows serial measurements, but which has seldom been employed in practice.
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Echocardiography after myocardial infarction
The changes that occur in LV geometry post-myocardial infarction such as ventricular 
dilatation pose a problem for echo methods that assume a uniform geometric shape, 
such as the cubed formula for LV mass, or even 2-D estimation of ejection If action. 
Such assumptions of LV shape appear to be valid in healthy animals and even 
hypertensive animals, but the asymmetry of infarcted ventricles can lead to serious 
errors. The only simple way to describe LV structure and function post-MI in the rat is 
via one-dimensional regional analysis. To say anything about systolic function as a 
whole it would be necessary to either:
1. Use Simpson’s rule. This requires the ability to obtain reliable long-axis views and 
short-axis views at multiple levels. In rats after MI, Litwin et al. (1994) concluded 
that the long-axis view was unreliable and inconsistent. Therefore they could not 
make use of Simpson’s rule for calculating volume in asymmetric chambers.
2. Use free-hand 3-D echo facilities. However, this technique does not yet have the 
spatial resolution for rat work.
3. Use echo doppler for cardiac output and ejection fraction estimations. Again, 
technically difficult in the rat, with imaging of the aortic root often unobtainable 
(Pawlush et a l, 1993).
In this study, serial echocardiography was used to follow the temporal evolution of LV 
structural and functional changes. However, echocardiographic results for this chapter 
will only discuss data that does not require assumptions concerning LV geometry such 
as wall thickness, and from 2-D images, end-diastolic cross-sectional area and ejection 
fraction.
Further characterisation of the extent of insult will be obtained by measuring relative 
abundance of ANP & BNP mRNA in the LV of sham and ligated rats. While increased 
ANP mRNA expression has been well characterised in this model (Passier el a l,  1996), 
there is a relative paucity of data on the role of BNP in post-infarction rats, despite the 
known importance of plasma BNP as a prognostic marker in human heart failure 
(Mukoyama ei a l, 1991).
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The aims of this study were as follows:
1) To introduce the rat CAL model into our laboratories for the first time.
2) To demonstrate the utility of serial echocardiography to chart changes in LV 
structure and function over time in heart failure rats.
3) To determine the changes in ANP & BNP gene expression in the surviving 
myocardium.
4) To confirm whether endothelial dysfunction is present in the thoracic aorta of rats 
after coronary artery ligation.
5) To determine if there are alterations in small artery structure at a cellular level, using 
laser scanning confocal microscopy (LSCM) for the first time in this model.
5.2 Methods
Protocol
Male Wistar-Kyoto (WKY) rats weighing 300-400g were used from the colony of 
Professor Dominiczak at the University of Glasgow. Prior to surgery, a baseline 
echocardiogram was performed to measure ejection fraction, LV cavity cross-sectional 
area (CSA) and posterior wall thickness (described in Chapter 3). They were then 
subjected to thoracotomy and either ligation of the left anterior descending coronary 
artery or sham operation (described below). Further echocardiograms were taken at 2-, 
4-, 6- and 8-weeks post-surgery.
At 8-weeks after surgery, animals were euthanased by overdose of halothane anaesthetic 
and the tissue utilised as follows:
1. Blood was removed by cardiac puncture and plasma extracted. Plasma 
concentrations of renin, ANP and BNP were quantified (see Methods chapter).
2. Heart chambers were weighed and blotted, also lung, liver and kidney were 
dissected free of connective tissue, blotted and weighed (see Methods chapter).
3. A portion of the non-infarcted posterior left ventricular wall was removed and snap 
frozen in liquid nitrogen. This was used for subsequent Northern blot analysis as 
described in Methods chapter.
4. The remaining LV was placed in formaldehyde for histological measurement of 
infarct size (described below).
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5. The descending thoracic aorta was placed in physiological salt solution (PSS) at 
4°C for subsequent organ bath studies of endothelial function (described below).
6. The mesenteric arcade was dissected out and stored in PSS at 4°C, from which 3“' 
order mesenteric resistance arteries were later dissected. Measurement of vessel 
structure was performed by laser scanning confocal microscopy (LSCM) as 
described in Methods chapter.
Coronary artery ligation in the rat
Twenty-four hours before surgery, animals were given an intramuscular (IM) injection 
of 0.2ml anhydrous ampicillin lOOmg/ml (Amfipen® LA, Intervet UK Ltd.) as 
prophylaxis against infection. The next day anaesthesia was induced by an 
intraperitoneal (IP) injection Hypnorm (fentanyl + fluanisone) and Hypnovel 
(midazolam). The left side of the chest was shaved and the animal intubated. 
Mechanical ventilation was provided at a rate of 72 breaths per minute and a stroke 
volume of 2.5ml, using a Harvard Apparatus rodent ventilator (model 683). Halothane 
0.25-2% in O2 was used to maintain adequate anaesthesia. Positive end expiratory 
pressure was applied by exhausting the exhaled gases into 0.5cm of water.
A thoracotomy was performed between the 4^ '' and 5^ '’ intercostal space, the left lung 
collapsed, and the pericardium opened. The heart was then exteriorised and an apical 
tie placed to aid manipulation. A 4/0 Ethibond Excel (Ethicon W6935) suture was 
placed around the left anterior descending coronary artery a few millimetres from its 
origin, and tied tight. The infarcted area was immediately apparent due to blanching of 
the affected myocardium. The target infarct size was around 30-40% of the left 
ventricular free wall, and in animals with smaller infarcts, further sutures were placed 
closer to the artery origin until this figure was achieved. In sham operated animals 
neither apical tie nor ligation suture were placed in the heart.
The heart was replaced into the pericardium and the chest wall closed using an 
interrupted chromic 3/0 suture (Ethicon W437). Hyperinflation of the lungs during 
closer ensured expulsion of air, and prevention of a pneumothorax. The muscle layer 
was closed with an interrupted Ethibond 4/0 suture, and the skin using a continuous 
Dexon II 2/0 (Sherwood Davis & Geek 6160-87B) subcutaneous suture.
To reverse the effects of the fentanyl and provide adequate post-operative pain relief, 
0.2ml buprenorphine (Vetergesic) was administered IM. A further pain relieving dose
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was given the next day after an assessment of pain in the individual. In some of the 
animals this dose was not necessary. Further post-operative care included 3-5ml 
subcutaneous normal saline, depending on extent of blood loss, supplemental oxygen, 
and a heating blanket until such times as the righting reflex had been regained.
A more detailed description of the surgical technique is provided in appendix II, along 
with suppliers for all drugs.
Histological measurement o f  infarct size
The methodology for estimating infarct size is identical to that used by the groups of Jos 
Smits and Jo de Mey in Maastricht (Stassen et a i ,1991, with further modifications from 
Dr. Gregorio Fazzi in a personal communication).
Preparation
The excised heart was immediately placed in neutral buffered formalin (NBF) and 
stored at room temperature until processed. The first stage was a 70% ethanol wash for 
at least an hour. A set of razor blades 2mm apart was used to cut sections of the heart. 
The first blade was set level with the apex and four slices were made. These slices were 
stored in 70% alcohol until processed further. The slices are dehydrated by alcohol and 
xylene followed by embedding in paraffin wax overnight. Only the third slice was used 
to determine infarct size. Experience in Maastricht has shown that it is the most 
representative of the whole myocardium, and yields comparable results to averaging 
many slices at varying levels of the heart.
The paraffin wax embedded slice was cooled and 4pm sections cut using a microtome 
and placed on glass slides. The slides were then washed in xylene and ethanol to 
remove the paraffin wax, as detailed in the wax removing protocol in appendix I. 
Staining was with Azan dyes according to the staining protocol, also detailed in 
appendix I. Using this protocol, the infarcted area stained bright blue, and the viable 
myocardium as red.
Measurement o f  infarct size
Only one section is required for the measurement of infarct size which calculates the 
percentage involvement of the left ventricular circumference as follows :-
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lep (leîigtli of infarcted epic ar dial circumference) 
len (lengtli of infaixte d endo cardial circumferenc e)
•  Tep (total epic ardial circumference)
® Ten (total endocai'dial cil'cumference)
lep len+Tep Ten / 2 '^'100% = Infai'ct size
Organ bath studies
Aortas were cleaned of connective tissue under a dissecting microscope and cut into 
4x4mm ring segments. These were suspended in 10ml organ baths by fine wire hoops, 
taking care not to damage the endothelium. The upper wire was attached by thread to a 
Grass FT03c transducer, interfaced to a Linseis L2006 chart recorder for display of 
isometric tension. The lower wire was connected to a glass tissue holder. The mounted 
rings were immersed in PPS and continuously bubbled with 95% O2 : 5% CO2 at 37°C. 
They were placed under an initial tension of 3 g and re-tensioned to that level after 20 
minutes. A minimum of 40 minutes was then given for equilibration before starting the 
experimental protocol. Indomethacin (IpM ) was present throughout to block 
endothelium-derived prostanoids. After equilibration, vessels were exposed to a 
sighting dose of noradrenaline (NA) 1 pM, followed by acetylcholine (ACh) 1 pM to test 
for the presence of a functioning endothelium, then washed for 20 minutes. 
Concentration response curves for NA and ACh were constructed in the range 10'*  ^ to 
lO'^M in half log increments, with 30 minutes wash-out between curves. Vessels were 
then incubated for 30 minutes with L-NAME lOOpM, before constructing new 
concentration response curves for NA and ACh. At least one bath in each experiment 
was used as a time control, whereby L-NAME was not added. After a final 30-minute 
wash, a concentration response curve was constructed to sodium nitroprusside (SNP) 
10"^  ^ to lO’^ M. At the end of the experiment, aortic rings were blotted and weighed. 
Contractile responses were expressed as generated tension per milligram tissue weight. 
Relaxant responses were expressed as percentage relaxation of NA contractile response.
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5.3 Results
Survival
A  total of 26 WKY males were subjected to either sham or CAL surgery, of these, 19 
remained alive for the 8-week duration of the study giving a survival rate of 73%. 
Unusually, survival was poorer in the sham-operated animals at 69% (9/13) compared 
to 77% in ligated (10/13). No clear explanation was found for the death of the sham- 
operated animals, all of which died suddenly a few days after the procedure. As a 
precaution antibiotic cover was introduced for all subsequent procedures after the first 
two fatalities, however, there was no evidence of infection when the pathology results 
were returned from a full post-mortem. The tlii’ee fatalities in the ligated group all 
occurred between 1 and 14 days after surgery, with the most likely cause being acute 
congestive heart failure. All these animals exhibited either laboured breathing 
immediately prior to death, or had very large infarcts coupled with severe congestion of 
the lungs and liver on post-mortem. There were no fatalities during surgery in either 
group.
Infarct Size
Azan staining was performed with the help of Dr. Ian Montgomery, for visualisation of 
the infarct region. Representative heart slices are shown in Figure 5.1. Panel A shows a 
cross-section of the left ventricle in a sham-operated animal at the level of the papillary 
muscles, which are clearly visible as round discs “floating” in the cavity space. There 
are a few artifactual tears in the myocardium, but otherwise the heart tissue is healthy, 
staining bright pink to indicate viable myocardium. The right ventricle was removed 
for weighing at post-mortem and so is no longer visible. Flowever, it is possible to see 
where it was attached at the top left aspect of the image.
Panel B shows the same view in a heart 8 weeks after coronary artery ligation. The 
infarcted area is clearly visible as an extremely thin blue staining region. This is the 
connective tissue laid down during scar formation, which still contains a few pockets of 
viable myocytes staining pinlc. This is typical of the type of infarct observed in these 
animals, all of which were full-thiclaiess affecting the anterior aspect. The cross- 
sectional area of the LV cavity is grossly oversized in this example indicating
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significant dilatation. This infarct is large affecting approximately 48% of the left 
ventricular free wall.
It was originally planned to estimate infarct size from these histological sections using 
computerised planimetry, however, in many of the animals sections had been cut too 
high in the heart for this purpose. This has been remedied for futm*e experiments when 
infarct size will be available. For this study, emphasis has been placed on changes in 
function using echocardiography as a measure of infarct severity.
Organ weights
There was no significant difference in body weight between groups before entering the 
study or on completion 8 weeks after singery (Table 5.1). Wliole heart weight and heart 
weight minus the right ventricle were both significantly elevated in the ligated group 
indicating a degree of compensatory hypertrophy. Right ventricular weight was also 
significantly increased. The spread of data is indicated in Figure 5.2.
Table 5.1 Body and organ weights 8 weeks after sham or CAL surgery.
Sham Ligated P value
n=9 n=10
Body weight at baseline (g) 361 ±59 370 ± 54 0.71
Body weight at 8 weeks (g) 409 ± 47 407 ± 29 0.87
Heart weight (g/Kg) 3.37 ± 0.16 3.73 ± 0.28 0.007
Right ventricle (g/Kg) 0.56 ±0.10 0.67 ± 0.06 0.012 *
Heart -  RV (g/Kg) 2.81 ±0.14 3.06 ±0.26 0.03
Long-axis (mm) 14.6 ±0.9 14.7± 1.0 0.96
Lung (g/Kg) 3.99 ±0.62 4.61 ± 1.04 0.14
Liver (g/Kg) 33.27 ±2.82 35.31 ±2.83 0.14
Kidney (g/Kg) 5.48 ±0.27 5.30 ± 0.48 0.35
All data are mean ± SD. * and ** denote P<0.05 and P<0.01 respectively for sham 
versus ligated by unpaired Student’s t test.
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#Figure 5.1 Examples of infarct size histology using the Azan dye technique. Panel 
A shows the heart of a sham-operated animal, panel B the heart from an animal 8 weeks 
after coronary artery ligation. In both cases the heart has been cut in cross-section 
through the centre of the left ventricle. The right ventricle is not visible as this was 
removed for weighing at post-mortem. Healthy myocardium is dyed pink, blue staining 
represents connective tissue.
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Figure 5.2 Organ weights normalised to body weight in sham and ligated animals 8- 
weeks after surgery. Panel A is whole heart weight, panel B heart weight minus RV, 
panel C right ventricular weight, panel D liver weight. Horizontal bars represent mean 
values.
Lung and liver weights tended to be heavier in ligated animals, although this failed to 
reach significance. More detailed analysis in Figure 5.2 (panel D) indicates that for 
liver weights most animals remained normal, while two animals in the ligated group had 
a much higher liver/body weight ratio. It is interesting to note that these two also had 
the lowest ejection fraction, and their livers had a mottled, nutmeg appearance at post­
mortem. This suggests that congestion was present in these animals.
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Echocardiography
Ejection fraction was measured by echocardiography at baseline and at 2-week intervals 
for the duration of the study. The mean values are shown in Figure 5.3. Immediately 
prior to surgery, ejection fraction in sham and ligated groups was almost identical, 
77.8±2.4 and 76.1±1.4% respectively. By 8-weeks after surgery ejection fraction was 
76.5±5.0 in shams and 45.9±6.6 in ligated rats. At all time points following surgery, 
animals with a coronary artery ligation exhibited a significantly lower ejection fraction 
(P<0.0001) commensurate with impaired left ventricular function.
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Figure 5.3 Ejection fraction measured by echocardiography in rats before and after 
sham or CAL surgery. All data points are mean ± sem. There was no significant 
difference between groups at baseline, but at all subsequent time points difference in 
mean are highly significant (P<0.0001, unpaired Student’s t test, significance level 
P<0.01 to correct for multiple comparisons).
Two-dimensional images were used to calculate cross-sectional area of the left 
ventricular cavity during diastole. Before surgery, there was no significant difference 
between groups. After CAL there was a progressive enlargement of the LV cross-
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sectional area representing increasing ventricular dilatation. This was significantly 
larger than sham-operated animals at 4, 6 and 8 weeks post surgery (Figure 5.4). 
Representative echocardiograms are shown in Figure 5.
35-1
*****
CMEET  30-
^  - oo
oü5(0■B 25-
20
0 2 4 6 8
A Ligated
o Sham
Weeks after surgery
Figure 5.4 Cross-sectional area (CSA) of the left ventricular cavity measured at 
diastole by echocardiography in rats before and after sham or CAL surgery. Data points 
are mean ± sem. *, ** and *** denotes P<0.05, P<0.01 and P<0.001 respectively for 
sham versus ligated animals by unpaired Student’s t test. Significance level is P<0.01 
to correct for multiple comparisons.
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Diastole Systole
Figure 5.5 Representative 2-D eehoeardiograms from the parasternal short-axis 
view. Top panels are from a WKY rat before surgery at end diastole and systole; lower 
panels are from the same rat six weeks after coronary artery ligation. Note the enlarged 
eavity area at diastole and anterior infarct resulting in systolic dysfunction.
M-mode images were used to measure non-infareted posterior wall thickness. CAL 
resulted in a progressive compensatory hypertrophy of the LV wall, which was 
significant from week 4 onwards and continued to rise in a linear fashion (Figure 5.6). 
Representative echocardiograms are shown in Figure 5.7.
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Figure 5.6 Thickness of the non-infareted posterior LV wall measured at diastole by 
echocardiography in rats before and after sham or CAL surgery. Data points are mean ± 
sem. ** and *** denote P<0.01 and P<0.001 respectively for sham versus ligated 
animals by unpaired Student’s t test. Significance level is P<0.01 to correct for multiple 
comparisons
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Figure 5.7 Sample M-mode eehoeardiograms of the left ventricle in a WKY rat 
before (A) and eight weeks after (B) coronary artery ligation in the same animal. The 
anterior wall is uppermost in these images, with the posterior wall below. Wall 
measurements are superimposed in white. Note increased wall thickness and end- 
diastolic dimension.
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Natriuretic peptides
Qualitative measurement of ANP and BNP mRNA expression were obtained in the atria 
and surviving left ventricle of rats eight weeks after surgery. ANP gene expression was 
high in the atria of sham rats and was unaltered by coronary artery ligation (Figure 5.8). 
Atrial levels of BNP mRNA were also unchanged (Figure 5.9). However, levels of 
ANP mRNA in the left ventiicle were more than doubled in ligated animals, and this 
was statistically significant (P<0.05, Figure 5.10), BNP gene expression in the left 
ventricle tended to increase after ligation, but despite being an average 34% higher, this 
failed to reach significance (Figure 5,11). The densitometry analysis of mRNA 
expression is summarised in Table 5.2.
Table 5.2 Densitometric analysis of ANP & BNP mRNA expression in the heart.
Atria Left ventricle
Sham (n=5) Ligated (n-7) Sham (n=6) Ligated (n=8)
ANP 2.45 ±0.39 2.61 ± 0.30 1.14±0.27 2.54 ±0.50
BNP 1.43 ±0.10 1.64 ±0.25 0.65 ± 0.06 0.87 ±0.10
Values are mean ± standard error of the mean for arbitrary densitometry units. 
denotes P<0.05 by Student’s /-test.
188
Atria
GAP
ANP
B igated  ^
0.4
(0
^  0 .3
Û.<  0.2 CD
Û.
<  0 . 1-
0.0 sham  atria ligated atria
Figure 5.8 Northern blot analysis of ANP gene expression in the atria of sham (n=5) 
and ligated (n=7) WKY rats. There was no significant difference in mRNA expression.
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Figure 5.9 Northern blot analysis of BNP gene expression in the atria of sham 
(n=5) and ligated (n=7) WKY rats. There was no significant difference in mRNA 
expression.
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Figure 5.10 Northern blot analysis of ANP gene expression in the left ventricle of 
sham (n=6) and ligated (n=8) WKY rats. Data are mean±sem, compared by Student’s f- 
test.
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Figure 5.11 Northern blot analysis of BNP gene expression in the left ventricle of 
sham (n=6) and ligated (n=8) WKY rats. Data are mean±sem, compared by Student’s t- 
test.
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Endocrine
Plasma concentrations of Renin, ANP and BNP were measured 8 weeks after surgery 
(summarised in Table 5.3). There was no significant difference in renin levels, and a 
non-significant increase in plasma BNP. However, plasma ANP concentration was 
80% higher in ligated animals. In two sham animals there was insufficient plasma to 
obtain ANP and BNP measurements, therefore n=7 in these groups.
Table 5.3 Plasma concentrations of renin, ANP & BNP eight weeks post-infarct.
Sham Ligated P value
n=7- 9 n=10
Renin uU/ml 10.9± 1.4 12.1 ± 1.6 0.59
ANP pg/ml 123 ± 9 222 ± 32 0.01
BNP pg/ml 90±  13 113±9 0.15
All values are mean ± standard error of the mean. Comparison by Student’s /-test. 
Vascular funct ion
Aortic rings were mounted in an organ bath for study of endothelial function. 
Contractile responses to noradrenaline were identical for both sensitivity and maximum 
tension between sham and ligated animals (Figure 5.12).
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Figure 5.12 Noradrenaline concentration response curves in isolated aortic rings from 
sham (n=5) and coronary artery ligated (n=8) rats. Values are mean ± standard error of 
the mean.
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There was no difference in relaxant response to acetylcholine. Aortas pre-contracted 
with noradrenaline exhibited 73% relaxation in ligated and 72% in sham animals, with 
almost identical sensitivity (Figure 5.13).
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Figure 5.13 Aeetyleholine concentration response curves in isolated aortic rings pre­
contracted with noradrenaline, from sham (n=5) and coronary artery ligated (n=8) rats. 
Values are mean ± standard error of the mean.
Basal release of NO was also similar. Blockade of NOS in unstimulated vessels by 
incubation with L-NAME (lOOpM) for 30 minutes resulted in an average increase in 
resting tension of 103±12 mg/mg tissue in sham animals compared to 96±23 mg/mg 
tissue in the ligated group. This resulted in an identical inhibition of acetylcholine- 
induced relaxations in both groups, at only 3% relaxation. This was not due to a time- 
dependent loss of endothelial function as control vessels not reeeiving L-NAME 
continued to relax in response to ACh.
Very powerful relaxations to sodium nitroprusside (SNP) were obtained in both groups. 
All vessels relaxed to below baseline tone and neither maximal response nor sensitivity 
were different between sham and ligated animals (Figure 5.14).
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Figure 5.14 Sodium nitroprusside (SNP) concentration response eurves in isolated 
aortic rings pre-contracted with noradrenaline, from sham (n=5) and coronary artery 
ligated (n=8) rats. Values are mean ± standard error of the mean.
Resistance artery structure
Laser scanning confocal microscopy (LSCM) was used to determine vascular structure 
at a cellular level in 3‘^  order mesenteric resistance arteries. Vessels from seven sham 
animals and nine ligated were available for measurements. The thickness of the vessel 
wall was greater in arteries from ligated rats, although this just failed to reach 
significance (P=0.07). The relative proportions of the eomponent parts are indieated in 
Figure 5.15. This shows that while adventitia and media thielaiess were similar, most of 
the increased wall thickness can be explained by a thicker intimai layer (again not quite 
significant, P=0.06).
External diameter was almost identical, while lumen diameter was smaller in ligated 
rats, but not significantly so (Figure 5.16, Table 5.4). Thus, there appears to be a 
thickening of the intimai layer that encroaches into the lumenal space. This could not 
be explained by changes in endothelial cell number, which were comparable between 
sham and ligated groups (Table 5.4).
There were fewer smooth muscle cells in the media of ligated animals. Since medial 
cross-sectional area was almost identical between groups, this resulted in a significantly 
lower smooth muscle cell density, whereby ligated animals had 24% fewer cells per unit 
volume of media (figure 5.17 and 5.18).
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Figure 5.16 Measurement of lumen diameter in mesenteric resistance arteries of 
sham and ligated rats by LSCM. Yellow lines are approximately 200pm and 180pm for 
sham and ligated images respectively.
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Figure 5.15 Relative thickness of the component parts o f the arterial wall as 
measured by LSCM. All data is mean ± sem, sham n=7, ligated n=9.
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Figure 5.17 Smooth muscle cell density (number of cells per mm^ of media) from 
mesenteric resistance arteries o f sham and ligated rats. Mean ± sem.
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Figure 5.18 Representative 3-D reconstructions through the arterial wall of 
mesenteric resistance arteries. Smooth muscle cells (SMC) are oriented in the vertical 
plane, while endothelial cells lie perpendicular to this. Adventitial cells are more 
rounded with stronger signals. Note that the ligated animal has fewer SMCs.
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Table 5.4 Measurements of 3*^  ^ order mesenteric resistance artery dimensions and 
cell numbers using LSCM.
Sham Ligated P value
n=7 n=9
Wall thiclmess pm 46 ± 9 55 ± 9 0.07
Adventitia thickness: pm 1 5 ±4 1 8 ± 7 n.s.
Media thickness pm 22 ± 4 23 ± 4 n.s.
Intima thiclmess pm 9 ± 4 1 5 ± 7 0.06
Wall CSA pm^ 34779 ±7846 40364 ± 9450 n.s.
Adventita CSA pm^ 13001 ±3495 15043 ± 6687 n.s.
Media CSA pm^ 16357 ±4390 16328 ±3962 n.s.
Intima CSA pm^ 5421± 1574 8993 ± 4949 0.09
Lumen diameter pm 200 ± 60 177 ± 30 n.s.
Wall/lumen ratio % 25 ± 10 32 ± 9 n.s.
Media/lumen ratio % 1 2 ±4 13 ± 3 n.s.
External diameter pm 292 ± 52 287 ± 32 n.s.
Adventita cell number 21.0±8.6 18.4 ±5.7 n.s.
SMC number 45.4 ±9.0 37.1 ± 10.2 0.11
EC number/mm^ 1274 ±323 1083 ±502 n.s.
nA cells/A volume 131038 ± 87894 106447 ±81767 n.s.
nSMC/media volume 205357 ±32148 157057 ±26840 0.006
All data are derived from one vessel per animal and is presented as mean ± standard 
deviation. CSA, cross-sectional area; SMC, smooth muscle cells; A, adventitia; EC, 
endothelial cell; n.s., not significant. Comparison by Student’s /-test, significance level 
P<0.05.
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5.4 Discussion
Survival was good in the ligated animals at 77%, especially as this includes the learning 
curve for this procedure. There was no difference between survival when the procedure 
was performed by an experienced animal surgeon (M.Hicks) or by the author. The level 
of sham fatalities is puzzling, and was not resolved despite veterinary advice. Why 
similar types of death were not observed in the ligated group is iinlaiown.
There were no early arrhytlimic deaths, which may be a benefit of the anaesthetic 
regime used. In a direct comparative study, rats anaesthetised with halothane had fewer 
arrhytlmiias and lower mortality after CAL than those animals receiving pentobarbitone 
(All et a l, 1983).
Infarct size
Ligation of the left coronary artery of the rat results in transmural anterior infarction 
(Figure 5.1). Within the scar tissue, which is much thinner than the surviving 
myocardium, there is a central core of connective tissue strongly staining blue. This 
area is surrounded by macrophages (ghost cells) which stain lightly red with large 
nuclei. Sometimes there is a thin layer of healthy myocardium near the lumen, which 
may have been able to obtain enough nutrients from intra-luminal blood to survive. 
Small arteries and veins may also be visualised within the scar tissue.
Organ weights
Cachexia may be present in severe heart failure in humans (Levine el ai., 1990), but was 
not observed in these rats, whose body weight remained close to sham values (Table 
5.1). Indeed, in all but two ligated animals, body weight increased over the duration of 
the study. The two that lost weighed had the poorest cardiac function as measured by 
ejection fraction, but weight loss was not great at only 3 - 4  %. However, true weight 
loss could be masked in the presence of peripheral oedema.
Ligated animals had a higher heart weight and heart -  RV weight i.e. left ventricle + 
atria + great vessels (Table 5.1). This represents the balance between the lost 
myocardial mass of the infarct scar, and hypertrophy of the surviving myocardium. 
This suggests that even in those animals with a heart weight similar to sham, that 
hypertrophy was considerable to compensate for the loss of tissue. Right ventricular
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weight was higher in almost all of the ligated animals (Figure 5.2) and is indicative of 
an increased pulmonary pressure, probably due to mild congestion.
Congestion of the liver was present in two out of 10 ligated animals (Figure 5.2). Why 
these two exhibited congestion while the others did not, was probably due to their lower 
ejection fraction suggesting more severe dysfunction. However, the difference in 
ejection fraction between these and the non-congested animals was not great, win eh 
suggests that the level of insult inflicted in this study is on the borderline between LV 
dysfunetion and congestive heart failure.
Measurement of long-axis length from the mitral annulus to the apex was not possible 
by echocardiography, and so was measured at autopsy using digital callipers. Villarreal 
et a l (1999) reported shortening of the long-axis after myocardial infarction in the rat. 
However in the present study, long-axis geometry was almost identical between groups, 
with no evidence for spheration.
Echocardiography
In man, changes in cardiac position after surgical procedures can have a dramatic 
influence to reduce the number of acceptable echocardiograms (Wallerson & Devereux, 
1987). The same effect was apparent in rats after coronary artery ligation. In particular, 
image quality was often poor in the first echocardiogram after surgery, which was 
thought to relate to inflammation in the thoracotomy scar, and the fact that two adjacent 
ribs are splinted together when closing the chest wall. In most animals, image quality 
improved thereafter, presumably as the scar healed. In most animals where image 
quality remained poor, focal adhesions of the heart to the chest wall were noted at post­
mortem.
Left ventricular function was clearly compromised after CAL in these rats, with ejection 
fraction consistently lower than either baseline or sham values (Figure 5.3). Values for 
ligated animals ranged from 35 to 57% which does not sound particularly severe when 
compared to human heart failure. However, these figures are not directly comparable as 
rats have a higher normal ejection fiaction, and this study did not attempt to measure 
absolute values, but to demonstrate a change from baseline. The extent of dysfunction 
was fairly similar between all the ligated animals as can be seen from the small error 
bars in Figure 5.3. This uniform response may be due to using an inbred population. 
Infarcts in Lewis inbred rats are also highly reproducible (Liu et a i, 1997).
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Measuring ejection fraction after myocardial infarction by this method may introduce 
some additional errors. It assumes contractility to be constant at all levels of the heart, 
whieh will not be true at the infarct zone. In order to maintain reproducibility, all 
short-axis views were taken at the level of the papillary muscles. In the majority of 
animals this was above the infarct zone, as no evidence of papillary muscle involvement 
was observed. However, it must be aclmowledged that serious miss-ealculations may 
have occurred in the following instances; 1) where the function of the mitral valve was 
compromised such that a significant level of mitral regurgitation was present. In these 
circumstances, there will be an over estimate of ejection fraction using this method, as 
no account is made of a regurgitated volume. 2) Where the imaging plane overlaps the 
infarct zone. In this case, ejection fraction may be under-estimated especially when the 
infarct scar is akinetic, as ejection fraction is likely to be higher at areas of non-infareted 
myocardium. By the same reasoning, in the present study which contained only a few 
rats with infarct zones in the imaging plane, the actual ejection fraction is probably 
lower than the calculated values.
It is important to remember that no attempt was made to validate the ejection fraction 
measurements by comparison with a gold standard, such as the thermodilution 
technique (de Simone et a l, 1990). However, due to the longitudinal nature of this 
study, values of absolute ejection fraction were not of interest here, rather the change in 
ejection fraction relative to the baseline value. The issue therefore becomes one of 
reproducibility of day-to-day measurements, which was shown to be acceptable using 
this method (Chapter 3). Indeed, the very low week-to-week variability in sham 
animals suggests that reproducibility may have improved on that observed in Chapter 3, 
probably due to the increased experience of the sonographer.
Ejection fraction in the ligated animals did not significantly improve or worsen with 
time, indicating fairly stable pump performance. However, a slight dip in ejection 
fraction was observed at 4 weeks from 46% to 41% with reeovery to 47% by week 6. 
Although this was not significant, it is interesting because the week 4 measurement 
represented the nadir for every one of the ligated animals studied. This suggests that the 
dip may be real and not simply due to random variation. Although there is little or no 
evidence from this study to explain this phenomenon, it is tempting to suggest an 
explanation. Studies on infarct healing after myocardial infarction have sliown scar 
maturation to be taking place within this time frame (Sun & Weber, 1996).
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Alterations in left ventricular geometry may be connected to these phenomenon. A 
major increase in LV dilatation also occurred between weeks 2 and 4, which then 
steadied off, rising only slightly after that (Figure 5.4). It is of interest to note that LV 
cross-sectional area increased in both sham and ligated groups after surgery, although 
there was no subsequent increase in the sham animals. Why this slight dilatation should 
consistently occur after sham operations is not clear, but is probably a consequence of 
handling the heart and removing the pericardium. This demonstrates the importance of 
using sham animals as opposed to stock controls.
LVIT was significant and progressive (Figure 5.6) and looks to be increasing beyond the 
end-point of this study. There was a small, non-significant increase in wall thickness in 
sham animals, probably associated with ageing. The strong hypertrophic response in 
ligated animals indicates that they are compensating well for loss of function.
The results from this study are in agreement with other groups that have used 
echocardiography in post-infarction rats. Burrell el al. (1996) used short-axis images to 
examine regional changes in rats four weeks after CAL. They were able to show 
significant differences in LV cavity dilation, hypertrophy of surviving myocardium, and 
impaired systolic function, as did Litwin et al. (1994). However, this is the first study 
to use serial echocardiographic measurements to determine temporal changes in 
structure and function. It is interesting to note that ejection fraction did not deteriorate 
with time after infarct, despite a progressive LV dilatation. This is in accordance with 
the view that LV dilatation (in the short-term) is a positive adaptation to maintain stroke 
volume in the face of a reduced ejection fraction (Pfeffer et a l, 1984). Indeed, ejection 
fraction would be very low if LV dilatation did not occur in these animals. The ligated 
animals are obviously compensating well for the LV dysfunction, and it would be 
interesting to see if the continuing LV dilatation and hypertrophy will eventually result 
in decompensation to overt failure. Serial echocardiography in the rat may therefore 
represent a useful tool for future studies on the transition from compensated dysfunetion 
to failure.
Most of the ligated hearts exhibited wall motion abnormalities in the short-axis view, 
which may have contributed to systolic dysfunction. This type of dysfunction is 
difficult to quantify or describe, but is obvious to the observer from the moving images. 
Hunziker el al (1999) have recently devised a holographie method to portray these
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defects on the two-dimensional printed page. They describe a technique for printing 
holograms where the motion of the heart can be viewed through a complete cardiac 
cycle by tilting the image up and down. The printing technology is still at the prototype 
stage, but if it becomes available in the future, will aid communication of wall motion 
or valvular abnormalities.
Echocardiography may also be used to measure the degree and rate of left ventricular 
systolic contraction, and rate of diastolic relaxation. It would have been useful to be 
able to measure LV wall stress, as increased wall stress is thought to represent an 
increased risk of myocardial ischaemia (Liebson et a l, 1987). It may also be involved 
in regulating the gene expression of ANP (Wijbenga et a l, 1999). In order to calculate 
wall stress it is necessary to have simultaneous measurement of blood pressure. The 
original plan when designing this study was to implant radiotelemetry probes in these 
animals for continuous blood pressure monitoring, whieh would have allowed for 
calculation of wall stress. There were fears that strong reflections from the implanted 
probe may have swamped out the returning echo, but preliminary studies showed this 
not to be a problem. Llowever, concurrent use of radiotelemetry was not adopted as the 
extra surgical procedure is likely to have increased mortality. It remains an option for 
the future if mortality from the coronary artery ligation procedure remains low.
Natriuretic peptides
ANP levels may be increased by stretch of either atria (Garcia et a l, 1987), lelf 
ventricle (Kinnunen et al., 1992), or associated with LV hypertrophy and elevated 
Angll concentrations (Molkentin et a l, 1998).
Anaesthetic choice may affect natriuretic peptide levels. Administration of 
pentobarbital sodium in the rat increases plasma ANP in a dose-dependent manner for 
up to one week. ANP mRNA expression increases to peak at two-weeks after a single 
dose, and only returns to normal by week 6. The mechanism for this was not 
elucidated, but the effect was further exacerbated under conditions of surgical stress 
(Seul et a l, 1993). Whether other anaesthetics have similar effects on the natriuretic 
peptide system has not been established, however, significant effects after 8 weeks seem 
unlikely. Long-lasting effects caused by anaesthetics or due to surgery emphasises the 
importance of having sham-operated controls.
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The Northern analysis for RNA was not quantified, but where data was obtained from 
the same autoradiograph, it is possible to comment on relative abundance. The 
expression of ANP mRNA was exceptionally high in the atria. Exposure time for 
autoradiography was only 30 minutes for atrial samples, whereas LV samples on the 
same blot were optimally visualised at eight hours exposure. This indicates that 
expression in the LV was around 6% of that in the atria, which was confirmed in an 
intermediary timed blot when all bands were visible. This is in good agreement with 
the 7% LV/atria level observed in the WKY by Ogawa et a l, (1991), and is similar to 
normotensive human subjects (Mukoyama et a l, 1991; Saito et a l, 1989). CAL did not 
change ANP gene expression in the atria, but levels doubled in the surviving left 
ventricle. This is a common observation in the rat where it is a measure of LV 
dysfunction (Passier el a l, 1996; Oie et a l, 1998; Gidh-Jain et a l, 1998) and is 
probably triggered by a combination of myocyte hypertrophy and increased filling 
pressures (Wijbenga et a l, 1999). The increase in ANP mRNA expression results in an 
increased secretion of active protein, as there is a near doubling in plasma ANP 
concentration (Table 5.3). Thus, gene expression in the LV appears to be a reliable 
indicator of plasma concentration.
BNP mRNA expression was higher in the atria, with the level of expression in the LV 
around 45% of atrial levels. This confirms the work of Ogawa el al (1991), who 
observed a 40% relative abundance in the LV versus atria in normal WKY. When 
adjusted for tissue weight, they found the LV to be the major source of BNP in the rat. 
After CAL, atrial levels barely changed, while LV expression increased by 34%. 
Again, the increase in mRNA expression in the LV was mirrored by an increase (26%) 
in plasma BNP. Although just failing to reach statistical significance for either, this 
increase is likely to be real, as it was observed by independent measurements at both the 
mRNA and protein level. BNP is the best marker of prognosis in human heart failure, 
correlating with NYHA functional class (Mukoyama et a l,  1991). As with ANP, gene 
expression of BNP is switched-on by myocyte cellular hypertrophy (Molkentin et a l, 
1998), but is also thought to reflect wall stress, as levels have been found to correlate 
with LV dilatation (Nagaya et a l, 1999), low ejection fraction, and high LVEDP 
(Yamamoto et a l , 1996).
Activation of the BNP system is undoubtedly weak in this study and probably reflects 
the fact that these animals have left ventricular dysfunction and not overt failure. By
205
comparison, in the LV of the SHRSP, gene expression doubles compared to WKY 
(Ogawa et a l, 1991), and in human heart failure the BNP plasma concentration is 
higher than ANP, which is not the case here (Mukoyama et a l, 1991). Clear differences 
may have been obscured by mild activation of the BNP system in sham animals. Sham 
rats exhibited slight LV dilatation in the first two weeks (Figure 5.4), which may have 
increased BNP expression.
Vascular function
In rings of thoracic aorta, neither contractile response to noradrenaline (NA) nor 
endothelium-dependent relaxation to acetylcholine were altered in ligated animals when 
compared to their sham-operated controls (Figures 5.12 & 5.13). Thus, stimulated 
release of EDRF was normal in these vessels. When L-NAME was added to block 
nitric oxide synthase activity, the increase in baseline tension was similar between 
groups, indicating that in unstimulated vessels, basal release of nitric oxide is also 
normal.
That L-NAME resulted in total block of ACh-induced relaxation suggests that 
endothelium-derived nitric oxide is responsible for all of the relaxant response to ACh 
in the aorta of both sham and ligated animals i.e. other EDRFs are not involved.
Finally, no differences were observed in non-endothelium dependent relaxation to 
sodium nitroprusside i.e. the sensitivity and maximum response is not altered at the 
level of the smooth muscle (Figure 5.14). Therefore, endothelial-dysfunction was not 
observed at any level in the aorta of these CAL rats. This is in contrast to a number of 
other studies that have demonstrated impaired endothelium-dependent relaxation in the 
thoracic aorta of rats post-MI e.g. Ontkean et al (1991), Lindsay et a l (1992), 
Toyoshima et a l (1998). The obvious explanation is that infarct sizes were not large 
enough in this study for altered vascular function to become evident. In humans, the 
extent of vascular dysfunction correlates with the severity of heart failure (Carville et 
a l, 1998). However, recent evidence suggests that endothelium dependent relaxation is 
actually enhanced in rats with small (<20%) infarcts, and is impaired in animals with 
larger infarcts (Gschwend et a l, 1999). Therefore, one could speculate that since in the 
present study there was no stratification for infarct size, the response to ACh may 
represent an average of large and small infarcts, the result being no net difference in 
relaxation.
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Another explanation is that relaxation to ACh is thought to be due to a combination of 
endothelium derived relaxing factors (EDRF), hyperpolarising factors (EDHF) and 
contracting factors (EDCF). In a study by Nasa et al (1996), impaired relaxation to 
ACh was partially restored by inhibiting EDCF production using a cyclooxygenase 
inhibitor. In this study, indomethacin was present tlu’oughout and may have hidden any 
dysfunction caused by increased release of EDCFs.
In the aorta of rats with large infarcts, impaired endothelium dependent relaxation may 
be a result of reduced EDFIFs (Gschwend et a l, 1999). However, EDHF does not 
appear to have a significant role in relaxation in the present study as only 3% of the 
relaxation persisted in the presence of L-NAME and indomethacin.
In the ligated rats, vascular function may yet have been impaired in more distal portions 
of the vascular tree. In the few animals that underwent tail-cuff plethysmography, it 
was substantially more difficult to dilate the tail artery for blood pressure 
measurements, providing circumstantial evidence for impaired peripheral 
vasodilatation.
Resistance artery structure
Remodelling of mesenteric resistance arteries in the CAL rats was mild, with only 
minor changes in vessel dimensions at eight weeks after surgery. Lumen diameter was 
slightly reduced, mainly due to a thicker intimai layer. As there was no difference in 
endothelial cell number, this suggests an increase in connective tissue. However, the 
one study that has addressed this issue found no difference in collagen or elastin density 
in rat mesenteric resistance arteries at a variety of time points up to one year (Mulder et 
a l,  1996). Intimai thickening has not been previously described in any heart failure 
model, and the reason for this type of remodelling remains obscure.
The most striking difference observed in this study was a reduced number of smooth 
muscle cells in the media of ligated animals, despite an identical media cross-sectional 
area (Figure 5.17). Therefore, despite there being no net change in the volume of 
material, there was a substantial restructuring of the medial layer i.e. eutrophic 
remodelling. The loss of smooth muscle cells must have been counterbalanced by an 
increase hi connective tissue, or hypertrophy of the remaining cells to maintain the same 
volume. This is the first time that such remodelling has been described in heart failure.
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Only a handful of studies have examined resistance artery structure in heart failure and 
they are all in broad agreement, that changes in vessel dimensions are minor or not 
apparent. In rats after CAL, Mulder et a l, (1996) found no differences in either femoral 
or mesenteric resistance artery structure at 0, 30 or 365 day’s post-MI. Likewise, at 5 
weeks there was no difference in media CSA, lumen diameter, or wall-to-lumen ratio in 
mesenteric small arteries in a study by Stassen et a l (1997a). Resistance arteries in the 
surviving myocardium are also unaffected at 3- and 8-weeks, with no change in media­
te-lumen ratio (Kalkman et a l, 1996). In human gluteal subcutaneous resistance 
arteries the picture is the same, no change in vessel dimensions or media-to-lumen ratio 
(Stephens et a l, 1998). The results from the present study fall into this pattern, with no 
significant differences in media-to-lumen ratio, lumen diameter or wall thickness.
Only two studies have reported small artery remodelling, both in 3'^ ' order mesenteric 
resistance arteries after CAL in the rat. Buus et al (1999) describe remodelling of 
existing material around a slightly enlarged lumen i.e. outward eutrophic remodelling, 
while Heeneman et al (1995) show outward hypertrophic remodelling. In both, lumen 
diameter tended to increase, resulting in a reduced media-to-lumen ratio. However, in 
the study by Buus et a l (1999) media CSA remained normal, while there was a 
tendency for medial CSA to increase in the report by Heeneman et a l (1995). The 
reason for this discrepancy is likely to be changes in regional blood flow. In the former 
study, blood flow to the small intestines was unchanged, but in the latter, flow was 
significantly increased. Thus, the increase in material in the media observed by 
Heeneman and colleagues was probably due to flow-induced hypertrophy. Why there 
was a difference in small intestine blood flow between these studies is not apparent. 
However, it is probably not related to severity of heart failure as both studies employed 
Wistar rats with identical average infarct size, examined at comparable time points, 
when heart failure was well compensated.
In all the studies described above, structure was determined by either wire or perfusion 
myography or by standard histology in perfusion fixed vessels. Therefore, no 
information was available at a cellular level, making the reduction in SMC density 
observed in this study unique. Loss of smooth muscle cells may have a functional 
significance. Stassen et a l (1997a) describe a generalised hyporeactivity to all major 
vasoconstrictors in mesenteric resistance arteries from rats 5-weeks post-MI. They also 
determine vascular structure, but noted no change in media thickness, CSA, lumen
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diameter or wall-to-lumen ratio. They conclude that the decrease in contractility cannot 
be explained by a reduction in media mass. However, although in a further study they 
attempt to explain this in terms of impaired agonist-induced calcium influx (Stassen et 
a l,  1997b), an alternative explanation would be a reduced number of smooth muscle 
cells as observed in the same vessels in the present study.
The loss of SMC could be due to decreased blood pressure or reduced flow as a direct 
effect of myocardial infarction. However, Buus et al (1999) measured blood flow to 
the small intestine in heart faihne rats and found no difference between sham and 
ligated animals. The drop in blood pressure is typically around 15-20inmlig after 
coronary artery ligation in the rat (Mulder et a l, 1996). Whether this small difference is 
still apparent at the level of the resistance arteries has not been established. Although 
elevated blood pressure is a known stimulus for vascular hypertrophic remodelling, 
little is known about the effect of hypotension on vascular remodelling.
It is surprising that small artery structure is not radically altered in heart failure given 
the number of vasoactive substances that become elevated, many of which can modulate 
vascular growth. Angiotensin II promotes growth and SMC hypertrophy (Heeneman et 
a l,  1997), as do noradrenaline and endothelin (Wu et a l, 1997). All have been reported 
as increased after myocardial infarction. Counterbalancing these effects are NO, TNF-a 
and ANP which have growth inliibitory effects, and may induce SMC apoptosis 
(Stassen et a l, 1997a; Wu et a l,  1997; Pinsky et a l, 1999). It is tempting to speculate 
that the loss of smooth muscle cells in the ligated animals was due to programmed cell 
death. Apoptotic cell death has been documented in myocytes in the failing 
myocardium (Ruffalo et a l, 1998), and in cultured SMCs obtained from the 
hypertensive rats (Hamet et a l, 1995). However, to the best of our knowledge, has yet 
to be described in the vasculature of rats with heart failure. It is interesting to note that 
plasma ANP remains strongly activated in the ligated animals, while plasma renin is 
normal (Table 5.3). Other groups have noted that plasma noradrenaline and angiotensin 
II have returned to normal five-weeks after infarction in the rat, while ANP remains 
elevated (Stassen et a l, 1997a). This could represent a pro-apoptotic or growth 
inliibitory mechanism, whereby persistently raised ANP is the prevailing influence on 
SMC growth in the longer term. However, this remains speculative and merits further 
study.
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Summary
This study examined cardiac and vascular function and structure in WKY rats eight 
weeks after occlusion of the left anterior descending (LAD) coronary artery, and 
compared them with sham operated controls. The main findings were:
• The rat model of coronary artery ligation was successfully introduced to this 
laboratory with an acceptable level of mortality.
• Occlusion of the LAD coronary artery resulted in anterior transmural infarcts.
• Echocardiography two-weeks post-surgery demonstrated that ligated hearts had a 
significantly reduced ejection fraction with LV dilatation hypertrophy.
• LV dilatation increased progressively for the duration of the study, while there was 
no further change in ejection fraction.
• Compensatory hypertrophy of the surviving posterior wall was apparent from week 
4 onwards and increased in a linear fashion.
• In the surviving myocardium, ANP mRNA expression is significantly elevated, 
which corresponds with a similar increase in plasma ANP concentration.
• BNP mRNA was only weakly induced with a corresponding non-significant 
increase in plasma BNP.
• In isolated aortic rings, endothelial function was normal in ligated animals.
• Gross structural alterations in mesenteric resistance arteries were not significant. 
However, using LSCM, extensive eutrophic remodelling of the medial layer was 
apparent, with ligated animals having 24% fewer smooth muscle cells.
5.5 Conclusions
The rats in this study exhibit left ventricular dysfunction resulting in moderate 
impairment of ejection fraction. Over the time period observed, the responses of LV 
hypertrophy and dilatation are adequately compensating for the loss of functioning 
myocardium. However, both these parameters were still increasing at the study end­
point, and serial echocardiography may be a useful tool to determine when cardiac 
remodelling becomes detrimental. The absence of strong BNP activation and aortic 
endothelial dysfunction probably confirms that heart failure is mild in these animals. 
Despite this, a novel type of remodelling was observed in the mesenteric resistance 
arteries, which could have implications for small artery function.
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6. Coronary artery ligation in SHRSP: feasibility study
6.1 Introduction
Hypertensive patients are at greater risk of developing ischaemic heart failure and when 
they do, prognosis is particularly bleak. In the Framingham heart study, only 24% of 
men and 31% of women with hypertension and myocardial infarction survived five 
years (Levy et a l,  1996). To mimic this situation in the clinic, some groups have used 
CAL in hypertensive animal models to determine the factors in hypertension that 
contribute to poor prognosis. Fletcher et a l (1982) compared haemodynamic 
parameters after MI in the SFIR and WKY rat strains. Animals were stratified 
according to infarct size and measurements taken at 26 days. Compensatory LV 
hypertrophy was not yet detectable in normotensive animals. Despite the presence of 
LV hypertrophy in the SHR rats, absolute values for peak LV developed pressure, peak 
stroke volume and stroke work were comparable to normotensive rats, although the 
initial values prior to ligation were higher in the SHR. Therefore, the percentage 
decrease was greater in the SHR, such that the increased pressure developing capacity 
of the hypertrophied myocardium was lost. The greater effect on SHR hearts could not 
be explained by alterations in LV dilatation, which were similar between strains.
The reduction in blood pressure post-MI was doubled in the SHR, bringing them within 
the normotensive range, but was still higher than WKY. Thus, afterload remained 
elevated, which may have accounted for the relatively reduced cardiac function 
(Fletcher a/., 1982).
There is evidence for an increased infarct size in the hypertensive heart, which would 
contribute to poor prognosis, as many of the haemodynamic indicators of LV 
dysfunction correlate with infarct size (Fletcher et 982). When the SHR is 
subjected to CAL, mortality is significantly greater than in WKY animals for the same 
insult. This is due to increased infarct size and sudden death, mainly in the first 30 
minutes (Morita et a l, 1996).
In dogs with renal hypertension, CAL resulted in a 50% increase in infarct size over 
normotensive animals, and a 3-fold increase in sudden death due to ventricular 
fibrillation (Inou et a l, 1987). Infarct size and mortality were almost normalised by
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infusion of sodium nitropmsside for 7 % hours, starting 30 minutes after occlusion. 
This effectively lowered blood pressure without affecting LV hypertrophy, suggesting 
that high blood pressure is more important than LVH in the increased susceptibility to 
infarct expansion and sudden death. Likewise, infusion of pressure-agents after MI in 
pigs also increases infarct size, while pacing induced tachycardia had no effect (Garcia- 
Dorado et o l, 1988). Presumably, increased afterload is placing more stress on the 
failing heart.
Later studies in the dog model indicated that the rate of infarct expansion (i.e. the rate of 
spread of myocyte necrosis) was increased in hypertensive animals, and could be 
modulated by blood pressure control (Dellsperger et a l, 1991). Sudden death could be 
normalised by immediate treatment with a |3-blocker but not ACE inliibitor, despite both 
drugs reducing infarct size and blood pressure. This suggests that the risk of sudden 
arrhythmic death is not related to blood pressure or infarct size, but is due to other 
factors such as sympathetic activation or i^resence of LV hypertrophy.
In contrast to Fletcher et a l (1982), LV dilatation was increased in SFIRs after 
infarction in a study by Nishikimi el a l (1995), indicating a more rapid deterioration in 
LV geometry. The reason for these conflicting results is not clear, as both studies took 
measurements at around three weeks with similar sized infarcts.
All these studies dealt with immediate or early (< 3 weeks) effects. Very little 
information is available on the natural progression to heart failure in the longer-term. 
From the limited data, progression appears to be accelerated. In the absence of a control 
group Itter et al (1998) describe ligated SFIRs as exhibiting severe heart failure at five 
weeks, with peripheral and lung oedema, ascites, enlarged left and right ventricles and 
impaired ejection fraction. Mean survival was only 15 weeks. The influence of 
neurohormonal or vascular alterations due to hypertension on the progression to heart 
failure has never been studied.
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6.2 Results & discussion
A total of eleven SHRSP were subject to coronary artery ligation. The surgical 
procedure was identical to that in WKY animals, with no additional precautions. 
Mortality was high with only tlnee animals surviving the full eight weeks. This is 
similar to the 24% survival reported at one week in the SHR by (Morita et c//.,1996). 
Outcome for individual animals is given in Table 6.1.
Table 6.1 Outcome in SHRSP after coronary artery ligation.
Animal numbers Outcome
C2113 Confirmed stroke at day 14 post-ligation.
C2273 Sudden death day 13.
C2392 Sudden death day 12.
C2313 Survived but infarct very small
C2359
C2360
C2312 Died 5 minutes after surgery -  confirmed arrhythmias
C2391
C2311 Blood loss during surgery, died next day
C2383 Sudden death day 3 after good recovery from surgery.
C2384
Due to the exceptionally high blood pressure in these animals, blood loss during surgery 
tended to be greater than in WKY rats. The act of placing the suture was frequently 
accompanied by spurts of blood from the left ventricle that required rapid application of 
pressure to bring under control. Despite this, only one animal died as a direct result of 
blood loss from the surgical procedure. Two animals died immediately post-surgery of 
confirmed arrhytlunic death, and this corresponds with the known period of increased 
ventricular fibrillation and tachycardia that occurs in the first 30 minutes after ligation 
in the rat (Opitz et a l, 1995). A further two animals recovered well after surgery, but 
were found dead on day 3, while three more animals died suddenly at around 2 weeks 
after being otherwise well. In one of these animals, the cause of death was due to
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stroke, and a large haemorrhage was observed on post-mortem. This is unsurprising as 
this animal was old by SHRSP standards at 10-months of age, well within the time 
frame that strokes are common in these animals (Okanioto et a l,  1974). In the 
remainder, cause of death was not established, although acute heart failure was unlikely, 
as lung pathology was normal and at 4-5 months old, stroke is less common. Deaths 
were probably due to myocardial infarction or fatal arrhytlimias, although stroke was 
not excluded. Unfortunately, all of the thi'ee animals that survived the eight-week 
follow-up period had no evidence of LV dysfunction by echocardiography, and were 
found to have very small or no infarcts on post-mortem. Since none of the WKY rats in 
the previous chapter had such small infarcts and the ligation was placed in the same 
position, this may represent a divergence in coronary artery anatomy between SLIR and 
WKY rats which merits further investigation. However, in these rats with no apparent 
infarct at 8-weeks, blanching of the myocardium was still observed on tying the suture, 
indicating that ischaemia was present in these animals, at least initially. This apparent 
recovery of the infarcted myocardium may be due to the hypertrophied myocytes 
representing a physical barrier to protect the artery from total occlusion. Another 
explanation could be that; because hypertrophy was well established in these animals, 
they might have developed a more extensive collateral circulation to compensate i.e. 
new capillaries to feed the enlarged myocardium.
It is not possible to say from this preliminary work whether it is feasible to produce 
SHRSPs with moderate to large infarcts within acceptable mortality limits. Obviously 
there is a learning curve for ligation in the SHRSP and more animals are required. 
Cardiovascular pathology is already well advanced in these morbidly hypertensive 
animals and it is perhaps optimistic to use eight weeks as the study period. We would 
expect progression to heart failure to be more rapid in hypertensive compared to 
normotensive rats. Indeed, if the study time had been reduced to 10-12 days, then 
survival would have doubled in this study. An echocardiogram was obtained in one of 
the animals that died at two-weeks which clearly shows an anterior infarct, resulting in 
impaired systolic function (Figure 6.1). The ejection fraction in this animal reduced 
from 82% to 45% after infarction.
Other approaches may yet be tried to bring mortality within acceptable limits. These 
could include administration of anti-arrhythmic drugs, using females as a moderately
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less severe hypertensive model, or lowering blood pressure during and immediately 
after surgery to minimise infarct expansion.
Before surgery
After CAL
Diastole Systole
Figure 6.1 Parasternal short-axis view of the left ventricle in a SHRSP rat before 
and two weeks after surgical ligation of a coronary artery. Infarcted area is clearly 
visible during systole resulting in a larger end systolic volume.
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7. Venous function in the rabbit after coronary artery ligation
7.1 Introduction
A rabbit model of coronary artery ligation was developed in Glasgow as part of the 
Medical Research Council’s Clinical Research Initiative in Heart Failure. The model 
was produced centrally, and tissue distributed to several research groups studying 
cardiac and vascular function. This section will describe work undertaken by the author 
on venous function in this model.
There is a dearth of information on the venous circulation in general, and no published 
analysis of venous function during heart failure. Despite this, there are good reasons to 
suspect that heart failure may be associated with altered venous function. In rat models 
of coronary artery ligation, central venous pressure is elevated (Mulder el a l, 1996; 
Mulder et a l, 1997), thereby contributing to increased pre-load on the heart. In the 
same model, increased peripheral resistance may be explained, in part, by impaired 
endothelium-dependent relaxation in large conduit arteries such as the aorta (Lindsay et 
a l,  1992; Toyoshima et a l, 1998) and in the resistance arteries (Drexler & Wenyan, 
1992). It is conceivable that similar dysfunction may occur in the venous circulation. 
The venous circulation is highly imiervated by sympathetic nerves at all levels in the 
vascular tree, and due to the relatively thin smooth muscle layer, when compared to 
arteries, neurogenic constriction is more pronounced in veins (Nilsson et a l, 1986). 
Since heart failure is associated with a strong activation of the sympathetic nervous 
system in man (Meredith et a l, 1993) and animal models (Deck et a l, 1992), studies on 
neurogenic vasoconstriction are a logical starting point for examining venous function 
during heart failure.
This provides the rationale for the following study, which examined endothelium- 
dependent relaxation to acetylcholine, and vasoconstriction in response to electrical 
field stimulation in isolated rings of saphenous vein from stock and CAL rabbits. Since 
vascular alterations may be a long-term consequence of LV dysfunction, animals were 
studied at two time points, 8-weeks and 32-weeks after surgery.
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7.2 Methods
The rabbit model of coronary artery ligation (CAL) was provided by the University 
Department of Medical Cardiology using New Zealand white rabbits obtained from 
stocks kept at Glasgow Royal Infirmary, Methods for this surgery and 
echocardiography are published in (Pye et a l, 1996). This study includes full validation 
of echo cardiographie estimation of ejection fraction in the rabbit, by comparison with 
the thermodilution method. Two sets of experiments were conducted: in rabbits 8- 
weeks after surgery and 32-weeks after surgery.
Stock and ligated rabbits were killed by overdose of anaesthetic. Skin was cut away 
from the leg to expose the lateral saphenous vein which runs from the knee up towards 
the femoral, as far as the first visible bifurcation. A 2cm portion was taken from just 
above the knee and stored in cold physiological salt solution (PSS) until required. On 
some days an identical portion was taken from both legs to allow a second day of 
experiments on the same animal. There was no difference in responses when tissue 
was used immediately compared to the same experiment repeated after 24 hours 
refrigeration.
Saphenous vein was cleaned of connective tissue under a dissecting microscope and cut 
into 4x4mm ring segments. These were suspended in 30ml organ baths by fine wire 
hoops, taking care not to damage the endothelium. The upper wire was attached by 
thread to a Grass FT03c transducer, balanced by Fly de Electronics FE BBS bridge 
conditioners, to a Linseis L2006 chart recorder for display of isometric tension. The 
lower wire was connected to a glass tissue holder, which incorporated dual platinum 
plates parallel to the tissue for electrical field stimulation (EFS). A multi-channel 
stimulator from Applegarth Electronics produced square wave pulses.
The mounted rings were immersed in PPS and continuously bubbled with 95% O2 : 5% 
CO2 at 37°C. They were placed under an initial tension of 2g, which in this preparation 
gives the optimal contractile response, and re-tensioned to that level after 20 minutes. 
A minimum of 40 minutes was then given for equilibration before starting the 
experimental protocol.
Protocol
After equilibration, a sighting concentration of 1 pM noradrenaline (NA) was added to 
each bath and the tissues allowed to contract to the plateau phase. The presence of a
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functioning endothelium was then assessed by relaxation to IpM  acetylcholine (ACh). 
After a 30-minute wash out, this was repeated in 8-week animals or a full ACh 
concentration response curve (CRC) constructed in 32-week rabbits. After a further 30- 
minutes wash period, frequency response curves were constructed for the range 4,8,  16, 
32, and 64Hz. Each square wave pulse was delivered at 5-minute intervals, with a train 
duration of Is, 0.1ms pulse width, at 35 volts. FRCs were repeated after 30 minutes 
incubation with IpM  cocaine and then lOOpM L-NAME. Optimal blockade of nitric 
oxide synthase by L-NAME was confirmed by absence of relaxation to ACh.
Drugs
Composition of PSS was as follows (niM): NaCI, 118.4; KCl, 4.7; CaCb, 2.5; 
MgS0 4 .7 H2 0 , 1.2; NaFICOg, 24.9; KH2PO4 , L2; and glucose, 11.1. Na2 EDTA at 
23 pM was included to prevent oxidative degradation of NA.
The following drugs were used: noradrenaline bitartrate (Sigma), acetylcholine chloride 
(Sigma), N“-nitro-L-arginine methyl ester (L-NAME) (Sigma), and cocaine LI Cl 
(Macarthys).
7.3 Results
Results with animals 8- and 32-weeks after coronary artery ligation were essentially 
identical and are presented side-by-side. The results are not directly comparable 
between 8- and 32-weeks as electrodes for electrical field stimulation were replaced 
between these two groups of animals. Therefore, results are not drawn on the same 
graphs. After washing, and a further 30-minutes
Ejection fraction measured by echocardiography for 32-week animals is shown in 
Figure 7.1. Systolic dysfunction was mild in the ligated animals, with a mean ejection 
fraction of 48.5%, but the difference was highly significant.
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Figure 7.1 Left ventricular ejection fraction in rabbits 32-weeks after coronary 
artery ligation. Data are mean ± sem, n=6 in each group.
The maximum relaxant response to acetylcholine (ACh) was tested in rings pre­
contracted with noradrenaline (NA). In the 8-week animals, there was a trend for 
ligated animals to exhibit reduced relaxation, however, this difference was small and 
failed to reach significance (Figure 7.2). A full concentration response curve for ACh 
was constructed in the 32-week animals (Figure 7.3). Again there was a trend for a 
reduced maximal response and sensitivity to ACh that was not statistically significant.
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Figure 7.2 Relaxation responses to IpM ACh in rabbit saphenous vein from sham 
and ligated animals. Rings were pre-contracted with 1 pM NA. Data are mean ± sem, 
there was no significant difference between groups (n=l I in each).
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Figure 7.3 ACh concentration response curves in rabbit saphenous vein 32-weeks 
after CAL. There were no significant differences in either maximal responses or 
sensitivity between sham and ligated animals (mean ± sem, n=6 in each).
Frequency response curves were constructed in the range of 4-64Hz in the presence and 
absence of cocaine (IpM ) to block neuronal uptake of noradrenaline, and of L-NAME 
(lO'^^M) to inliibit nitric oxide synthase. Responses at 8- and 3 2-weeks show the same 
picture. There are no differences between sham and ligated animals in their response to 
electrical field stimulation (Figure 7.4), nor in the presence of cocaine (Figure 7.5) nor 
in the presence of L-NAME (Figure 7.6). All data are presented as raw developed 
tension in milligrams, however, the same results are obtained when responses are 
normalised to maximum contractile response.
Contractions are potentiated by cocaine by around 100%, and this increase is similar in 
both sham and ligated groups. Likewise, a further doubling of contractile response is 
observed on incubation with L-NAME, with again no difference between groups.
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Figure 7.4 Frequency response curves in rabbit saphenous vein from sham and 
ligated animals. Data show developed tension at 8-weeks (A) and 32-weeks (B) after 
coronary artery ligation. Data are mean ± sem, n=l 1 in each group at 8-weeks, and n=6 
for each group at 32-weeks.
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F igure  7.5 Frequency response curves in rabbit saphenous vein in the presence of 
cocaine (lO'^M) from sham and ligated animals. Data show developed tension at 8- 
weeks (A) and 32-weeks (B) after coronary artery ligation. Data are mean ± sem, n=l 1 
in each group at 8-weeks, and n=6 for each group at 32-weeks.
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Figure 7.6 Frequency response curves in rabbit saphenous vein in the presence of 
L-NAME (IC'^M) from sham and ligated animals. Data show developed tension at 8- 
weeks (A) and 32-weeks (B) after coronary artery ligation. Data are mean ± sem, n=l 1 
in each group at 8-weeks, and n=6 for each group at 32-weeks.
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7.4 Discussion
After coronary artery ligation in these rabbits, LV systolic function was compromised, 
as evidenced by a reduced ejection fraction (Figure 7.1). As dysfunction was only 
moderate, this diminishes the ability of this study to distinguish changes that may only 
be apparent in more severely affected animals.
Responses to ACh were similar in both sham and ligated groups, although responses in 
ligated animals tended to be less (Figures 7.2 & 7.3). The fact that this trend was 
observed in both groups suggests that this small difference may be real, but is unlikely 
to be physiologically important. Contractions of saphenous vein were not observed at 
high concentrations of ACh (Figme 7.3), therefore, endothelium-derived 
vasoconstricting prostanoids are not prominent in this tissue.
Electrical field stimulation was used to determine alterations at the neuromuscular 
junction. Sympathetic activity is elevated in heart failure and could result in altered 
sensitivity to neurotransmitters, or changes in sympathetic imiervation, or alterations in 
NA clearance. A parallel exists for this in hypertension, where blockade of NA uptake 
with cocaine causes a leftward shift in the concentration response curve for NA, which 
is greater in small arteries from hypertensive subjects than in their normotensive 
counterparts, suggesting increased uptake o f NA in hypertension (Mulvany, 1991). 
However, no such difference was observed in this heart failure model. Frequency 
response curves were normal between sham and ligated rabbits at both tinie-points 
(Figure 7.4), and were potentiated to a similar extent when neuronal amine uptake was 
blocked by cocaine (Figures 7.5).
Nitric oxide has been shown to modulate neurogenic vasoconstriction in the rabbit 
saphenous vein (Gordon et a l, 1992), and this was confirmed in the present study. 
Inliibition of nitric oxide production with L-NAME strongly increased the responses to 
electrical field stimulation. However, once again, there was no difference between 
sham and ligated groups in this regard (Figure 7.6). This is in contrast to the arterial 
circulation where impaired endothelium-dependent release of nitric oxide has been 
implicated in the vascular dysfunction observed in the aortas of rats after CAL (Ontkean 
et a l, 1991; de Vries et a l , 1997).
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7.5 Conclusions
In the saphenous vein of rabbits after coronary artery ligation, there is no alteration in 
responses to endothelimn-dependent relaxation, nor to electrical field stimulation. In 
particular, neuronal uptake of NA is normal, as is the modulation of neurogenic 
vasoconstriction by nitric oxide. These observations were true, whether compared early 
at 8-weeks or late at 3 2-weeks after coronary artery ligation.
These results do not exclude a role for venous dysfunction in animals with more severe 
left ventricular dysfunction.
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8. General Discussion
Several teclniiques used in this thesis were common to more than one chapter. This 
section will discuss the overlap between these chapters and make suggestions for further 
work where appropriate.
Echocardiography in the rat was used extensively in this thesis. In Chapter 3, the 
estimation of LV mass by echo cardiography was validated against actual LV mass 
measured at autopsy, and a good positive correlation was obtained. Measures of 
repeatability were also calculated for serial measurements, and these were utilised in 
Chapters 4&5. Altogether, experience was gained of over 300 echocardiographic 
examinations in the rat. The optimum conditions were the use of light sedation with 
Hypnorm, with the rats in the left lateral position, the chest fur closely shaved, and 
using copious amounts of gel. In this way, parasternal short-axis views at the level of 
the papillary muscles were readily obtained.
The results in Chapter 3 were collated during the learning curve for this procedure, and 
the measures of repeatability reflect this. It is fair to say that echocardiographic 
measmements were probably more accurate in the subsequent chapters. For example, 
serial assessment of ejection fraction in sham operated rats exhibited very little variation 
in Chapter 5 (Figure 5.3), as did LV lumenal cross-sectional area (Figure 5.4). Chapter 
5 also indicated that useful data could be obtained using echocardiography in the 
infarcted heart without the need to make assumptions concerning LV geometry. For 
example wall thickness measurements of the siuviving myocardium (Figure 5.6).
Further work in this area could include validation of ejection fraction measurements 
against ejection fraction calculated using the thermodilution method (Pye el a l, 1996). 
This would allow determination of an absolute value for ejection fraction in these rats. 
This would be paiticulariy useful to validate in rats after coronary artery ligation, since 
the assumptions made in calculating ejection fraction in these animals are even greater 
than in normal rats. Doppler flow measurements would also be an attractive proposition 
in these animals, in order to more accurately assess LV global function. Flowever, this 
would require the acquisition of a higher frequency transducer (lOMHz), as the present 
set-up did not have the resolution to image the LV outflow diameter.
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Another attractive proposition would be to combine radiotelemetry with 
echocardiography. A telemetry probe implanted with a catheter to the abdominal aorta, 
would be capable of accurate measurements of systolic and diastolic blood pressure and 
heart rate. Combined with simultaneous echocardiographic measurements this would 
allow calculation of such parameters as wall stress, which is thought to be an important 
factor in myocardial thickening and dilatation after myocardial infarction (Hu et a l, 
1998a). It would also allow the measurement of blood pressure before, during and after 
coronary artery ligation in order to study the interaction between elevated blood 
pressure and infarct size. There is extensive experience of radiotelemetry in this 
laboratory, and it remains an option for future work if mortality after coronary artery 
ligation can be kept low.
Northern blot analysis for measurement of natriuretic peptide gene expression was 
utilised in both hypertensive (Chapter 4) and heart failure rats (Chapter 5). The relative 
abundance in atrial and left ventricular tissues reported in Chapter 4 mirrored the 
published values for the SHRSP (Ogawa et a l, 1991). Given that BNP concentration is 
a good prognostic indicator in heart failure in man (Nagaya et al., 1999), it was 
surprising that activation of mRNA in the left ventricle failed to reach statistical 
significance after coronary artery ligation in the rat. This was the first such 
measurement in the rat, and may simply represent a species difference, or the moderate 
infarct size in this model. Another possibility is that BNP gene expression is elevated in 
the LV by sham operation, such that any difference is masked. It would be interesting 
to compare levels of BNP mIfNA between sham, ligated and age-matched stock animals 
to clarify this point.
The two most interesting observations in this thesis arise from the laser scanning 
confocal microscope work. In Chapter 4, treatment with either irbesartan or H+H was 
found to be equally effective in preventing the vascular hypertrophy observed in control 
SHRSP. This was surprising given the wealth of evidence implicating Ang II in this 
type of structural remodelling (discussed fully in Chapter 4). As this technique used a 
nuclear dye it was not possible to determine whether the greater medial thiclmess in 
untreated hypertensive animals was due to hypertrophy of smooth muscle cells or 
deposition of extra-cellular matrix. Work is ongoing in this laboratory to answer this 
problem by the use of extracellular dyes.
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In Chapter 5, confocal microscopy allowed the description of a novel type of structural 
adaptation not previously described in vessels from heart failure animals. Namely, a 
24% reduction in the density of smooth muscle cells in the medial layer. This could 
have obvious implications to impair vascular function. Given more time, it would have 
been interesting to assess function in these vessels using wire or perfusion myography. 
From the structural data, you would hypothesise a generalised hyporeactivity to 
vasoconstrictors, particularly in response to KCl.
In also tempting to speculate that apoptosis may be involved in the loss of smooth 
muscle cells. Nuclear condensation and fragmentation should be observable using 
propidium iodide in the confocal studies. This would be an interesting experiment for 
the future, but was not performed due to the time consuming nature of this type of 
search. It may also be necessary to examine rats at different time points after ligation to 
determine if apoptosis is more prevalent at a particular stage.
The use of the above tecluiiques in both hypertensive and coronary artery ligated rats 
has provided valuable data that begs the question of what would happen if both 
conditions were superimposed, as is commonly observed in man. For example, can the 
already severely hypertrophied SHRSP heart exhibit further hypertrophy in response to 
CAL? What effect will this have on progression to heart failure? Likewise, will loss of 
smooth muscle cells from the media of the resistance arteries also occur in vessels with 
medial hypertrophy? Is there a functional consequence of this? This was the rationale 
for attempting to ligate the coronary arteries of SHRSP in Chapter 6, and this model 
will be further developed in this laboratory.
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Appendix I Drugs & solutions
Tris "Acetate tTAE) Buffer
Stock solution made at 50x strength
Tris base 242g
Glacial Acetic Acid 57.1ml
0.5M EDTA (pH8.0) to 100ml
Stock solution was diluted with HjO for 1 x TAE buffer.
Agarose Blue Loading Dye 
For a 6x solution
Ficoll 1.5g
Bromophenol Blue 25mg
Xylene Cyanol 25mg
HjO to 10ml
20x SSC
NaCl 175.3g
Na^Citrate 88.2g
Distilled FI^O 800ml
Adjusted to pFI 7.0 with IM FICl, made up to 1000ml with li^O and auto clayed. 
TE
IM Tris pH 8.0 200pl
0.5M EDTA pH 8.0 40^il
Distilled FI20 to 20ml
20x SSPE
NaCl 175.3g
NaH.PO, 27.6g
Na2EDTA.2H20 7.4g
Distilled FI^O 900ml
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Adjusted to pH 7.4 with IM NaOH, made up to 1000ml with H2O and autoclaved.
Sodium Dodecvl Sulphate tSDS 10% w/v)
Electrophoresis grade SDS 50g
Distilled water 450ml
Solution was heated to 6 8 °C to aid dissolution, pH adjusted to 7.2 with IM HCl and 
made up to 500ml with distilled water.
Northern blot -  wash protocol & solutions
1 . 2 x rinse at room temperature with 2 0 ml wash solution 1 .
2 . 2x 15 minute at 42°C with 20ml wash solution 1.
3. 2x 1 Ominute at 42°C with 20ml wash solution 2.
4. 2x 30 minutes at 42°C with 20ml wash solution 2.
Wash solution 1 : 20x SSPE 20ml
10% (w/v) SDS 2ml
Distilled H 20 178ml
Wash solution 2 : 20x SSPE 10ml
10% (w/v) SDS 2ml
Distilled H 20 188ml
Physiological salt solution (PSS or Ki'cbs)
Composed of(mM) NaCl 118.4, KCl 4.7, CaCl^ 2.5, MgS0 4 .71-l2 0  1.2, NaHCO, 24.9, 
KH2PO4 1.2 and glucose 11.1 made up in distilled water at pH7.4 
NazEDTA was added at 23 pM to prevent oxidation of noradrenaline.
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Infarct Histology -  wax removing protocol 
xylene 5mins 
xylene 5mins
100% ethanol quick wash
100% ethanol “ “
96% ethanol “ “
96% ethanol “ “
70% ethanol “ “
deionised water “ “
Infarct Histology -  Staining protocol
1. Azan I at 37°C for 30mins
2. Wash in deionised water
3. 5% phosphotungstic acid at room temperature for 45mins
4. Wash in water
5. Azan II 1:3 in deionised water at room temp, for 10 mins
6. Wash in 96% alcohol
7. Dehydrate: wash in 70% alcohol, 96%, 96%, 100%, 100%, xylene, xylene
8. Fix coverslip.
Azan I
Azocarmine G 0.5g (Sigma)
Deionised water 100ml
Conc. acetic acid 1ml
Dissolve by heating, cool down and filter.
Azan II
Aniline blue, water soluble 0.5g (Clin-tech; colour index 42755))
Orange G 2g (Sigma)
Conc. acetic acid 8ml
Deionised water 100ml
Dissolve by heating, cool down and filter.
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Suppliers
1 Ox denaturing gel buffer Ambion
Northern sample loading dye Ambion
Pre-hybridisation / hybridisation solution Ambion 
Ready to Go DNA labelling beads Pharmacia Biotech
Agarose electrophoresis grade Ambion
Nick Columns Pharmacia Biotech
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Appendix II
Detailed notes on Thoracotomy & Coronary Artery Ligation in the rat.
Pre-operatively.
1. Administer 0.2ml of ampicillin I.M. 24-honrs prior to procedure.
2. Switch on heating pad at least 30 minutes before procedure. Temperature under a 
500g weight should be ~35°C.
3. Rats should weigh a minimum of 270g, preferably 300g, to achieve the lowest 
mortality rates.
4. Make Hypnorm + Hypnovel mixture: Draw 1ml of Hypnovel (midazolam) into 
syringe and make to 10ml with normal saline. Take 0.2ml of this mixture and add 
0.2ml of Hypnorm (fentanyl + fluanisone). Administer the full 0.4ml mixture I/P. 
This dose will suit a 300-400g rat and can be adjusted accordingly outside this 
range.
5. Once the animal has lost consciousness shave entire left chest from sternum to half­
way across back. Give supplemental oxygen until ready for intubation.
Intubation
6. To intubate: lie animal on its back. It is important to keep the animal straight with 
the head raised. The mouth is kept open by an elastic band looped round the 
incisors and pulled downward. A better view can be obtained by using forceps to 
push apart the animal’s cheek pouches. Shine one light source into the mouth and 
the other directly onto its tlmoat. The head is pulled back and the tongue lifted out of 
the way. The intubation spatula is advanced to the back of the pharynx and used to 
push the tongue upwards. A cotton bud wetted with normal saline may be used to 
moisten the entrance to the trachea, which can be visualised by the appearance of a 
small spot of light appearing with each inhalation. The cannula is directed towards 
this and a few moments of gentle pressure gains entrance into the trachea and 
advancement of the cannula approximately x cm. Intubation is with a white cannula 
(or red cannula for large rats) the tip of which has been cut diagonally and the edges
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blunted. When placing the tube, the long end of the tip must be orientated upwards. 
Marking the tip black will aid visibility while intubating. The cannula is in the 
trachea if you can still see the light when you look down the tube. If it is pinlc then 
the tubing has entered the oesophagus.
7. Lie the animal on its right side and start ventilating. Ensure cannula is in the lungs 
by listening for breath sounds with a stethoscope. A whooshing sound should be 
heard entering the lungs in time with the ventilator. If this sound can be heard in the 
stomach, then the lungs are not being ventilated, the tube should be removed and 
intubation re-started. If the animal looks blue then give it oxygen for a few minutes 
before trying again. The whooshing sound should be at the same volume on both 
sides of the chest. If it is not then adjust the depth of cannula until it is. It is of 
fundamental importance to ventilate both lungs, as during the procedure, the left 
lung is collapsed.
8. When ventilation is satisfactory, tape the tube in place. Immobilise the head relative 
to the tube by taping the animals paw over its head on to the table. Place a gauze 
swab over its eye and tape the head to the cannula. The object being to prevent the 
possibility of the cannula advancing further or being pulled out during surgery.
Monitoring
9. The assistant applies light pressure to the throat in order to obtain a good seal. This 
can be assessed by the waste gases, which are vented to a glass beaker filled with ~ 
1cm of water. To apply positive end expiratory pressure, the exit tube should be 
0.5cm below the water surface. If there is a good seal then the bubbles leaving the 
tube will be of a regular size and speed. A squeaking sound in the throat means air 
is escaping around the vocal chords and the seal should be readjusted.
10. The assistant should also monitor heart rate tlnoughout the procedure by feeling for 
the femoral pulse. Any change in strength or rate should be noted. If the pulse is 
lost then the heart should be felt for tlmough the chest. The finger should be rested 
periodically to prevent desensitisation. If the pulse slows or weakens this may be a 
sign that too much halothane has been given, as this is a cardiac depressant. Action 
should be rapid to reduce or switch off the halothane. A level of 0.25 - 0.5% in 
oxygen (flow rate 0.4L/min.) is usually sufficient for the procedure. However, the
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minimum should be used depending on the individual reaction of the rat, and some 
may not even need any. N.B. If nitrous oxide is available then this should be used at 
a continuous flow rate of 200ml/min, and will greatly reduce the amount of 
halothane required (nitrous oxide is less cardiac depressant). Another cause of a 
depressed or irregular heart rate is mechanical stimulation of the carotid body 
possibly interfering with the baroreceptor reflex. This is due to the position of the 
assistant’s hand on the tlmoat, and often simply repositioning this will solve the 
problem.
11. Tlri'oughout the procedure it is a good practice to keep an eye on the colour of 
extremities such as feet and ears as an indicator of how well the animal is being 
perfused.
Thoracotomy
12. Spray the surgical area with chlorhexidine skin disinfectant. Take the paper 
surgical towel and cut a 2 inclf hole to form a hernia towel.
13. The incision should be made between the 4^ '' and 5‘^' intercostal space. As the ribs 
are diffieult to count accurately in the rat, you should feel for the first ribs that attach 
to the sternum (as opposed to loosely attached to the xiphisternum). The rib space 
one up from this is where to make the incision with the scalpel blade. The incision 
should be around 3 cm long, running parallel with the ribs, and just breaking the 
skin. Open the top connective tissue layer by blunt dissection using the small 
curved scissors. Any bleeding from superficial arteries may be stopped or prevented 
using electrocautery. If this is not available then use the gauze swabs to exert 
pressure on the bleeding area for a few minutes. Also, if arteries are cut cleanly in 
one motion, perpendicular to their flow, then they should not bleed. Use blunt 
disseetion to loosen the skin all around the incision.
14. The muscle layer should be prised apart and cut in a similar fashion, this seldom 
bleeds in the rat.
15. Great care should be taken when the intercostal muscles are reached. One hand is 
used to steady the animal while a pair of fine blunt forceps are used to slide 
underneath the muscle layer. This can then be held up out of the way of the lungs to
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allow cutting with scissors (remember to always keep the points upwards away from 
the lungs). Continue in this way until the sternum is reached, and the lungs exposed.
16. The obvious danger is that the lungs may be damaged or punctured during this 
procedure. If you suspect that the lung has been punctured confirm this by drawing 
a few millilitres of saline into a syringe barrel and dribbling over the lungs looking 
for air bubbles. A very small hole may heal spontaneously if covered with a Q-tip 
for a few minutes, but most punctures will necessitate the removal of that lung. To 
do this, collapse the lung with a piece of gauze and use a length of mersilk 0 to tie 
off the entire lung at the level of the bronchi. Then cut off the lung close to this tie. 
Care must also be taken to avoid the internal thoracic artery, which runs alongside 
the sternum.
17. Collapse the left lung by folding a small square of gauze and using it to envelope 
the lung which can then be gently pushed downward and away from the heart using 
a Q-tip. If at this stage the animal starts breathing against the pump, this is 
indicative that the right lung is not being ventilated, if this is the case, the heart will 
fall down, away from the incision as the right lung no longer supports it. (N.B. do 
not give more anaesthetic, the gasping is a strong chemoreceptor reflex due to the 
lack of oxygen, not because the animal is too light.) Action must be immediate, to 
re-gain the seal, re-position intubation tube or re-inflate left lung as soon as possible.
18. The pericardium may now be removed by pinching with a pair of bent blunt 
forceps and tearing a hole by counter pressure with a Q-tip. This is best done close 
to the level of the atria, as near the apex there is the risk of also rupturing the pleura 
of the right lung. With the Q-tip, brush the pericardium down and behind the heart, 
such that the heart is fully exteriorised. Slight pressure with the hand to the outer 
chest wall will lift the heart up and out of the cavity which may be useful for 
ligation, however, cardiac function is compromised due to incomplete filling of the 
ventricles, and so this position should not be maintained for long.
Ligation
19. To ligate the coronary artery an apical tie is first placed in the apex. This consists of 
a simple suture pulled through the myocardium but not tied. The ends of this can be 
pulled to exteriorise the heart and hold it steady, and after the ligation is complete
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the suture is pulled out again. Ethibond 4/0 can be used for this and also for the 
coronary artery ligation (remember the right ventricle extends down to the apex and 
care should be taken not to put suture through this). Locate the coronary artery by 
looking for the coronary vein, the artery is embedded in the myocardium just to the 
right of this. To ligate, use the curve of the needle to take a small bite the full 
thickness of the myocai'dium a few mm from the origin of the artery. When tying, 
take care not to lift the heart upwards to avoid tearing the myocardium. The 
infarcted area will appear blanched within minutes and an estimate of infarct size 
can be made at this point. If this is less than 30-40% then a further ligation can be 
made closer to the origin of the artery, or taking out another branch.
20. After ligation, replace the heart back in the chest and wait with the incision open for 
15 minutes. This represents the most likely time period for cardiac arrhythmia’s 
after myocardial infarction in the rat i.e. at 7 and 14 minutes. If the heart stops 
during this time it is possible to manipulate it manually to re-start rhythm. After 15 
niins the chest may be closed as outlined for sham animals
Closing up.
21. The heart is then coaxed back into the pericardium using a Q-tip and the gauze 
removed from around the lung, which will slowly begin to inflate. In this time the 
ribs are closed using cloi'omic catgut as an interrupted suture. The ribs should be 
held using toothed forceps, and extreme care taken not to puncture the lungs. If 
necessary the assistant can take pressure off the throat to decrease ventilation and 
allow the lung to fall back out of the way. The first suture is most important in 
getting the wound to line up evenly and ensure adequate healing. The ribs form a 
natural elbow, and the first suture should be placed here, splinting both ribs together. 
When pulled together, the whole wound should approximate to a perfect fit. A 
further two sutures are placed equidistant along the wound, then the first is tied. 
Pull the suture up to expand the thorax, and hyper-inflate if necessary to expel any 
air from the lung cavity, thereby preventing a pneumothorax. Tie the remaining two 
sutures.
22. Close the muscle layer using the Ethibond sutures and an interrupted stitch. 
Ragged pieces of muscle should be cut off at this stage as these will become necrotic
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if left. Finally, use the Dexon to close the skin layer with a continuous 
subcutaneous stitch. When finishing the stitch, pull the knot back into the wound 
and exteriorise about 1cm away, and cut short. Gaseous anaesthetics may be 
stopped at this stage. Tluee lai-ge holding stitches are then placed equidistant to one 
another along the wound. These serve as extra support, but also as something for 
the animal to nibble rather than attack the more important sutures.
23. Give 0.2ml buprenorphine S.C. to reverse the actions of the Fentanyl. Then 
remove the tape restraints and unplug the intubation tube from the ventilator. The 
animal should start spontaneous respiration within ~30 seconds. If it does not, then 
continue ventilation testing periodically. If the animals respiration is good and even, 
then remove the tube and place it on its front.
Post-operative care.
24. Give ~3ml of normal saline S.C. Place in a recovery cage with some vet bed and a 
heat lamp if cold. Keep an eye on the animal until it regains a righting reflex when 
gently pushed over. At this stage it can return to the animal facility. Keep the vet 
bed for the first 24 horns.
25. First thing next morning the animal should be checked and given a second 0.175ml
S.C. dose of buprenorphine as pain relief. Pain should be assessed on an individual 
basis, and particularly with sham animals, it may be appropriate to reduce or forgo 
this dose. A further 3-4ml of S.C. saline should be given daily until the animals 
weight begins to rise. Try and tempt the animal to eat by making mash out of water 
and chow and placing on the floor of the cage, add sweetened condensed milk if the 
animal is still not eating. If weight loss >20% then inform the vet. The animal may 
require to be euthanased.
26. Post-operatively look at regularity of breathing, listen for breath sounds. Is the 
animal moving freely? Is there fresh faeces and urine in the cage? Are there signs 
that the animal has been eating? A red discharge from the eyes, which may colour 
surrounding fur pinlc, is a common sign of stress in the rat. This should only last a 
few days post-operatively. Pilo-erection is a sign of pain, as is a lack of interest in 
the surroundings and absence of grooming, resulting in loss of sheen from the coat.
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Check the wound daily for signs of infection. Remaining sutures should be removed 
7-10 days post-op.
Equipment suppliers.
Adams Healthcare -  there are no laryngoscopes small enough for the rat, and finding the 
right shaped tool can be difficult. We have used a Macdonald dissector 19cm (51-5299) 
Fine Science Tools -  selection of surgical instruments 
Harvard Apparatus -  small animal ventilator
Ethicon -  Ethibond Excel 4/0 (W6935) polyester braided non-absorbable suture 
Clnomic 3/0 (W437) catgut absorbable suture 
Mersilk 0 (W224) silk braided non-absorbable suture 
Sherwood Davis & Geek -  Dexon II 2/0 (6160-87B) braided polyglycolic acid with 
polycaprolate coating.
Drugs
Anhydrous ampicillin Ph. Eur. 1 OOmg/ml (Amfipen® LA) Intervet UK Ltd, Cambridge. 
Midazolam HCl B.P.10mg/2ml (Flypnovel®) Roche, Welwyn Garden City, UK. 
Buprenorphine HCl 0.3mg/ml (Vetergesic®) Reckitt & Colman Products Ltd., York. 
Fentanyl citrate 0.315mg/ml + fluanisone lOmg/ml (Hypnorm®) Janssen Animal 
Health, Fligh Wycombe, UK.
Halothane Ph. Eur. 100% w/w (Fluothane®) Zeneca, Macclesfield, UK.
Pentobarbitone Sodium B.P. 200mg/ml (Euthatal®) Rliône Mérieux, Flarlow, UK. 
Sodium Chloride 0.9% for injection, Baxter Flealthcare, UK.
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